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Born in 1957, Dr. José Gazulla performed his medical studies at the Uni-
versity of Navarra, and received training in Neurology at the Hospital 
Universitario Marqués de Valdecilla, in Santander (Spain). He worked at 
the Hospital General de Teruel and Hospital San Jorge, in Huesca, before 
joining the Service of Neurology of Hospital Universitario Miguel Servet, 
in Zaragoza (Spain). His deployment as a general neurologist has not 
impaired his interest in the degenerative diseases of the nervous system, 
especially of the cerebellum, spinal cord and peripheral nerves. Deeply 
interested in neurological semiology and pathophysiology, as well as in 
genetics, imaging and molecular biology of central and peripheral nervous 
system disorders, his interest in the field of degenerative ataxias became 
evident from early in his professional career. As a result of this, a number 
of reports concerning the clinical manifestations, imaging, neurochemistry 
and pharmacological treatment of the degenerative ataxias have been pub-
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Preface 
The purpose of this book has been to depict as many biochemical, genetic and
molecular advances as possible, in the vast field of the spinocerebellar ataxias. In
addition, potential lines of pharmacological treatment in spinocerebellar ataxia type 3,
enumerated by Professor Luis Pereira, are complemented by a chapter in which the
pharmacological trials of the cerebellar ataxias have been reviewed in depth. Clinical
manifestations of the spinocerebellar ataxias are also included in the text, like the
description by Dr. Luis Velázquez‐Pérez of those in spinocerebellar ataxia type 2, and
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Model Systems for Spinocerebellar Ataxias: 
Lessons Learned About the Pathogenesis 
Thorsten Schmidt*#, Jana Schmidt* and Jeannette Hübener*  
Eberhard-Karls-University Tuebingen, Medical Genetics 
Germany 
1. Introduction 
Model systems are important tools for the investigation of pathogenic processes. Especially 
for diseases with a late onset of symptoms and slow progression, like most spinocerebellar 
ataxias (SCA), it is time-consuming or even impossible to analyze all aspects of the 
pathogenesis in humans. Due to the reduced lifespan of model organisms, it is possible to 
study disease progression in full within a reasonable timeframe and due to the shorter 
generation time of most model organisms more individuals can be generated and analyzed, 
thereby strengthening the reliability of data via an increased number of replicates. Detailed 
studies of the histopathology can only be performed as endpoint analyses in humans, but 
with the help of an animal model, multiple time points can be analyzed throughout the 
course of the disease. In addition, model systems allow not only for the reduction of time 
from idea to results but also reduce the complexity due to their smaller genome sizes, less 
genes, nonredundant pathways, and a simpler nervous system. 
Before using a specific species to model a disease it is of interest to check whether the 
proteins affected in humans are conserved within the respective model organism in order to 
increase the probability that binding partners and other keyplayers, involved in the 
pathogenesis of this disease, are likewise conserved. For those SCA which are caused by 
polyglutamine (polyQ) expansions, the respective affected genes are conserved in most 
organisms used as models (Table 1). Especially the proteins affected in SCA2, SCA6 and 
SCA17 are conserved with high similarity down to even yeast. This is not surprising as the 
TATA-binding protein (affected in SCA17) or a subunit of a voltage-dependent calcium 
channel (affected in SCA6) are important proteins for cellular maintenance. Although polyQ 
repeats are comparatively frequent in drosophila (Alba et al., 2007), only the repeat region of 
the TATA-binding protein is conserved. For most other non-mammalian model organisms, 
the respective orthologues are smaller and the polyQ repeats itself or even including the 
whole surrounding domains are not conserved. For analyses of SCA, various model systems 
have been employed. From the worm (Caenorhabditis elegans) and the fly (Drosophila 
melanogaster) all the way to mammals, i.e. the mouse (Mus musculus), model systems have 
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made important contributions to the understanding of disease progression and will be 
important tools for the first line tests of potential treatment strategies.  
This review aims to sum up the model systems used for the investigation of SCA and 
especially focuses on the lessons learned from these models about the pathogenesis of SCA. 
We also compare commons and differences in the results obtained using these animal 
models and highlight the species-specific advantages and possible problems associated with 
the use of this species as a model organism. 
2. Lessons learned from non-mammalian models of SCA 
2.1 Lessons learned from worm models 
The nematode Caenorhabditis elegans is frequently used as a model organism, primarily 
because of its anatomic and biochemical simplicity as well as its genetic tractability. The 
worm genome encodes orthologues for about 65% of all known human disease genes. 
Moreover, it allows for easy and rapid establishment of transgenic lines, thus facilitating 
screening and characterization of human disease-causing mutations in vivo. Overall it is an 
often used model organism to analyze pathological features of neurodegenerative diseases 
(Huntington’s disease, Parkinson’s disease or Alzheimer’s disease) (reviewed in Driscoll 
and Gerstbrein, 2003 and Brignull et al., 2006b). Except for ataxin-7, the worm contains 
orthologues for all SCA caused by polyQ expansion. Interestingly, for SCA C. elegans strains 
have only been generated and characterized for SCA2 and SCA3 (Ciosk et al., 2004; Khan et 
al., 2006; Kiehl et al., 2000; Rodrigues et al., 2007; Teixeira-Castro et al., 2011).  
In the field of polyQ diseases (e.g. HD or SCA) the formation of aggregates, and therefore, 
the transition of polyQ proteins to their toxic forms is not well understood. Due to its 
transparency, C. elegans is especially suitable to address this question. PolyQ proteins can be 
attached to a fluorescent protein (e.g. GFP, YFP, CFP) and the dynamics of aggregate 
formation both within individual cells and over time can be examined throughout the worm 
lifespan. Transgenic lines can be rapidly generated by feeding C. elegans wildtype strains 
with genetically transformed bacteria or by microinjection of manipulated DNA into the 
germline. The worm’s life-cycle of about 2 to 3 weeks under suitable living conditions is 
short. This allows studying the aggregate formation of many different constructs with 
various polyQ lengths, with or without flanking sequences of the endogenous protein and 
under control of a wide range of different promoters. When expressed in the body wall 
muscle of C. elegans, even short polyQ stretches (with less than 40 Qs) without any flanking 
sequences from endogenous proteins tend to aggregate in old worms indicating a balance of 
different factors including repeat length and changes in the cellular protein-folding 
environment over time (Morley et al., 2002). In neurons, however, the pathogenic threshold 
turned out to be about 35-40 repeats, which correlates well with the human disease. This 
means that in comparison with muscle cells, neuronal cells have a higher aggregation 
threshold (Brignull et al., 2006a). By way of contrast, the analysis of aggregation in the 
protein context of (full-length) ataxin-3 revealed that only a highly expanded polyQ stretch 
(Q130) was able to induce the formation of aggregates in the cytoplasm and nucleus of 
neuronal cells in transgenic C. elegans lines. Non-expanded (Q14, Q17) and even pathological 
expanded polyQ stretches (Q75, Q91) were diffusely distributed within neurons  
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without aggregation (Khan et al., 2006; Teixeira-Castro et al., 2011). In a truncated protein of 
ataxin-3, however, just 63Q are sufficient for aggregation mainly in the perinuclear region 
but rarely in the nucleus (Khan et al., 2006). These results are in line with observations made 
in mouse models, where a truncated form of the polyQ expanded protein induced more 
aggregates and a more progressive neurological phenotype than the full-length protein 
(Ikeda et al., 1996).  
C. elegans is also a useful organism for studying the normal distribution and function of 
polyQ proteins both during development and throughout the full lifespan. For example, a 
SCA2 transgenic model, which expressed the C. elegans orthologue of the human ataxin-2 
gene under the control of the endogenous promoter, revealed a strong expression of ataxin-2 
in the central nervous system of adult worm, but also allowed the detection of ataxin-2 even 
in the early embryo, beginning around the 4-cell stage (Kiehl et al., 2000). Likewise, the 
expression of the worm orthologue of the human ataxin-3 was strongly detected during the 
late embryogenesis and during all stages of postnatal development. Interestingly, ataxin-3 
was not only detected in the central nervous system (in the neuronal dorsal and ventral cord 
as well as in neurons of the head and tail) but was also observed in the spermatheca, vulval 
muscle, hypoderm, coelomocytes and body muscles (Rodrigues et al., 2007).  
Using knock-out strains or knocking down expression of polyQ proteins with a siRNA 
loaded diet has provided another method for the study of polyQ distribution and function. 
The knockdown of ataxin-2 by siRNA results in reduced numbers of eggs and 
developmental arrest whereas the knock-out of this gene was embryonically lethal (Kiehl et 
al., 2000). In comparison, the knock-out of ataxin-3 results in viable animals, which show no 
obvious morphological abnormalities as well as normal lifespan and behaviour (Rodrigues 
et al., 2007) but a significantly increased resistance to stress (Rodrigues et al., 2011).        
Aside from protein distribution C. elegans has been used to study synaptic function (Khan et 
al., 2006) and to perform genome-wide RNAi-based genetic screens to identify modifiers 
(Poole et al., 2011). Such a RNAi screen identified that the aggregation of pure polyQ repeats 
was enhanced by factors involved in RNA metabolism and protein synthesis (leading to an 
increased production of misfolded proteins) as well as factors involved in protein folding, 
transport and degradation (leading to decreased protein clearance) (Nollen et al., 2004). 
Invertebrate models, like C. elegans, are also particularly useful models for first-line 
screenings of possible therapeutic compounds, especially in late-onset neurodegenerative 
diseases such as SCA. The useful nature of C. elegans in such screenings was demonstrated 
in 2007 when a first drug screening for Huntington’s disease was published. Voisine et al. 
developed a so called food clearance assay by exploiting that C. elegans can easily be 
cultured in solution. For this assay, wildtype C. elegans were incubated in E. coli liquid 
culture to determine the optimal drug concentration. The optical density was used to 
measure the consumption of E. coli (food source) to indicate the growth or survival of C. 
elegans. Drugs in the established concentrations were then used to treat worms with a polyQ 
expanded huntingtin (Htn-Q150) and analyzed using a starvation assay (by measuring the 
presence or absence of GFP expression in neurons). In this assay, a HDAC inhibitor 
(Trichostatin, TSA) was able to suppress neurodegeneration and LiCl decreased polyQ-
induced neurodegeneration, while NaCl had no effect (Voisine et al., 2007).   
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Although no single model organism is able to recapitulate all features of a human disease, C. 
elegans models have proven to be a very good starting point. Worm models allow answering 
research relevant questions in vivo in an easy to handle and “low-cost” organism, before 
generating a more complex and expensive, but also more comparable model to human 
diseases, like mouse models. 
2.2 Lessons learned from fly models 
A big advantage of disease models involving Drosophila melanogaster is the so called GAL4-
UAS system (Brand and Perrimon, 1993; Fischer et al., 1988). A specific promoter controls 
the expression of the transcription factor GAL4 which binds the UAS (upstream activating 
sequence) in the responder construct containing the gene of interest. The use of different 
promoter GAL4-lines, thereby, allows controlling the expression strength and/or directing 
the expression of the disease–causing gene to different organs or cell types. A frequently 
chosen promoter is the mainly eye specific gmr-GAL4 driver (Freeman, 1996) directing the 
transgene to the flies eyes. Drosophila eyes are highly organized structures thereby allowing 
a macroscopic observation of the degeneration of (visual) neurons without the need of even 
preparing and staining brain sections. The high reproducibility, the simple breeding and the 
ease of analyzing neurodegeneration macroscopically make Drosophila models the ideal tool 
for the screening for and analysis of factors influencing neurodegenerative events in SCA. 
However, not all genes causing SCA are conserved in flies, e.g. there are no natural 
orthologues for ataxin-3 and ataxin-7 in Drosophila melanogaster. However, the CACNA1A, 
the affected gene in SCA6, as well as ataxin-1 (Tsuda et al., 2005) and ataxin-2 seem to be 
conserved albeit with only reduced homology (Rubin et al., 2000) as the CAG repeat is 
missing in these genes. This lack of endogenous genes excludes any knock-in or knock-out 
approaches and at first sight questions the chance of successful generation of transgenic 
models for these diseases as relevant binding partners for the affected proteins may also not 
be conserved. Interestingly, the sole overexpression of the Drosophila orthologue of ataxin-1 
(dAtx-1) induced a similar phenotype than the overexpression of human ataxin-1 (hATXN1) 
although dAtx-1 misses more than 60 % of hATXN1 amino acids including the polyQ repeat 
(Tsuda et al., 2005). Not even a polyQ expansion is required as a high level of hATXN1 with 
normal repeat length (30Q) caused neuronal degeneration (Fernandez-Funez et al., 2000). 
This data indicates that both Drosophila and human ataxin-1 are “intrinsically toxic at high 
levels” (Lu and Vogel, 2009). Likewise, the overexpression of dAtx2, the Drosophila 
orthologue of human ataxin-2, caused developmental defects and degeneration of tissues 
(Satterfield et al., 2002). As well the loss of dAtx2 had comparable effects, stressing the 
importance of maintaining normal ataxin-2 activity (Satterfield et al., 2002).  
Analyses using Drosophila connected pathogenic mechanisms in SCA1, SCA2, and SCA3 and 
identified ataxin-2 as a potential key player both in SCA1 and SCA3 (Al-Ramahi et al., 2007; 
Lessing and Bonini, 2008): In both cases, the overexpression of dAtx2 enhanced the 
neurodegeneration caused by ataxin-1 and ataxin-3, respectively, and downregulation of 
dAtx2 had the opposite effect. Comparable observations were made even for a non-polyQ 
disease, amyotrophic lateral sclerosis (ALS) (Bonini and Gitler, 2011). This influence of dAtx2 
seems to be linked to the conserved PAM2 motif (PABP-interacting motif 2) within ataxin-2 
which mediates the interaction of ataxin-2 with the Poly(A)-binding protein (PABP) (Lessing 
and Bonini, 2008) implicating ataxin-2 in the regulation of translation of specific mRNAs 
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polyQ repeat were first addressed using pure polyQ repeats which proved to be toxic in 
Drosophila in expanded, but not in normal lengths (Marsh et al., 2000). However, adding as 
few as 26 additional amino acids (such as addition of a myc and a FLAG tag) and even 
more, adding the surrounding amino acids of a full protein is able to even neutralize the 
toxic effect of expanded polyQ repeats (Marsh et al., 2000).  
Drosophila models were also used to assess the relevance of the intracellular localization of 
the affected protein: Ataxin-2 is normally a cytoplasmic protein and the occurrence of 
intranuclear aggregates in SCA2 patients is still controversial as both the presence and 
absence of nuclear aggregates have been described (Huynh et al., 2000; Koyano et al., 2000). 
However, the intracellular localization of dAtx2 strongly influences the phenotype in flies. 
While nuclear dAtx2 induces strong neurodegeneration, the phenotype of flies with 
cytoplasmic dAtx2 is much milder (Al-Ramahi et al., 2007).  
As SCA are neurodegenerative disorders, with ubiquitous expression of the disease causing 
gene in humans, glial cells are usually not the main focus of interest. However the choice of 
different driver lines allows for the analysis of glial vs. neuronal expression of the disease-
causing genes in Drosophila. Data suggest that the effect of glial expression of the transgene 
is more pronounced than of neuronal expression (Kretzschmar et al., 2005). 
Another strong advantage of Drosophila as a model organism is the suitability for large-scale 
screens for modifying factors. Such screens for ataxin-1, ataxin-3 or even pure polyQ repeats 
identified somehow expected proteins involved in protein folding (like chaperones) and 
protein degradation (components of the ubiquitin-proteasome system and autophagy) (Bilen 
and Bonini, 2007; Fernandez-Funez et al., 2000; Kazemi-Esfarjani and Benzer, 2000; Latouche et 
al., 2007). In addition, these screens gave insight into further mechanisms relevant for polyQ 
disease pathogenesis like cellular detoxification, protein transport, transcriptional regulation 
and RNA and miRNA processing (Bilen and Bonini, 2007; Bilen et al., 2006; Fernandez-Funez 
et al., 2000; Latouche et al., 2007). The identification of muscleblind (mbl) as a modifier of an 
SCA3 fly model drew attention to the role of CAG repeat RNA in the pathogenesis of SCA3 (Li 
et al., 2008) and led to the conclusion that not only the expanded polyQ repeat but also the 
RNA coding for it has an effect on the pathogenesis of polyQ diseases at least in Drosophila. 
Muscleblind is known to be involved in Myotonic dystrophy caused by aberrant RNA 
containing massive CUG expansions (Jiang et al., 2004). The expression of an untranslated 
CAG repeat caused neurodegeneration in Drosophila. This toxicity was mitigated just by the 
interruption of the pure CAG repeat by replacing it with a CAACAG repeat (Li et al., 2008). 
These results were in line with previous data for a non-polyQ SCA, SCA8, also caused by non-
coding RNA. Both a normal and an expanded CAG repeat led to neurodegeneration in a fly 
model of SCA8 (Mutsuddi et al., 2004). Interestingly, a screen for modifiers of this phenotype 
caused by non-coding RNA (containing expanded CAG repeats) pointed to several pathways 
which were also identified as modifiers of a phenotype caused by (translated RNA coding for) 
expanded polyQ repeats (Mutsuddi et al., 2004). Taken together, disease models in Drosophila 
facilitated both the identification and further analysis of multiple factors and mechanisms 
involved in the pathogenesis of SCA. 
3. Lessons learned from mammalian models of SCA 
In contrast to disease models in the worm or the fly, mouse models resemble pathogenic 
processes in humans much closer than their non-mammalian counterparts. For example the 
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brain structure of mice is much closer to that of humans than those of flies or worms and 
mechanisms of special importance for late-onset diseases like SCA, e.g. gene expression 
changes during aging (Bishop et al., 2010), are better conserved. In particular, mouse models 
allow analyzing aspects of the disease which cannot be analyzed in simpler organisms. 
Although behavioural analyses are possible in C. elegans and Drosophila models, they are 
rather basic compared to more sophisticated behavioural tests possible with mouse models 
which even allow for e.g. fear and spatial learning analyses (Huynh et al., 2009). 
3.1 Lessons learned from knock-out mouse models 
In mouse models, it is possible to selectively inactivate a specific gene-of-interest via gene 
targeting. There is a large amount of insight to be gained from generating such knock-out 
models and a lot of information has been uncovered about the functional roles of specific 
genes in mammalian biology (Capecchi, 2005). To learn about the native function of genes 
affected in SCA knock-out mice were generated for SCA1, 2 and 3. All mice were viable, 
fertile and had a normal lifespan with no severe ataxic phenotype or neurodegeneration 
(SCA1: Matilla et al., 1998; SCA2: Kiehl et al., 2006; Lastres-Becker et al., 2008; SCA3: Schmitt 
et al., 2007; Switonski et al., 2011), providing evidence that loss-of-function is not the 
primary cause for ataxic symptoms in these disorders. However, these mice served to give 
indications for normal functions of the respective knock-out genes. For ataxin-1, the gene 
affected in SCA1, a role in learning and memory was identified (Matilla et al., 1998) and its 
function as a transcriptional co-regulator was elucidated (Goold et al., 2007). Knocking out 
the ataxin-2 gene led to adult-onset obesity and reduced fertility (Kiehl et al., 2006; Lastres-
Becker et al., 2008a) as well as hyperactivity and abnormal fear-related behaviour (Huynh et 
al., 2009). In ataxin-3 knock-out mice increased levels of ubiquitinated proteins were 
detected reflecting its function as a deubiquitinating enzyme (Schmitt et al., 2007). However, 
in a second SCA3 knock-out model changes in the ubiquitination level were not observed. 
The authors suggested compensational effects as the cause for this opposing result 
(Switonski et al., 2011). Other analyses on SCA3 knock-out mice were able to show a 
protective function of ataxin-3 in the heat shock response pathway (Reina et al., 2010).  
In contrast to only mild effects observed with the deletion of genes responsible for polyQ 
products, the knock-out of genes affected in non-polyQ SCA resulted in severe ataxic 
phenotypes. The deletion of the Klhl1 gene which is mutated in SCA8 led to the loss of 
motor coordination due to degeneration of Purkinje cell function (He et al., 2006). The 
analysis of mice showing signs of a severe autosomal recessive movement disorder revealed 
a deletion in the inositol 1,4,5-triphosphate receptor (ITPR1 gene) as the cause of the 
observed symptoms. Knowing that the gene correlated to SCA15 in humans maps to the 
ITPR1 genomical region, it was possible to identify a deletion in this gene as the cause of this 
autosomal dominant disorder (van de Leemput et al., 2007).  
Taken together, the analyses of SCA knock-out mice demonstrated a toxic gain-of-function 
as the cause for SCA due to polyQ expansions, whereas for non-polyQ SCA loss-of-function 
seems to be the primary mechanism of pathogenesis.   
3.2 Lessons learned from classical transgenic mouse models for SCA 
Transgenic mouse models gave insight into various pathogenic mechanisms in SCA. Here, 
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degeneration, the aggregation and localization of the affected protein as well as 
transcriptional dysregulation caused by expanded polyQ proteins.  
3.2.1 Lessons learned about the cell-type specificity of neurodegeneration 
A classical transgenic mouse model is generated by using a specific promoter typically 
controlling the expression of a cDNA construct of the respective gene-of-interest. The effect 
of expressing different transgenes in a specific subgroup of neurons can be nicely compared 
among several proteins affected in SCA as the Purkinje-cell-specific promoter (Pcp2/L7 
promoter) (Vandaele et al., 1991) was used for the generation of transgenic mice for SCA1 
(Burright et al., 1995), SCA2 (Huynh et al., 2000), SCA3 (Ikeda et al., 1996), SCA7 (Yvert et 
al., 2000) and SCA17 (Chang et al., 2011), respectively. In the SCA1, SCA2 and SCA17 mouse 
models the expanded full-length transgene causes a strong degeneration of Purkinje cells 
(Burright et al., 1995; Chang et al., 2011; Huynh et al., 2000). By contrast, in the SCA7 mouse 
model, the sole expression of full-length ataxin-7 with 90 Q induced a behavioural 
phenotype, but only mild degeneration of Purkinje cells in quite old mice (Yvert et al., 2000). 
Ironically, the expression of full-length ataxin-7 (92 Q) in most neurons except for Purkinje 
cells (Garden et al., 2002; La Spada et al., 2001) or even just in Bergmann glia cells (Custer et 
al., 2006), led to a strong degeneration of Purkinje cells (Custer et al., 2006). Likewise, when 
a full-length ataxin-3 protein with 79 Q was expressed using the same promoter, no 
phenotype was induced. Only a fragment containing not more than a few amino acids 
surrounding the expanded polyQ repeat was able to induce a phenotype (Ikeda et al., 1996). 
These data demonstrate that Purkinje cells in transgenic mice seem to be more vulnerable by 
a repeat expansion within ataxin-1, ataxin-2 and ataxin-17, than by an expansion within 
ataxin-3 and ataxin-7, thereby –at first sight- nicely replicating the situation in humans where 
Purkinje cells are strongly affected in SCA1 (Cummings et al., 1999a), SCA2 (Lastres-Becker 
et al., 2008b) and SCA17 (Rolfs et al., 2003), but the loss of Purkinje cells can be observed but 
is not so prominent in SCA3 patients (Rüb et al., 2002a; Rüb et al., 2002b). In SCA7, however, 
Purkinje cells are typically affected (Holmberg et al., 1998), thereby possibly indicating that 
the pathogenic processes leading to Purkinje cell death in SCA7 differ from those in SCA1, 
SCA2 and SCA17. 
3.2.2 Lessons learned about the aggregation of polyQ proteins and their localization 
A common feature of polyQ as well as other neurodegenerative diseases is the accumulation 
of insoluble proteins in neurons, a feature recapitulated by most model systems of these 
disorders. Despite this fact the role of these so called neuronal nuclear inclusions (NIIs) in 
the pathological processes of polyQ diseases is still controversially discussed but it is known 
that these structures are associated with pathogenesis. Analysis of a C. elegans model of 
SCA3 directly linked the formation of aggregates to neuronal dysfunction (Teixeira-Castro 
et al., 2011), whereas several opposing results in mouse models exist. Observations in 
transgenic mouse models for SCA1, SCA2, SCA3 and SCA6 (Boy et al., 2010; Cummings et 
al., 1999b; Huynh et al., 2000; Klement et al., 1998; Silva-Fernandes et al., 2010; Watase et al., 
2008) reveal that the development of a pathological phenotype is independent of the 
formation of inclusions excluding large aggregates as a primary cause for neuronal 
dysfunction. Even more, evidence exists for a protective role of inclusion bodies (Bowman et 
al., 2005). Inclusions in human SCA patients and respective mouse models stain positive for 
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ubiquitin and other components of the ubiquitin-proteasome-system (UPS) (Bichelmeier et 
al., 2007; Cummings et al., 1998; Holmberg et al., 1998; Klement et al., 1998; Koyano et al., 
1999; Paulson et al., 1997; Schmidt et al., 2002; Watase et al., 2002; Yvert et al., 2000) pointing 
to an involvement of this protein degradation system in the clearance of proteins with 
expanded CAG repeats. In C. elegans it was observed that expanded polyQ tracts impair the 
functions of UPS (Khan et al., 2006). In brains of SCA3 patients a marked misdistribution of 
proteasomal subunits was detected leaving only a subpopulation of neurons with the 
possibility to form functional proteasome complexes (Schmidt et al., 2002). Comparable 
results were obtained for SCA1 patients and transgenic mice (Cummings et al., 1998) and 
further studies revealed that an impairment or altered function of the ubiquitin and the 
proteasomal degradation system could contribute to the SCA1 pathogenesis (Cummings et 
al., 1999b; Hong et al., 2002). Data gained using a knock-in model, though, excluded an 
impairment of the ubiquitin-proteasome-system as a major neuropathological cause of SCA7 
(Bowman et al., 2005). 
The mechanism which leads to the formation of aggregates is not well understood. It has 
been proposed that proteolytic cleavage of polyQ-containing proteins is required for 
aggregate formation, because polyQ-containing fragments are predominantly found in NIIs. 
Another indication for the cleavage hypotheses is the detection of protein fragments in 
brains of mouse models for SCA3 (Goti et al., 2004), SCA7 (Garden et al., 2002) and SCA17 
(Friedman et al., 2008) as well as human SCA patients (Garden et al., 2002; Goti et al., 2004). 
As possible protein cleavage enzymes, caspases or calpains are under controversial 
discussion. For ataxin-3, calpain (Haacke et al., 2007; Koch et al., 2011) and caspase cleavage 
was analyzed in vitro (Berke et al., 2004; Pozzi et al., 2008). It was shown that a C-terminal 
fragment of ataxin-3 containing the polyQ stretch leads to a more progressive phenotype 
(Ikeda et al., 1996), but also an N-terminal fragment without the CAG repeats can cause 
SCA3 symptoms (Hübener et al., 2011). In addition, mice expressing a fragment of the 
TATA-binding protein (affected in SCA17) exhibit a more severe phenotype (Friedman et 
al., 2008) than those expressing a full-length protein (Friedman et al., 2007). These studies 
suggest that cleavage of the affected protein is important for the pathogeneses of polyQ 
SCA. Although neuronal nuclear inclusions (NIIs) are a common feature of polyQ diseases, 
in some SCA the affected protein is normally localized in the cytoplasm. For this reason, the 
question arose whether the intracellular localization of the affected protein is of relevance 
for the pathogenesis of SCA. For an polyQ expansion within an ectopic protein context 
(Jackson et al., 2003), for ataxin-1 (Klement et al., 1998) and for ataxin-3 (Bichelmeier et al., 
2007) it was demonstrated that the nuclear localization of the affected protein is a 
requirement for the manifestation of symptoms. Mice in which the respective protein was 
kept in the cytoplasm typically had less and smaller aggregates and milder or even almost 
no behavioural phenotype. For SCA1, Emamian et al. (2003) even went one step further 
demonstrating that although the nuclear localization of ataxin-1 is required, it is not 
sufficient to induce a phenotype. A serine residue close to the endogenous NLS within 
ataxin-1 (S776) was required additionally for the induction of a phenotype (Emamian et al., 
2003). 
3.2.3 Lessons learned about transcription dysregulation 
Transcriptional dysregulation is a common feature of most polyQ diseases, but the 
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3.2.3 Lessons learned about transcription dysregulation 
Transcriptional dysregulation is a common feature of most polyQ diseases, but the 





proteins affected in polyQ diseases are functioning as transcription factors/cofactors or at 
least interact with transcription factors: TBP (SCA17) is a general transcription factor, ataxin-
7 is a part of a transcriptional co-activator complex and both ataxin-1 and ataxin-3 interact 
with various transcription factors (Helmlinger et al., 2006). 
Especially for SCA1, the molecular basis of transcriptional dysregulation and therefore its 
influence on the pathogenesis is thoroughly studied. Transcriptional dysregulation 
mediated by ataxin-1 has been attributed to the interaction with the polyQ binding protein 1 
(PQBP1). This interaction interferes with the cellular RNA polymerase-dependent 
transcription (Okazawa et al., 2002). Microarray analyses of SCA1 knock-in and knock-out 
mice revealed differential expression of proteins involved in calcium signaling (Crespo-
Barreto et al., 2010). In SCA3 and SCA7, components of the NIIs are transcriptionally 
dysregulated, including subunits of the proteasome and heat shock proteins (Chou et al., 
2010; Chou et al., 2008). Several other transcription factors such as CREB (cAMP response 
element binding protein) and HDAC proteins and therefore histone deacetylation is often 
differential regulated in polyQ diseases (McCampbell et al., 2000; McCullough and Grant, 
2010). For this reason, treatment studies using HDAC inhibitors such as sodium butyrate 
were performed (Chou et al., 2011; McCampbell et al., 2001). In several studies, 
transcriptional dysregulation is associated with the degeneration of specific neurons: for 
SCA17, a downregulation of TrkA (nerve growth factor receptor) is linked to Purkinje cell 
degeneration (Shah et al., 2009), or for SCA1 an interaction of ataxin-1 and PQBP1 and 
therefore transcriptional dysregulation leads to selective neuronal loss in the cerebellum 
(Okazawa et al., 2002). 
3.3 Lessons learned from YAC, BAC and knock-In mouse models 
In the process of generating classical transgenic mice it is only possible to insert cDNA 
randomly into the animal genome, not allowing for controlling the expression of the 
pathogenic gene in the native genetic environment at endogenous levels or excluding 
alternative splicing events. Therefore, different techniques have been developed to 
overcome these limitations and to generate models which more closely resemble human 
disease conditions. One strategy was the use of a yeast artificial chromosome (YAC) 
containing a large fragment of the human MJD1 locus for the generation of a model for 
SCA3 thus enabling the expression of a full-length ataxin-3 gene with the endogenous 
regulatory elements needed for cell specificity and endogenous levels of expression (Cemal 
et al., 2002). Mice with expanded CAG tracts showed mild and slowly progressing cerebellar 
symptoms with nuclear inclusions and cell loss in specific brain regions closely resembling 
main features of the SCA3 disease in humans (Cemal et al., 2002). A likewise approach was 
used to generate a model for SCA8. Moseley et al. (2006) used a bacterial artificial 
chromosome (BAC) to control the expression of the SCA8 locus encoding a non-expressed 
transgene. If they would have used just a classical transgenic construct without 116 kb of 
flanking sequences they may not have observed that the construct is indeed expressed in 
both directions encoding both a non-translated RNA containing a CTG expansion as well as 
a polyQ containing protein expressed from the opposite strand (Moseley et al., 2006). 
A different more widely used strategy in the generation of SCA mouse models is to take 
advantage of homologous recombination techniques leading to knock-in models. This 
allows for endogenous levels of expression in proper spatio-temporal patterns (Yoo et al., 
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2003). The first knock-in model generated for SCA1 targeted an expanded CAG tract of 78 
repeats to the endogenous ataxin-1 mouse locus. These mice reflected genetic repeat 
instability observed in human SCA1 patients, but showed only mild behavioural changes in 
late life with no clear neuropathological changes (Lorenzetti et al., 2000). From this first 
attempt the conclusion was drawn that the short lifespan of mice seems to be a limiting 
factor and that the longer exposure of the mutant protein in humans might be necessary for 
the development of neuronal dysfunctions. This drawback can be overcome by either 
overexpression of mutant proteins or by the use of extremely long CAG tracts to produce 
neurodegeneration (Yoo et al., 2003; Zoghbi and Botas, 2002). Therefore, in the next knock-in 
model for SCA1, more CAG repeats (154 repeats) were used and this model then indeed 
resembled main features of the human SCA1 disease (Watase et al., 2002). Analyzing these 
mice it was also shown that there is no direct relationship between the degree of somatic 
instability and the selective neuronal toxicity (Watase et al., 2003), but that the selective 
neuropathology rather arises from alterations in the function of the ataxin-1 protein 
(Bowman et al., 2007). Furthermore, these mice served to demonstrate that a partial loss-of-
function contributes to the SCA1 pathogenesis (Bowman et al., 2007; Crespo-Barreto et al., 
2010; Lim et al., 2008). SCA6 knock-in mice with up to 84 (hyperexpanded) CAG repeats in 
the CACNA1A gene (encoding for a calcium channel subunit) gave evidence against the 
assumption that the SCA6 pathogenesis is caused by alterations of channel properties and 
rather indicated that it is due to the accumulation of mutant calcium channels (Saegusa et 
al., 2007; Watase et al., 2008). In infantile cases of SCA7 expansions of 200-460 CAG repeats 
were documented (Benton et al., 1998; van de Warrenburg et al., 2001) and knock-in mice 
with 266 CAG repeats indeed reproduced hallmark features of the infantile disease (Yoo et 
al., 2003). Using this knock-in model it was shown that polyQ nuclear inclusions seem to 
have a protective role against neuronal dysfunction, that an impairment of the ubiquitin-
proteasome-system can be excluded as a major neuropathological cause (Bowman et al., 
2005) and that SUMOylation influences the aggregation process of ataxin-7 (Janer et al., 
2010). A most recent publication reported on the attempt to generate the first knock-in 
mouse model of SCA3, but due to unexpected splicing events ended up creating another 
SCA3 knock-out model (Switonski et al., 2011) showing some of the difficulties which may 
occur generating animal models.  
3.4 Lessons learned from an alternative strategy to generate mouse models 
An alternative approach for the generation of animal models is the use of viral injections. By 
using lentiviral vectors it was possible to overexpress wildtype or polyQ expanded ataxin-3 
in brain regions of adult wildtype rats. An expression of polyQ-expanded ataxin-3 in the 
substantia nigra, an area affected in SCA3, led to the formation of ubiquitinated ataxin-3 
positive aggregates, loss of dopaminergic markers and an apomorphine-induced turning 
behaviour. If polyQ expanded ataxin-3 is overexpressed in the striatum or cortex, regions 
previously not linked to SCA3 pathogenesis, by the lentiviral-based system it results in 
accumulation of misfolded ataxin-3 and loss of neuronal markers especially in the striatum 
(Alves et al., 2008b). Using the lentiviral vector system it is also possible to co-express 
ataxin-3 with knock-down vectors or other proteins and to analyze direct effects in specific 
brain regions. For example a co-expression of expanded ataxin-3 with beclin, an autophagic 
protein, led to stimulation of autophagic flux, clearance of mutant ataxin-3 and 
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3.5 Treatment approaches using mouse models 
At the moment, curative treatment for SCA is not possible. Only treatments directed 
towards alleviating symptoms are available (Duenas et al., 2006).  Therefore, one or the most 
important goal in the research of SCA is the development of a cure.  
The basic question of whether any treatment -if available- would be able to even reverse 
symptoms already manifested was addressed using conditional mouse models. With these 
models which allow to turn off the pathogenic trangene expression using the Tet-off system 
it was possible to demonstrate that already developed symptoms of SCA1 and SCA3 indeed 
can be reversed (Boy et al., 2009; Zu et al., 2004). Inhibiting or reducing the production of 
pathogenic proteins could therefore be a powerful tool in the therapy of dominant 
neurodegenerative diseases. Using the RNA interference (RNAi) technology (Mello and 
Conte, 2004) to inhibit the expression of mutant ataxin-1 in a mouse model of SCA1 led to 
improved motor coordination, restored cerebellar morphology as well as resolved ataxin-1 
inclusions demonstrating the in vivo potential of this strategy (Xia et al., 2004). RNAi 
knockdown was also successfully used for a selective allele-specific silencing of mutant 
ataxin-3 showing to mitigate neuropathological abnormalities in a lentiviral-mediated 
model of SCA3 (Alves et al., 2008a; Alves et al., 2010) and may be a possible treatment 
approach. As protein misfolding and impaired protein degradation is implicated in the 
pathogenesis of polyQ SCA and other related diseases that present with intracellular 
inclusion bodies, supporting the correction of these alterations might be a therapeutic 
strategy. In this manner it was possible to show that crossbreeding of SCA1 transgenic mice 
with mice overexpressing a molecular chaperone leads to the mitigation of the SCA1 
phenotype (Cummings et al., 2001). 
In addition to genetic approaches, some of the published mouse models have already been 
used to test the effect of different compounds on the movement phenotype, neuronal loss 
and aggregate formation: Lithium carbonate enhanced the motor performances and 
improved spatial learning, but had neither an effect on the distribution and formation of 
aggregates nor did it improve the lifespan of the SCA1 knock-in mice (Watase et al., 2007). A 
treatment approach using lithium chloride in a C. elegans model for Huntington’s disease, 
however, was beneficial (Voisine et al., 2007). A dietary supplementation with creatine 
improved survival and motor performance and delays neuronal atrophy in the R6/2 
transgenic mouse model of Huntington's disease. In a SCA2 transgenic mouse model, 
however, creatine extended the Purkinje cell survival, but was not able to improve or delay 
ataxic symptoms (Kaemmerer et al., 2001). Two promising studies were performed using 
transgenic models for SCA3: The HDAC inhibitor sodium butyrate (SB) delayed the onset of 
ataxic symptoms and improved the survival rate by reversing polyQ induced histone 
hypoacetylation and transcriptional repression (Chou et al., 2011). In addition, a rapamycin 
ester (also called temsirolimus or CCI-779) which inhibits the mammalian target of 
rapamycin and upregulates the protein degradation by autophagy, reduced the number of 
aggregates and improved the motor performance (Menzies et al., 2010). In a study using a 
SCA2 mouse model, the Ca2+ stabilizer dantrolene was able both to alleviate motor 
symptoms and to reduce the loss of Purkinje cells in this model (Liu et al., 2009). Another 
group used a specific mouse model, the so called rolling mouse Nagoya, which has been 
suggested as an animal model for some human neurological diseases such as autosomal 
dominant cerebellar ataxia (SCA6). This model was treated with talrelin, a synthetic 
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analogue of the thyrotropin-releasing hormone (TRH) which alters the metabolism of 
acetylcholine and dopamine and therefore activates the dopaminergic system. Talrelin 
significantly elevated the cerebellar dopamine and serotonin levels of mice and improved 
the locomotion phenotype (Nakamura et al., 2005).  
Other therapeutical attempts are based on the functional restoration of affected cell 
populations. Expanded ataxin-1 causes the degeneration of Purkinje cells thereby also 
negatively effects the synthesis of the insulin-like growth factor–I (IGF-I) a factor promoting 
Purkinje cell development (Fukudome et al., 2003). Administering this factor to SCA1 
transgenic mice (SCA1[82Q]) intranasally led to significant improvement of motor 
coordinative abilities as well as to partial restoration of Purkinje cell survival (Vig et al., 
2006). Using the same SCA1 transgenic model, improved motor skills and a higher Purkinje 
cell survival rate was reached after grafting neural precursor cells into the cerebellar white 
matter (Chintawar et al., 2009). Although there is a long way from successful treatment 
approaches in animal models to clinical application, the recent results give hope that 
treatment of SCA will be possible in the future. 
4. Commons and differences between SCA models in worms, flies and mice 
It is self-evident that the data acquired in different model organisms especially those 
obtained in non-vertebrate compared with those from vertebrate models cannot be identical. 
However, if results obtained in a specific model are to be translated to the situation in 
humans one would expect that basic mechanisms in the pathogenesis of SCA are conserved 
among species. Previous studies revealed that many pathogenic mechanisms are indeed 
comparable among species, however, also indicated that there are some differences between 
model organisms (Table 2). Orthologues of ataxin-2 can be found all the way down to 
simple organisms and even in yeast (Table 1). However, the knock-out of ataxin-2 gave rise 
to contradictory results among model organisms: The knock-out of the endogenous SCA2 
gene in the worm and the fly is embryonic lethal. In contrast to that, SCA2 knock-out mice 
are viable and showed no developmental defects. Further analyses of SCA2 knock-out 
worms demonstrated that ataxin-2 is functioning during development, since the knockdown 
by RNAi results in developmental arrest. 
These results indicate that the function of homologous proteins as well as the interaction of 
different proteins in special pathways is not conserved in the species analyzed (Kiehl et al., 
2006; Kiehl et al., 2000; Lastres-Becker et al., 2008a; Satterfield et al., 2002). Since in C. elegans 
the polyQ repeats in all orthologous genes are not conserved, one could assume that much 
shorter repeat expansions than e.g. in the mouse may already give rise to a phenotype. 
However, the exact opposite seems to be true: Within the full-length context of a protein, 
much higher polyQ repeat numbers are required to be toxic (Khan et al., 2006; Teixeira-
Castro et al., 2011). Proteins with polyQ repeats are frequent in Drosophila (Alba et al., 2007), 
but these repeats are generally encoded by interrupted rather than pure CAG repeats and, 
therefore, more resistant to expansion (Alba et al., 2001). This could lead to the assumption 
that pure CAG repeats may behave unstable in Drosophila as observed in human SCA 
patients and mouse models (Boy et al., 2010; Kaytor et al., 1997; Lorenzetti et al., 2000).  
However, CAG repeats seem to be perfectly stable in Drosophila even within a challenging 
genomic context (Jackson et al., 2005) pointing to a specific protection mechanism against 
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 Caenorhabditis elegans 
Drosophila 
melanogaster Mus musculus 
knock-out SCA2: lethal (1) SCA3: viable (2) SCA2: lethal (3) SCA1/2/3/8: viable (4-9) 
overexpression of pure polyQ causes 
phenotype yes (10; 11) yes (12) yes (13; 14) 
truncated protein requires less  
repeats to induce phenotype yes (15) yes (16) yes (13) 
full-length protein causes phenotype yes (≥ 130 Q) (15; 17) 
wt: no or mild 
exp: strong  
(3; 18-22) 
wt: no 
exp: mild to strong 
(23-26) 
instability of repeats  no (27) SCA1/3: yes (28-30) SCA2: no (24) 
repeat numbers causing phenotype ≥ 130 Q (15; 17) ≥30 Q (18) ≥ 30 Q (18; 24; 26) 
increasing repeat length intensifies 
phenotype yes (15; 17) yes (3; 18-22) yes (23-26) 
formation of aggregates yes (15; 17) yes (31) 
yes (33; 25) 
no (24; 32) 
late (30; 34) 
neurodegeneration/ neuronal loss  yes (18; 19; 35) 
wt: no 
exp: mild to strong 
(13; 23; 24; 36) 
switching-off led to reversal  
of symptom  yes (31) yes (30; 37) 
transgene leads to reduced lifespan yes (17) yes (31) yes (25) 
References: (1) Kiehl et al., 2000; (2) Rodrigues et al., 2007; (3) Satterfield et al., 2002; (4) Matilla et al., 
1998; (5) Kiehl et al., 2006; (6) Lastres-Becker et al., 2008a; (7) Schmitt et al., 2007 ; (8) Switonski et al., 
2011; (9) He et al., 2006; (10) Brignull et al., 2006a ; (11) Morley et al., 2002; (12) Marsh et al., 2000; (13) 
Ikeda et al., 1996; (14) Ordway et al., 1997; (15) Khan et al., 2006;  (16) Lu and Vogel, 2009; (17) Teixeira-
Castro et al., 2011); (18) Fernandez-Funez et al., 2000; (19) Al-Ramahi et al., 2007; (20) Warrick et al., 
1998; (21) Warrick et al., 2005; (22) Moseley et al., 2006; (23) Burright et al., 1995; (24) Huynh et al., 2000; 
(25) Bichelmeier et al., 2007; (26) Friedman et al., 2007; (27) Jackson et al., 2005; (28) Kaytor et al., 1997; 
(29) Lorenzetti et al., 2000; (30) Boy et al., 2009; (31) Latouche et al., 2007; (32) Silva-Fernandes et al., 
2010; (33) Cummings et al., 1999b ; (34) Watase et al., 2008; (35) Lessing and Bonini, 2008; (36) Aguiar et 
al., 2006; (37) Zu et al., 2004  
Table 2. Exemplary phenotypical features of human SCA patients compared among model 
organisms. For clearness, only examples for the respective phenotypic features are listed. 
The table is not intended to be exhaustive. (wt, normal repeat; exp, expanded repeat). 
5. Conclusion 
Multiple successful attempts generating transgenic animal models for SCA were performed 
in different species. While each model organism has its own advantages and disadvantages, 
all animal models contributed to the knowledge about the pathogenesis of SCA. The 
transparency of C.elegans together with the simplicity to generate transgenic models as well 
as the option to study neurodegeneration even macroscopically by targeting the gene of 
interest to the Drosophila eye make smaller organisms like the worm or the fly especially 
suitable for the screening of compounds or genetic modifiers. Since many pathologic 
mechanisms in SCA are conserved in these models, there is a high probability that results 
obtained in worms and flies can be translated to mammals. Although unsuitable for large-
 
Model Systems for Spinocerebellar Ataxias: Lessons Learned About the Pathogenesis 
 
15 
scale (genetic and compound) screening approaches, mouse models are the ideal tools for 
verification of screening results in mammals. Viral injections now even allow a 
comparatively rapid analysis without the need of breeding or even generating transgenic 
mice. Especially to answer questions which require brain structures closer to humans or for 
analyses of ataxic movement or even emotional phenotypes, mammalian models are 
required. Taken together, model organisms are indispensable tools for the analysis of 
pathogenic mechanisms important for SCA in vivo. 
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Monogenic disorders of Mendelian nature, defined as those resulting of mutation at a single 
locus, and in which the observed alteration is both necessary and sufficient for phenotypic 
manifestation (Gropman & Adams, 2007), constituted, until recently, the main target of 
gene-finding studies. Mendelian or otherwise “simple” phenotypes are frequently referred 
in the scientific literature in opposition to the “complex” ones; the designation of 
“Mendelian”, therefore, should reflect the occurrence of such diseases in accordance with 
simple, predictable family patterns, with a single locus determining its manifestation. It has, 
however, become very evident that even in the case of individual causative genes, the 
associated phenotypes can display attributes which result in non-Mendelian patterns of the 
trait or disease whose expression is being considered (Gropman & Adams, 2007; Sherman, 
1997). In practical terms, this implies that the number of diseases for which the respective 
phenotypes can be explained by the effect of mutations at a single locus is dramatically 
diminishing (Gropman & Adams, 2007). Several diseases, initially characterized as 
monogenic, are now known to be modulated by a yet undetermined number of loci. 
Incomplete genotype-phenotype correlations observed in a large number of diseases have, 
therefore, forced the widening of the monogenic model, to allow the accommodation of the 
remaining factors, which can potentially explain the spectrum of the phenotypic variability 
(Badano & Katsanis, 2002). The incompleteness of the genotype-phenotype correlations seen 
in such situations confirms that the product of the primary mutation is imbedded in a highly 
complex system, in which polymorphic variation, mutations at other loci as well as 
environmental variables modulate the differences observed amongst individuals (Van 
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Factors that produce atypical or irregular patterns of inheritance are frequently referred as 
“complicating factors”. The understanding of the mechanisms on the basis of such patterns 
is pertinent not only at a theoretical level, but also due to implications in terms of diagnosis 
and genetic risk assessment, conditioning, furthermore, the ability to predict the initiation 
and course of  disease (Haines & Pericak-Vance, 2006; Van Heyningen & Yeyati, 2004). On 
the other hand, in the context of research related with the identification of deleterious genes, 
such irregularities can  imply, amongst other aspects, severe obstacles in the interpretation 
of pedigrees, as well as difficulties in the selection of families (e.g., in the context of  linkage 
studies). Several of such complicating factors are frequently cited, namely clinical 
variability, expressivity, pleiotropism, anticipation, incomplete penetrance, age-dependent 
penetrance and meiotic drive. Underlying these observations are mechanisms such as allelic 
and locus heterogeneity, presence of modifier genes, intergenerational instability, somatic 
instability, genomic imprinting and de novo mutations (Gilchrist et al., 2000). 
Amongst the several diseases with a known causative mutation but which, nevertheless, 
display complicating features are those associated with triplet repeat expansions. Four 
classes of triplet repeat disorders are usually considered, based on the location of the repeat 
motif in 5´or 3´untranslated regions, in introns or in coding regions (revised in Bettencourt 
et al., 2007). Polyglutamine (Poly-Q) disorders are part of this “expansion disorders” group, 
being caused by a CAG repeat expansion in the coding region of the respective causative 
genes; enclosed within this group are several spinocerebellar ataxias (SCAs), namely SCA1, 
SCA2, SCA3, SCA6, SCA7, SCA17 as well as dentato-rubro-pallido-luysian atrophy 
(DRPLA). Poly-Q diseases exhibit atypical features, difficult to integrate in the classic 
mendelian expectations (Tsuji, 1997). Machado-Joseph disease (MJD/SCA3) is considered 
the most frequent SCA worldwide (Cagnoli et al., 2006; Paulson, 2007; Schöls et al., 2004); 
using MJD as a paradigm, this review aims to explore complicating, non-Mendelian aspects 
of Poly-Q SCAs, from a perspective that synthesizes the current knowledge concerning such 
complicating factors as well as their implications at several levels, namely at the level of 
genetic counseling (GC).  
2. Machado-Joseph disease: general perspective 
Machado-Joseph disease, also known as spinocerebellar ataxia type 3 (MJD/SCA3 - MIM 
109150) is an autosomal dominant neurodegenerative disorder. Described as a disorder of 
adulthood, with an average age at onset rounding 40 years (Coutinho, 1992), this disease 
has, nevertheless, reported onset extremes of 4 (Carvalho et al., 2008) and 70 years 
(Coutinho, 1992). Average survival time is of 21 years (Coutinho, 1992; Kieling et al., 2007). 
MJD is characterized by a complex and pleiotropic phenotype, involving the cerebellar, 
oculomotor, pyramidal, extra-pyramidal and peripheral systems. The high clinical 
variability observed in this disorder has led to its systematization into three clinical types, 
which can occasionally be present in a single family (Coutinho & Andrade, 1978). 
MJD was originally described in North American patients of Azorean ancestry, residing in 
the United States (Nakano et al., 1972; Rosenberg et al., 1976; Woods & Schaumburg, 1972). 
The history of its initial description, as three distinct clinical entities, clearly reflects the high 
phenotypic variability that characterizes this disorder, whose unification was dependent of 
the identification, in a single family, of the different clinical forms that were described in the 
original reports (Coutinho & Andrade, 1978). The common ancestry of the three families 
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that were described between 1972 and 1976 (known as Machado, Thomas and Joseph), has 
largely conditioned the interpretations about the origin of the disease, initially considered as 
Azorean, and designated as “Azorean disease of the nervous system” (Romanul et al., 1977). 
The molecular screening of MJD’s causative mutation allowed, afterwards, the differential 
diagnosis, which has led to an epidemiological profile clearly distinct from the one obtained 
on the basis of clinical criteria alone (Lopes-Cendes et al., 1996). In Portugal, MJD represents 
about 58% of the families with dominant ataxias (Vale et al., 2009). In the Azores, more 
precisely in the small island of Flores, the disease achieves the highest values of prevalence 
reported worldwide (Bettencourt et al., 2008a; Lima et al., 1997).  
Two main studies have addressed the issue of the worldwide origin of the MJD mutation. 
Gaspar et al. (2001), using flanking and intragenic markers, have identified two main 
haplotypes in 94% of the families studied. In the Azores, these two haplotypes were present, 
and were related with the islands of higher prevalence (Flores and São Miguel), indicating 
that two mutational events were responsible for the presence of MJD in the families of 
Azorean origin, a result previously disclosed by genealogical analysis (Lima et al., 1998). 
Aiming to determine the origin, age and dispersion of these two main mutational events, 
Martins et al. (2007) have conducted a more extensive haplotype analysis, which revealed 
that the TTACAC lineage, the most frequently found in the expanded alleles of patients 
from all over the world, achieved its highest variability in Asia (specifically in the Japanese 
population). A “Short Tandem Repeat” (STR) based haplotype was identified in this 
population and an approximate age of 5774±1116 years was suggested. 
The MJD locus was mapped to 14q24.3-q32 in 1993 (Takiyama et al., 1993). In the following 
year, Kawaguchi and colleagues (Kawaguchi et al., 1994) isolated and characterized a cDNA 
clone, designated as MJD1a, identifying MJD’s causative mutation as an expansion of a CAG 
motif in the coding region of the ATXN3 gene. Initially described as containing 11 exons, 
ATXN3 spans a genomic region of around 48 kb, with the CAG tract located in exon 10, at 5’ 
(Ichikawa et al., 2001). Two novel exons were identified recently, in a study that used 
information from cDNA clones of Azorean MJD patients and controls (Bettencourt et al., 
2010a). In the MJD locus, normal chromosomes have from 12 to 44 CAG repeats, whereas in 
patients, usually heterozygous, the number of repeats in the mutated allele consensually 
ranges between 61 and 87 (Maciel et al., 2001). Intermediate alleles are rare and, as a result, 
their behavior is poorly understood. For example, in a family described by Maciel and 
colleagues (Maciel et al., 2001), an allele with 51 repeats apparently was not associated with 
the disease. On the other hand, alleles of intermediate size have been associated with the 
MJD phenotype (e.g., Padiath et al., 2005; Van Alfen et al., 2001); in the study of Van Alfen et 
al. (2001), four symptomatic family members presented CAG tract sizes between 53 and 54 
repeats. Although rare, the cases of intermediate alleles imply that the distinction, initially 
very clear, between normal and mutated alleles has become much more difficult to establish. 
Alleles with around 50 repeats seem, in certain cases, to act as fully penetrant, a scenario 
that remains, nevertheless, rare (Paulson, 2007). In Portugal, and despite the high prevalence 
of the disease, a study of nearly 2000 chromosomes from the general population, 
representing all Portuguese districts, failed to detect the presence of intermediate alleles 
(Lima et al., 2005). Normal and pathogenic repeat size ranges are not definitive, and 
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The ATXN3 gene is ubiquously expressed in neuronal and non-neuronal tissues; it encodes 
for ataxin-3, a protein with an approximate molecular weight of 42kD, in its native form. In 
the neurons, ataxin-3 is found essentially in the cytoplasm (Paulson et al., 1997). Five 
products of the ATXN3 gene, referring to transcripts of different sizes, were described by 
Ichikawa and colleagues (Ichikawa et al., 2001). More recently, the sequence of 56 distinct 
transcripts, generated by alternative splicing, was described, and the high transcriptional 
variability of MJD’s causative gene has been demonstrated (Bettencourt et al., 2010a). 
Ataxin-3 belongs to the family of cysteine-proteases; structurally it is composed by 339 aa, to 
which a variable number of glutamines is added (Poly-Q tract) (Kawaguchi et al., 1994). This 
protein is composed by a Josephine domain (JD), located in its N-terminal portion, 
containing, at its C-terminal, two or three ubiquitin-interacting motifs (UIMs) and the Poly-
Q tract. It has been proposed that the native form of the protein acts as a deubiquitinating 
enzyme in the ubiquitin-proteossome pathway (revised in Bettencourt & Lima, 2011). 
Therefore, evidence concerning the proprieties of ataxin-3 suggests that this protein 
participates in cellular pathways related to quality control of proteins (see, amongst others, 
Schmitt et al., 2007). The involvement of the normal form of the protein in the regulation of 
transcription has also been suggested (Chou et al., 2008). 
In the MJD locus, the presence of an expanded allele leads to a protein enriched in 
glutamines. The Poly-Q tract expansion should lead to a gain of neurotoxic function of the 
corresponding protein and, as a consequence, to neuronal death, by a process which 
remains, nevertheless, incompletely understood. Models of pathogenesis include the 
formation of toxic oligomers of ataxin-3, as well as aberrant protein-protein interactions, 
which disrupt normal cellular functions; revisions on the aspects of MJD’s pathogenesis can 
be found, amongst others, in Paulson (2007) and Katsuno et al. (2008).  
Notwithstanding the fact that MJD constitutes a relatively well defined clinical entity, its 
clinical diagnosis can, in many situations, be difficult to establish. Such is the case, when the 
disease is at its initial stage and minor, but more specific signs are absent. Moreover, in 
apparently isolated cases, or in cases that appear associated to a less common geographic 
distribution, a clinical diagnosis can also be hard to establish with certainty (Lopes-Cendes 
et al., 1996). Therefore, in the differential diagnosis of MJD, molecular testing, available after 
the identification of the causative mutation, has become of major importance (Maciel et al., 
2001). Furthermore, predictive testing (PT), as well as prenatal diagnosis (PND) became 
available (Sequeiros et al., 1998). More recently, pre-implantation genetic diagnosis (PGD) is 
also feasible (Drüsedau et al., 2004). The program of PT and GC, available for MJD in 
Portugal since the end of 1995, was based on the previous experience with Huntington’s 
disease (HD) (Sequeiros, 1996). This program is ongoing in the Azores since 1996, and its 
impact in patients and families is periodically revised (Gonzalez et al., 2004; Lima et al., 
2001). 
Presently there is no effective pharmacological approach for SCAs. Specific drugs have been 
prescribed to minimize some of the symptoms, such as ataxia or dystonia (reviewed in 
Bettencourt & Lima, 2011). Cell and animal models have also been fundamental in the 
understanding of the pathogenesis and gene therapy search (e.g., Gould, 2005);  the use of 
interference RNA and the administration of antisense oligonucleotides showed promising 
results according to Alves et al. (2008;  2010) and Hu et al. (2009), respectively. 
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3. Complicating factors in MJD 
Several aspects of non-compliance with the Mendelian expectations can be readily 
recognized for MJD. Variation in the age at onset, variability in clinical presentation, 
presence of anticipation as well as repeat instability (somatic and germ line), have been 
described as the main complicating factors in MJD (Tsuji, 1997). Other factors, which will be 
referred, are also noteworthy. 
3.1 Clinical variability  
As previously referred, MJD is characterized by a complex phenotype, which is highly 
variable amongst patients. The recognition of its high degree of clinical variability has led to 
the proposal of Coutinho & Andrade (1978), in which patients could be classified into three 
clinical types. According to Coutinho (1992), type 1 has an early onset (average of 24 years) 
and a more rapid progression of symptoms, being characterized by pyramidal signs and 
dystonia. Type 2 is the most frequent, and occurs around 40 years of age, being dominated 
by ataxia and ophtalmoplegia, with or without pyramidal signs. Type 3 has a latter onset 
(average of 47 years) and progresses slowly, with amyothrophies. The three clinical types 
can, occasionally, be present in the same family. A fourth type, a rare presentation that 
associates parkinsonism to cerebellar signs (Suite et al., 1986), and a fifth type, associated 
with spastic paraplegia (Sakai & Kawakami, 1996), have also been proposed. 
Notwithstanding the fact that some clinical features, if present, can help in the differential 
diagnosis of MJD (e.g., ophthalmoplegia, bulging eyes or face and tongue fasciculations), 
phenotypic overlapping with other SCAs has implications for GC and PT. Therefore, at-risk 
individuals entering the PT program must have an affected close relative with a definitive 
molecular diagnosis - “mutation-positive” familial control (Sequeiros et al., 2010). 
Variation in age at onset, evidenced by its reported extremes (4 and 70 years) described by 
Carvalho et al. (2008) and Coutinho (1992), constitutes a particular aspect of the clinical 
variability of this disorder. A significant, but partial, negative correlation between the size of 
the expanded allele (and thus, the extension of the Poly-Q tract) and the age of appearance 
of symptoms explains between nearly 50 to 75% of the variation in the age at onset, 
depending on the analyzed series of patients (e.g., Maciel et al., 1995; Maruyama et al., 1995). 
The size of the mutated allele also correlates  with the frequency of particular clinical signs, 
such as pyramidal signs, which are more frequent in patients with larger repeats (Takiyama 
et al., 1995). In the Azorean series of patients, for example, the number of CAG repeats, 
determined in genomic DNA and in mRNA, explains 68% and 67% of variation in the age at 
onset, respectively (Bettencourt et al., 2010b).  The incompleteness of the correlation 
observed between the size of the CAG tract and the age at onset implies that such 
information cannot be used for counseling purposes; whether allele sizes should be 
disclosed in the molecular test report is still being debated (Sequeiros et al., 2010).  
The reported incompleteness of the genotype-phenotype correlation, observed in MJD as 
well as in other SCAs, confirms the involvement of non-CAG factors in the explanation of 
the phenotype, that can either be genetic or environmental (van de Warrenburg et al., 
2005). For MJD, the hypothesis that an important fraction of the residual of the disease 
onset (after accounting for the CAG repeat size) is of genetic nature has been reinforced 
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3. Complicating factors in MJD 
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Variation in age at onset, evidenced by its reported extremes (4 and 70 years) described by 
Carvalho et al. (2008) and Coutinho (1992), constitutes a particular aspect of the clinical 
variability of this disorder. A significant, but partial, negative correlation between the size of 
the expanded allele (and thus, the extension of the Poly-Q tract) and the age of appearance 
of symptoms explains between nearly 50 to 75% of the variation in the age at onset, 
depending on the analyzed series of patients (e.g., Maciel et al., 1995; Maruyama et al., 1995). 
The size of the mutated allele also correlates  with the frequency of particular clinical signs, 
such as pyramidal signs, which are more frequent in patients with larger repeats (Takiyama 
et al., 1995). In the Azorean series of patients, for example, the number of CAG repeats, 
determined in genomic DNA and in mRNA, explains 68% and 67% of variation in the age at 
onset, respectively (Bettencourt et al., 2010b).  The incompleteness of the correlation 
observed between the size of the CAG tract and the age at onset implies that such 
information cannot be used for counseling purposes; whether allele sizes should be 
disclosed in the molecular test report is still being debated (Sequeiros et al., 2010).  
The reported incompleteness of the genotype-phenotype correlation, observed in MJD as 
well as in other SCAs, confirms the involvement of non-CAG factors in the explanation of 
the phenotype, that can either be genetic or environmental (van de Warrenburg et al., 
2005). For MJD, the hypothesis that an important fraction of the residual of the disease 
onset (after accounting for the CAG repeat size) is of genetic nature has been reinforced 





identify MJD modifiers have used candidate gene approaches; Jardim et al. (2003), in a 
study that considers the effect of the CAG tract at several expansion loci (namely SCA2, 
SCA6 and DRPLA), only found a correlation between the severity of fasciculations and 
the size of the CAG tract at the SCA2 locus. Recently, Bettencourt and colleagues (2011) 
found a significant association between the presence of the APOE ε2 allele and an earlier 
onset in MJD. 
3.2 Gene dosage effect 
The reduced number of homozygous patients described for MJD makes any generalization, 
concerning the impact of gene dosage on clinical presentation, hard to perform. The few 
cases described in the literature, nevertheless, reinforce the fact that the phenotype is more 
severe and the onset is earlier in homozygous carriers of the mutated allele (e.g., Carvalho et 
al., 2008; Lerer et al., 1996). This indicates that gene dosage is an important determinant of 
the onset. The increased severity observed in homozygous is common in dominant diseases, 
which do not follow the Mendelian expectation of phenotypic overlapping between homo 
and heterozygous. In specific populations, known to have a particularly high prevalence of 
MJD, such as the Azorean island of Flores, the possibility of mating between carriers of the 
MJD mutation must be taken into consideration when planning GC sessions. 
3.3 Incomplete and age-dependent pattern of penetrance 
In MJD pedigrees, skipped generations are rarely observed. Coutinho (1992) refers that the 
majority of such cases can be explained by a premature death of the obligate carrier, in 
relation to the average onset of the disease. Other factors, such as migration, can further 
prevent the confirmation of the disease status in the obligate carrier. With an estimated 
value of 98%, the MJD gene penetrance presents an age-dependent pattern, which implies 
that the a posteriori, or residual risk, differs considerably depending on the age of the 
individual. Residual risk tables constitute, in this context, important tools for GC 
(Bettencourt et al., 2008a), since they allow the geneticist to estimate the probability that an 
asymptomatic at-risk individual has to develop the disease at a certain age. 
3.4 Intergenerational instability of the CAG tract 
Within the Poly-Q disorders, anticipation is more marked for DRPLA, SCA2, SCA7 and HD 
(Paulson, 2007; Takiyama et al., 1999).  In MJD, however, the aggravation of symptoms, and 
the decrease in the age at onset in successive generations, is also observed. On the basis of 
anticipation in MJD is the instability of the ATXN3 gene region containing the expanded 
CAG tract, which, during cellular division, can lead to alterations in the size of the repeat 
tract, resulting in expansions or, more rarely, in contractions. Although the decrease in the 
age at onset is highly related with the increase in the size of the CAG tract, families with a 
higher degree of anticipation than it would be expected for each repeat unit increase were 
identified (Takiyama et al., 1998). 
Germline mosaicism has been consistently described for MJD (e.g., Cancel et al., 1995). The 
tendency for the increase of the repeat size is more marked in male than in female meiosis; 
processes specific to sperm or oocyte development should be involved in such differences. 
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Maciel et al. (1995) reported that the size of the repeat tract varies in 55% of transmissions; 
from these, 78% correspond to expansions and 22% to contractions. 
Several factors have been implicated as modulating the intergenerational instability in MJD, 
such as the sex of the transmitting parent as well as the intragenic environment (see, 
amongst others, Igarashi et al., 1996; Maciel et al., 1999). The results obtained by Takiyama et 
al. (1997) suggests the presence of an inter-allelic association involved in the instability of 
the CAG tract, trough yet poorly known mechanisms. Other inter-allelic and cis factors have 
also been studied by Martins et al. (2008); these authors have concluded that distinct origins 
of the mutation (established on the basis of haplotypes constructed using intragenic SNPs) 
present different behaviors on what concerns repeat instability. Evidences gathered so far 
support the presence of a mechanism associated to DNA repair, rather than associated with 
replication, on the basis of meiotic instability observed in this locus (Martins et al., 2008).  
Little is known about the mutational process that leads to the emergence of repeats within 
the pathological size. It has been postulated that a mutational bias, in favor of expansions, 
exists in trinucleotide repeat loci, suggesting that the upper end of the normal allele 
distribution would provide a “reservoir” from which expanded alleles would be generated 
(Rubinsztein et al., 1994). The hypothesis that normal alleles of larger size could constitute 
such a reservoir was not supported by a study of nearly 2000 chromosomes of a 
representative sample of the general Portuguese population (Lima et al., 2005). On the 
contrary, the report from Lima and colleagues (2005), shows that the allelic distribution was 
skewed towards smaller size alleles. In a subsequent study, Martins et al. (2006) have 
integrated not only the analysis of the CAG repeat, but also information on haplotypes built 
using intragenic and flanking markers; the conclusions indicate that a multistep mechanism 
is on the basis of the evolution of the CAG repeats in MJD, originated either by gene 
conversion or DNA slippage. 
3.5 Somatic mosaicism 
The instability of the expanded polyglutamine-coding (CAG)n tracts during mitotic cell 
division can lead to changes in repeat length, either contractions or more frequently 
expansions, resulting in certain populations of cells carrying different repeat sizes. For MJD, 
the somatic mosaicism has been described by several authors (see, amongst others, Cancel et 
al., 1995; Lopes-Cendes et al., 1996; Maciel et al., 1997).  
In the central nervous system (CNS), the pattern of mosaicism for mutated alleles is similar 
in the several structures, with the exception of the cerebellar cortex, which presents slightly 
reduced tracts (Cancel et al., 1998; Hashida et al., 1997). In non-neuronal tissues, the 
instability is lower in muscle (Tanaka et al., 1999). The studies conducted have consistently 
failed to demonstrate a correlation between the degree of mosaicism and the selective 
neuronal vulnerability (Cancel et al., 1998; Ito et al., 1998). The pattern of mosaicism in 
genomic DNA is maintained in mRNA, and the variation in the size of the CAG repeat in 
mRNA is also not relatable with the severity of the pathological involvement of the several 
tissues (Ito et al., 1998). 
Somatic mosaicism contributes to the limitations in the precision of sizing the MJD repeat 
motif, since it originates differences in (CAG)n length among subpopulations of 
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cells (revised in Lima et al., 2006). Thus an error of ±1 CAG repeat is considered as 
acceptable (Maciel et al., 2001; Sequeiros et al., 2010). 
3.6 Segregation distortion 
Alterations to the Mendelian proportions in the segregation of the ATXN3 alleles were 
firstly highlighted by Ikeuchi and colleagues, in 1996. These authors suggested the 
occurrence of “meiotic drive” to justify the observation of an excess of affected descendents 
of MJD patients, a fact hardly explainable by the Mendelian principle of random segregation 
of alleles (Ikeuchi et al., 1996). Their results pointed to the existence of segregation 
distortion, in the male meiosis. This issue, however, is far from consensual. A single-sperm 
typing performed in Japanese patients, by Takiyama et al. (1997) indicated a preferential 
transmission of mutated alleles. On the other hand, a similar study by Grewal et al. (1999), 
which used sperm samples from patients of French origin, failed to report the presence of 
segregation distortion. Using a methodology based on the analysis of pedigrees of patients 
belonging to Azorean MJD families, Bettencourt et al. (2008a) also investigated the presence 
of segregation distortion in the transmission of mutated ATXN3 alleles. According to that 
study, segregation is done in agreement with the expected Mendelian proportions. 
The behavior postulated for the wild-type and the mutated ATXN3 alleles is not necessarily 
comparable. Nevertheless, studies with normal individuals have also been conducted, 
aiming to contribute to the understanding of this issue (Bettencourt et al., 2008b; MacMillan 
et al., 1999; Rubinsztein & Leggo, 1997). Rubinsztein and Leggo (1997), in a segregation 
study of MJD alleles in normal heterozygous individuals, reported the presence of 
segregation distortion only when the transmitting parent was a female, with the smaller 
allele being preferably transmitted. Results from another study, by Bettencourt et al. (2008b), 
followed the same trend, with a preference for the transmission of the smaller allele. These 
last authors also reinforced the importance of the genotypic constitution of the sample being 
analyzed, which may act as a confounding factor in the detection of segregation distortion. 
4. Conclusion 
Poly-Q diseases occur as a result of a mutation at the respective causative genes, 
representing, from that perspective, simple, monogenic diseases. Several aspects of 
complexity are, nevertheless, present in this group of disorders. Many of the complicating 
factors present are displayed by MJD and were approached here; the majority of them have 
implications for patients management and, therefore, its understanding is of major 
importance. 
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1. Introduction 
Spinocerebellar ataxias (SCAs) are a group of progressive and irreversible neurological 
diseases affecting gait and movement coordination. Many result from cerebellar 
degeneration or the impairment of a portion of the neuroaxis that contributes to cerebellar 
inflow or outflow (Embirucu et al., 2009). In the cerebellum, the dysfunction and death of 
Purkinje cells, granule cells or interneurons can cause SCA. Molecular mechanisms for this 
pathology include polyglutamine tract expansion (SCA1, SCA2, SCA3), flawed basal 
transcription (SCA17) and defective DNA repair (ataxia telangiectasia, spinocerebellar 
ataxia with axonal neuropathy (SCAN1) and ataxia with oculomotor apraxia type 1) (Hire et 
al., 2010).  
The mechanism by which defective DNA repair causes neuronal dysfunction and death is 
not yet fully understood, but damage to the nuclear and mitochondrial genomes underlie 
each potential explanation. Dysfunction of nuclear DNA repair enzymes results in nuclear 
DNA damage that impedes transcription and also induces programmed neuronal death 
(Fishel et al., 2007). Dysfunction of mitochondrial DNA repair enzymes leads to 
mitochondrial DNA damage that impairs mitochondrial gene expression causing 
mitochondrial dysfunction, oxidative stress and subsequently programmed neuronal 
death (Bender et al., 2006). Accumulation of DNA breaks within the neuronal nuclear 
genome has also been proposed to initiate expression of cell-cycle activators as a cellular 
response to repair genomic damage through replication-dependent mechanisms; 
however, these neurons are frequently unable to establish a new G0 quiescent state and 
this in turn activates neuronal death mechanisms (Kruman et al., 2004). Lastly, besides 
direct affects on the neurons, defective DNA repair also indirectly induces neuronal death 
by causing dysfunction of glia, which have trophic interactions with neurons and 
modulate neurotransmitter levels at synapses (Barzilai, 2011; Lobsiger and Cleveland, 
2007).  
For the purposes of this review, we focus on SCAN1, an autosomal recessive DNA repair 
disorder caused by the p.His493Arg active site mutation in tyrosyl-DNA phosphodiesterase 
1 (Tdp1), an enzyme that enables DNA repair by processing blocked 3’ DNA termini. This 
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Since the loss of Tdp1 activity predisposes to both nuclear and mitochondrial DNA damage, 
this review focuses on understanding SCAN1 etiology from the perspectives of DNA repair 
and mitochondrial dynamics.  
2. Spinocerebellar ataxia with axonal neuropathy (SCAN1)  
The only reported SCAN1 patients are from an extended Saudi Arabian family having nine 
affected individuals (Takashima et al., 2002). SCAN1 is characterized by normal intelligence 
and a late-childhood onset progressive cerebellar ataxia and peripheral neuropathy. Initial 
features include ataxic gait, gaze nystagmus and cerebellar dysarthria. As the disease 
advances, the affected individuals develop impaired pain, vibration and touch sensation in 
the hands and legs and eventually a steppage gait and pes cavus. With further progression 
of their cerebellar, motor and sensory symptoms, affected individuals become wheelchair-
dependent in early adulthood (Hirano et al., 1993). Magnetic resonance imaging studies 
show cerebellar atrophy, especially of the vermis (Takashima et al., 2002). Nerve conduction 
studies show decreased amplitudes characteristic of axonal neuropathy. These clinical 
findings suggest a disease of large, terminally differentiated, post-mitotic neurons, 
especially those of the cerebellum, dentate nuclei, anterior spinal horn and dorsal root 
ganglia.   
Currently, there are only symptomatic treatments for SCAN1. Physical therapy is 
recommended for maintaining activity. Prostheses, walking aids and wheelchairs are 
recommended for improving mobility. In addition, based on studies of cells from 
SCAN1 patients and animal models, SCAN1 patients should avoid exposure to 
genotoxic agents such as camptothecin, irinotecan, topotecan, bleomycin and radiation 
(Hirano et al., 2007). 
Clinically, SCAN1 can be considered in the differential diagnosis for individuals who have 
1) a slowly progressive cerebellar ataxia with onset in late-childhood or adolescence, 2) 
peripheral axonal neuropathy, 3) no signs of oculomotor apraxia and 4) no evidence of 
extraneurologic features such as telangiectasias, cancers or immunodeficiency. Supportive 
findings include increased serum cholesterol and decreased serum albumin (Takashima et 
al., 2002). The only known genetic defect causing SCAN1 is the c.1478A>G mutation in 
TDP1. This missense mutation, which encodes the p.His493Arg amino acid alteration, can 
be detected by DNA sequencing or by digestion of the PCR product with BsaAI (Hirano et 
al., 2007; Takashima et al., 2002). 
3. DNA repair mechanisms and progressive neurodegeneration 
As exemplified by SCAN1, many DNA repair defects cause progressive neurodegenerative 
disease (Table 1) (Barekati et al., 2010; Sahin and Depinho, 2010). Neurons are particularly 
vulnerable to the accumulation of unrepaired DNA lesions because they are long-lived, 
post-mitotic and not readily replaced.  
DNA lesions arise as a consequence of endogenous or exogenous genotoxic insults. 
However, the seclusion of central neurons, which are frequently more severely affected than 
peripheral neurons, by the blood-brain barrier suggests that the DNA lesions arise 
predominantly from endogenous genotoxic insults, particularly the oxidative damage 
arising from mitochondrial dysfunction (Harman, 1972, 1981) 
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Repair of DNA lesions is mediated by four major DNA repair pathways: double-strand 
break repair (DSBR), mismatch repair (MMR), nucleotide excision repair (NER), and base 
excision repair (BER). DSBR corrects double-strand breaks (DSB) in the DNA backbone; 
MMR corrects mismatches of normal bases; NER repairs bulky helix distorting DNA lesions, 
and BER repairs damage to a single nucleotide and handles single-strand DNA breaks (SSB). 
Dysfunction of each of these DNA repair processes causes or has been associated with 
progressive neurodegenerative disease (Table 1) (Jeppesen et al., 2011). 
 
 
Gene(s) DNA Repair Defect Clinical Syndrome Main Symptoms 




Axonal sensorimotor neuropathy 
Oculomotor apraxia 
Elevated serum concentration of alpha-
fetoprotein 
ATM Defective DSBR  Ataxia telangiectasia Progressive ataxia 
Defective muscle coordination 
Dilation of blood vessels in skin and eyes 
Immune deficiency 
Predisposition to cancer 
MRE11 Defective DSBR  Ataxia telangiectasia-
like 
Slowly progressive cerebellar ataxia 
Ionizing radiation hypersensitivity 
XPA, XPF, XPG, 
POLH, ERCC1-4, 
DDB2  
Defective NER  Xeroderma 
pigmentosum 
Sensitivity to sunlight 
Slow neurodegeneration 
Skin cancer 










Defective NER Trichothiodystrophy Sensitivity to sunlight 
Dystrophy 
Short brittle hair with low sulfur content, 
Neurological and psychomotoric defects 
TDP1 Defective BER Spinocerebellar ataxia 
with axonal 
neuropathy 1 
Progressive degeneration of post-mitotic 
neurons 
APTX Defective BER Ataxia with 
oculomotor apraxia 
type 1  
Slowly progressive cerebellar ataxia, 
followed by oculomotor apraxia 




Defective BER Amyotrophic lateral 
sclerosis 
Progressive degeneration of motor 
neurons 







Loss of deep-tendon reflexes  
Athetosis 
Table 1. DNA repair enzymes with mutations causing neurodegenerative disease. NER: 
Nucleotide excision repair, TC-NER: Transcription-coupled nucleotide excision repair, 
MMR: Mismatch repair, BER: Base excision repair, DSBR: Double-strand break repair, 
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3.1 Double-strand break repair 
DSBR corrects DNA double-strand breaks (DSBs) induced by exogenous sources such as 
ionizing radiation and genotoxic compounds or by endogenous sources such as reactive 
oxygen species, replication fork collapse, and errors of meiotic recombination (Ciccia and 
Elledge, 2010). The two major DSBR pathways in mammalian cells are homologous 
recombination (HR) and non-homologous end-joining (NHEJ). HR allows high fidelity 
repair of DSBs during DNA replication by using the intact sister chromatid as a template, 
whereas NHEJ allows for the error-prone repair of DSBs by modifying and ligating the two 
DNA termini of a DSB without using an undamaged template. HR is restricted to the late S 
to G2/M phase of the cell cycle when a sister chromatid is available in proliferating cells, 
whereas NHEJ operates throughout the cell cycle and can repair DSBs in differentiated cells. 
Therefore, since the mature nervous system is predominately post-mitotic cells, NHEJ is the 
major DSBR pathway in the postnatal brain. 
Two NHEJ disorders with progressive neurodegeneration of the postnatal brain are ataxia 
telangiectasia and ataxia telangiectasia-like disorder. The neurological symptoms of ataxia 
telangiectasia are an early childhood onset of ataxia that generally leads to wheel chair 
dependence before adolescence. The neurological symptoms of ataxia telangiectasia-like 
disorder are similar to those of ataxia telangiectasia but of later onset and slower 
progression. For both disorders, the neurodegeneration is characterized by the loss of 
cerebellar granule and Purkinje cells.  
3.2 Mismatch repair 
MMR removes base–base mismatches and insertion-deletion loops that arise during DNA 
replication and recombination. Base–base mismatches are created when errors escape DNA 
polymerase proofreading, and insertion-deletion loops arise when the primer and template 
strand in a microsatellite or repetitive sequence dissociate and re-anneal incorrectly causing 
the number of microsatellite-repeat units in the template and in the newly synthesized 
strand to differ. Interestingly, expression of MMR components is not limited to replicating 
cells but is also observed in non-replicating postnatal neurons suggesting that this pathway 
plays a role in maintaining the genomic integrity of differentiated cells too (Ciccia and 
Elledge, 2010). 
Consistent with a function in differentiated cells, studies of the Huntington trinucleotide 
repeat (CAG) in mice have shown somatic age-dependent repeat expansion that is 
suppressed by deficiency of some MMR components and is triggered by DNA glycosylases 
of the BER pathway (Kovtun et al., 2007; Owen et al., 2005). The relevance of the MMR 
pathway to trinucleotide repeat expansions of the human neurological disorders remains 
undefined however.  
3.3 Nucleotide excision repair 
In human cells, recognition of bulky helix distorting DNA lesions leads to the removal of a 
short single-stranded DNA segment surrounding and including the lesion. This creates a 
single-strand gap in the DNA that is subsequently filled during repair synthesis by a DNA 
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polymerase using the undamaged strand as a template. NER can be divided into two sub-
pathways, global genomic NER (GG-NER) and transcription-coupled NER (TC-NER). GG-
NER and TC-NER differ in the recognition of the DNA lesion but subsequently use the same 
excision mechanism. GG-NER recognizes and repairs DNA lesions anywhere in the genome, 
whereas TC-NER only resolves lesions in the actively transcribed DNA strand (de Laat et 
al., 1999).  
Two NER-associated disorders, xeroderma pigmentosum and Cockayne syndrome, feature 
progressive neurodegeneration (Kraemer et al., 1987). About 30% of xeroderma 
pigmentosum patients have neurological symptoms that include abnormal motor control, 
ataxia, peripheral neuropathy, dementia, brain and spinal cord atrophy, microcephaly and 
sensorineural deafness. In contrast, nearly all Cockayne syndrome patients have progressive 
neurological disease characterized by demyelination in the cerebral and cerebellar cortex, 
calcification in the basal ganglia and cerebral cortex, neuronal loss, sensorineural hearing 
loss and decreased nerve conduction (Nance and Berry, 1992). The progressive 
neurodegeneration in both xeroderma pigmentosum and Cockayne syndrome are 
attributable to apoptotic cell death (Lehmann, 2003).  
3.4 Base excision repair 
BER corrects the most common forms of DNA damage by recognizing, excising and 
replacing a broad spectrum of specific forms of DNA modifications including those arising 
from deamination, oxidation and alkylation. It is initiated by a distinct lesion-specific mono- 
or bi-functional DNA glycosylase and completed by either of two sub-pathways: short-
patch BER (SP-BER) that replaces one nucleotide or long-patch BER (LP-BER) that replaces 
2–13 nucleotides (Frosina et al., 1996). 
The BER proteins are also responsible for repairing DNA SSBs. SSBs are some of the most 
common lesions found in chromosomal DNA and arise via enzymatic cleavage of the 
phosphodiester backbone or from oxidative damage or ionizing radiation. Examples of 
enzymatic cleavage causing SSBs include those arising during BER (Connelly and Leach, 
2004) and during DNA topoisomerase I (Topo I) activity (Pommier et al., 2003). 
Ataxia with oculomotor apraxia type 1 and SCAN1 are both associated with defects in the 
repair of SSBs, specifically the processing of obstructive termini (Table 1). The 
neurodegenerative features of ataxia with oculomotor apraxia type 1 include progressive 
cerebellar atrophy, late axonal peripheral motor neuropathy, ataxia and oculomotor 
apraxia. The features of SCAN1, which is caused by a mutation of TDP1, have been 
described above. 
4. Tdp1 function  
TDP1 encodes tyrosyl-DNA phosphodiesterase 1 (Tdp1), a 608 amino acid enzyme that 
contains a bipartite nuclear localization sequence and two conserved HxKx4Dx6G (G/S) 
HKD (histidine-lysine-arginine) signature motifs. The two HKD motifs form a single 
symmetrical active site characteristic of the phospholipase D superfamily and catalyze a 
phosphoryl transfer that is common to enzymes in this superfamily (Interthal et al., 2001). 
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and DSBR by removing obstructing compounds linked by a phosphodiester bond to DNA 3’ 
termini and complements the 5’-phosphodiesterase function of TTRAP (Tdp2) (Cortes 
Ledesma et al., 2009; el-Khamisy and Caldecott, 2007; Zhou et al., 2009). Tdp1 endogenous 
substrates include 3’ tyrosine-DNA phosphodiester moieties, phosphoglycolates, 
mononulceosides and tetrahydrofurans, and exogenous substrates include 4-methylphenol, 
4-nitrophenol and 4-methylumbelliferone (Figure 1) (Dexheimer et al., 2008; Interthal et al., 
2005a). Tdp1 has the highest affinity for the 3’ tyrosine-DNA phosphodiester moieties, 
which are characteristic of Topo I-DNA intermediates (Dexheimer et al., 2010). 
 
Fig. 1. Substrates of Tdp1. Tdp1 can remove both physiologic substrates and non-
physiologic substrates. R = Substrates. 
During repair, replication, transcription, recombination and chromatin remodeling, Topo I 
relaxes superhelical tension by nicking DNA to allow controlled rotation of the broken DNA 
strand around the intact strand. After DNA relaxation has occurred, a nucleophilic attack by 
the DNA 5’ hydroxyl group on the phosphotyrosyl linkage between Topo I and the 3’ end of 
the DNA at the nick usually religates the DNA, and the Topo I dissociates. However, DNA 
damage such as abasic sites, nicks, and mismatched base pairs frequently impede removal 
of Topo I from the DNA by causing a misalignment of the 5’ hydroxyl end of the DNA that 
prevents it from acting as a nucleophile. (Pommier et al., 1998; Pommier et al., 2003; 
Pourquier and Pommier, 2001) Additionally, the 3’-Topo I-DNA intermediate can become 
unduly long-lived if Topo I binds oxidative base lesions (Interthal et al., 2005b). These 
trapped or long-lived Topo I-DNA covalent intermediates can then be converted to 
irreversible DNA breaks when the DNA replication machinery or RNA polymerase collides 
with the Topo I-DNA complex (Hsiang et al., 1989; Tsao et al., 1993; Wu and Liu, 1997)  
Clearance of the trapped or stalled 3’-Topo I-DNA intermediates occurs via SSBR or DSBR if 
the SSB is converted to a DSB by collision of the DNA replication machinery with the 
trapped or stalled 3’-Topo I-DNA intermediate. Following recognition of the break, the 
trapped or stalled Topo I is proteolytically cleaved leaving a peptide bound to the 3’ end of 
the DNA by the phosphodiester bond formed between the DNA and the Topo I active site 
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tyrosine (Tyr723). Tdp1 then acts on the phosphodiester bond and removes the obstructing 
Topo I peptide from the 3’ terminus (Debethune et al., 2002; Liu et al., 2002). The Tdp1 
reaction removes the peptide from the DNA by an SN2 nucleophilic attack of His263, which 
resides in the first HKD motif, on the phosphodiester bond; Tdp1 is then released from the 
DNA by the catalytic activity of His493, which resides in the second HKD motif (Figure 2). 
 
Fig. 2. Mechanism of Tdp1 catalytic activity. (A) Wild type Tdp1 removes proteolysed Topo 
I and forms a covalent intermediate with DNA before His493 of the second HKD motif 
excises Tdp1 from DNA through a nucleophilic substitution. (B) In SCAN1, the mutated 
Tdp1 (p.His493Arg) removes proteolysed Topo I but remains trapped on DNA and leads to 
accumulation of Tdp1-DNA adducts.  
4.1 Tdp1 and nuclear DNA repair 
Within the nucleus, Tdp1 is a component of the SSB multi-protein repair complex containing 
PARP1, LIG3, XRCC1 and PNKP (Das et al., 2009). This repair complex is activated after 
proteasomal degradation of stalled Topo I (Zhang et al., 2004). PARP1 is an important 
regulator of the SSBR/BER pathway as it enhances the recruitment of DNA repair proteins. 
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Fig. 3. Tdp1-dependent and Tdp1-independent pathways for the removal of Topo I-DNA 
covalent complexes. After Topo I is trapped on the DNA, proteolysis of Topo I occurs. The 
remaining Topo I peptide can be removed by either Tdp1-dependent pathway or Tdp1-
independent pathways. Topo I* = Topo I peptide. 
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molecules of acceptor proteins. The addition of poly-ADP ribosyl (PAR) polymers onto 
histones promotes the relaxation of chromatin, while SSBR proteins such as XRCC1 and 
Lig3a are electrostatically attracted to PAR and are thus recruited to the site of DNA damage 
(El-Khamisy et al., 2003; Krishnakumar and Kraus, 2010). It is thought that XRCC1 acts as a 
molecular scaffold for the binding of Tdp1 and Lig3a and stabilizes the enzyme complex in 
the processing of Topo I derived SSBs. Processing of the 3’ tyrosine-DNA phosphodiester 
moieties by Tdp1 leaves a 3’-P terminus that is converted to 3’-OH by the phosphatase 
action of PNKP. The kinase activity of PNKP phosphorylates the 5’-OH terminus, allowing 
gap filling by DNA polymerase Polß), and finally the DNA nick is sealed by lig3a with 
the aid of the XRCC1 scaffold (Figure 3).  
How Tdp1 processes obstructing 3’ overhangs on DNA DSBs has not been fully defined. 
The dependence of Tdp1 processing of DSB termini on the autophosphorylation activity of 
the NHEJ component DNA-PK suggests that Tdp1 contributes within the NHEJ pathway 
and that DNA-PK modulates the accessibility of DNA ends enabling Tdp1 to accomplish the 
processing necessary for eventual end-joining (Zhou et al., 2009). 
One redundant DNA repair activity for Tdp1 is the nucleolytic removal of several DNA 
bases beginning upstream of the stalled Topo I. This is mediated by 3'-flap endonuclease 
complexes in the nucleus such as Mus81-MMS4 and XPF-ERCC1 that cleave at the 3'-flap 
created by stalled Topo I to enable short-patch gap filling. In comparison to Tdp1 
processing, however, this mechanism is error-prone and less efficient.  
4.2 Tdp1 and mitochondrial DNA repair 
Besides its role in the repair of nuclear DNA, Tdp1 also plays a role in mitochondrial DNA 
(mtDNA) repair (Das et al., 2010). Mitochondria are membrane-enclosed organelles that 
generate most of the ATP via the electron transport chain at the inner mitochondrial 
membrane. This process leads to the generation of reactive oxygen species, and while 
mitochondria have various antioxidant enzymes to deactivate these highly reactive 
molecules, they do not constitute a perfect defense. This inevitably exposes the mtDNA to 
high levels of oxidative stress, particularly since the mtDNA is located in close proximity to 
the inner mitochondrial membrane and lacks protective histones (Ames et al., 1993). 
Consequently, the levels of oxidative base damage in mitochondrial DNA are 2–3 fold 
higher compared to nuclear DNA (Hudson et al., 1998), and the damage is more extensive 
and persistent than in nuclear DNA (Yakes and Van Houten, 1997). 
Several DNA repair activities and pathways that function in the nucleus have also been 
identified and characterized in mammalian mitochondria. These include BER, MMR, and 
some components of DSBR (Larsen et al., 2005). Given the prevalence of small lesions 
generated by oxidative stress in the mitochondria, BER is the predominant mtDNA repair 
pathway. Mitochondrial BER proteins are not encoded by the mitochondrial genome; rather 
they are mitochondrial versions of nuclear-encoded proteins (Larsen et al., 2005). Among 
these is Tdp1, which could participate in the repair of oxidative mitochondrial DNA damage 
via resolution of 3’-phosphoglycolate obstructive termini and processing the 
apurinic/apyrimidinic (AP) sites arising from the DNA glycosylase removal of DNA lesions 
such as 7,8-dihydro-8-oxoguanine (8-oxoG). These two abilities of Tdp1 are also shared by 
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Additionally, as there is a mitochondrial Topo I (mtTopo I) that has 71% identity and 87% 
similarity with the nuclear Topo I (Zhang et al., 2001), we hypothesize that the high level of 
mtDNA lesions predisposes to generation of long lived or trapped mtTopo I-DNA 
complexes similar to those in the nucleus and that the removal of mtTopo I peptides from 
mtDNA is also a function of mitochondrial Tdp1.  
5. The molecular basis of SCAN1 
In SCAN1, the p.His493Arg mutation in the second HKD motif of Tdp1 affects the active site 
of the protein and reduces its catalytic activity by 25-fold (Interthal et al., 2005b; Takashima 
et al., 2002). This alteration both decreases the processing of Topo I-DNA adducts and 
impairs the intermolecular reaction that would ordinarily release Tdp1. These Tdp1-DNA 
adducts can only be removed by wild-type Tdp1 (Figure 2) (Interthal et al., 2005b). This 
finding suggests that SCAN1 might arise, at least in part, from accumulation of the Tdp1-
DNA adducts and the inability of the cell to remove Tdp1H493R in a timely manner 
(Dexheimer et al., 2008; Hirano et al., 2007). 
Currently, the molecular basis of SCAN1 and the reason that mice deficient for Tdp1 do not 
develop ataxia are incompletely understood. Although there are no prominent tissue 
differences in gene expression nor evidence of positive selection of the Tdp1 protein (as 
reported in the Selectome database) between human and mouse (Proux et al., 2009), two 
observations suggest possible explanations for SCAN1 pathogenesis and the lack of ataxia in 
Tdp1-deficient mice. First, human Tdp1 is predominantly expressed in the cytoplasm of the 
neurons predicted to be affected in SCAN1, whereas mouse Tdp1 is predominantly 
expressed in the nucleus of the analogous neurons. Second, in vitro and cell culture 
experiments show that the p.His493Arg Tdp1 forms long lived Tdp1-DNA adducts (Hirano 
et al., 2007; Interthal et al., 2005b); therefore, development of SCAN1 may be dependent on 
this “mutagenic” property of p.His493Arg Tdp1.  
5.1 Mitochondrial dysfunction model 
The prominent cytoplasmic expression of Tdp1 in human Purkinje, dentate nucleus, anterior 
horn, and dorsal ganglion neurons suggests a cytoplasmic function for Tdp1. Given the 
mitochondrial localization of cytoplasmic Tdp1, this suggests 1) that the majority of Tdp1 in 
these neurons functions in the mitochondria and 2) that SCAN1 may be arising from 
mitochondrial dysfunction secondary to loss of mtDNA integrity. In contrast, the low 
expression of Tdp1 in the cytoplasm of these neurons in mice would suggest that Tdp1 
plays a minor role in maintenance of the mouse mitochondrial genome or that the analogous 
neurons have less mtDNA damage in mice than in humans. 
The human cerebellum contains post-mitotic neurons with a large mitochondrial 
population. Despite the non-proliferative nature of cerebellar neurons, the biogenesis of 
mitochondria and the maintenance of mitochondrial integrity are of central importance for 
survival of these neurons (Chen and Chan, 2009). The closed circular mitochondrial genome 
predisposes it to helical tension during mitochondrial replication, which is resolved by 
mtTopo I. In the nucleus, binding of Topo I to 8-oxoG rearranges the active site of Topo I 
and stabilizes it in an inactive conformation (Lesher et al., 2002). If the same occurs in 
mitochondria with mtTopo I, which encounters a much higher level of 8-oxoG, then Tdp1 
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will be critical for resolution of these lesions in mtDNA. Hypothetically, a repair process 
analogous to that in the nucleus would resolve these long-lived complexes: 1) protease 
cleavage of mtTopo I, 2) Tdp1 mediated cleavage and release of the mtTopo I peptide to 
leave an 8-oxoG 5’overhang and a 3’-phosphate, and 3) SP-BER.  SP-BER would proceed by 
PNKP removal of the 3’-phosphate and OGG1 removal of the 5’ 8-oxoG lesion, followed by 
mitochondrial polymerase-ϒ filling in the missing nucleotides and Lig3a ligating the DNA 
strand (Figure 4a).  
Based on these observations, we hypothesize that the processing of trapped or long-lived 
mtTopo I-DNA intermediates is hindered in cells from SCAN1 patients by the reduced 
catalytic activity of p.His493Arg Tdp1. Additionally, we hypothesize that mitochondria lack 
DNA repair pathways redundant for the activity of Tdp1 since 3’end processing flap 
endonucleases that could resolve mtTopo I-DNA adducts have not been detected in 
mitochondria (Liu et al., 2002). In this model, trapped or long-lived mtTopo I-DNA 
intermediates interfere with mitochondrial transcription and contribute to mtDNA damage. 
In turn, both transcriptional dysfunction and genomic instability cause mitochondrial 
dysfunction and thereby poor cellular health. Relative to other brain neurons, cerebellar 
neurons may be highly sensitive to this mitochondrial damage since they have a lower 
tolerance for mitochondrial dysfunction (Chen et al., 2007; Hakonen et al., 2008) (Figure  
4b).  
In summary, therefore, the dysfunction of mitochondrial Tdp1 may contribute to the 
pathogenesis of SCAN1. Also, the absence of ataxia in Tdp1 deficient mice may arise 
because mouse cerebellar and spinal cord neurons have a lower requirement for Tdp1 
processing of damaged mtDNA (Hirano et al., 2007). 
5.2 Tdp1 neomorph model 
The formation and accumulation of Tdp1-DNA adducts by the mutant p.His493Arg Tdp1 
causes increased DNA breaks in cells expressing this mutant Tdp1 (Hirano et al., 2007) and 
thus suggests that p.His493Arg Tdp1 acts as a mutagen. In vitro, wild type Tdp1 is the only 
identified enzyme that can remove the mutant Tdp1 from the DNA (Interthal et al., 2005a). 
However, in vivo it is possible that nuclear Tdp1-DNA adducts are processed by a DNA 
repair mechanism such as HR that is present in proliferating unaffected cells but not in 
affected quiescent neurons. Alternatively, there may not be an alternative repair pathway 
but simply replacement of cells that die from accumulated Tdp1-DNA adducts in 
proliferating tissues and a failure of replacement for non-proliferating neurons. 
As an extension of this hypothesis, one might consider that both mitochondrial dysfunction 
and the neomorphic properties of p.His493Arg Tdp1 contribute to the pathogenesis of 
SCAN1. The repair of damaged DNA is costly, and if the costs exceed cellular energy 
resources (ATP/NADH), then cell death results (Zong and Thompson, 2006). In this context, 
a mechanism that could lead to cell death is the depletion of NAD+ and ATP reserves by the 
over-activation of PARP1 due to accumulating SSBs created by Tdp1His493Arg-DNA adducts 
in the nucleus and mitochondria. In the context of compromised mitochondria, such 
depletion of cellular energy reserves, which triggers permeabilization of the outer 





Additionally, as there is a mitochondrial Topo I (mtTopo I) that has 71% identity and 87% 
similarity with the nuclear Topo I (Zhang et al., 2001), we hypothesize that the high level of 
mtDNA lesions predisposes to generation of long lived or trapped mtTopo I-DNA 
complexes similar to those in the nucleus and that the removal of mtTopo I peptides from 
mtDNA is also a function of mitochondrial Tdp1.  
5. The molecular basis of SCAN1 
In SCAN1, the p.His493Arg mutation in the second HKD motif of Tdp1 affects the active site 
of the protein and reduces its catalytic activity by 25-fold (Interthal et al., 2005b; Takashima 
et al., 2002). This alteration both decreases the processing of Topo I-DNA adducts and 
impairs the intermolecular reaction that would ordinarily release Tdp1. These Tdp1-DNA 
adducts can only be removed by wild-type Tdp1 (Figure 2) (Interthal et al., 2005b). This 
finding suggests that SCAN1 might arise, at least in part, from accumulation of the Tdp1-
DNA adducts and the inability of the cell to remove Tdp1H493R in a timely manner 
(Dexheimer et al., 2008; Hirano et al., 2007). 
Currently, the molecular basis of SCAN1 and the reason that mice deficient for Tdp1 do not 
develop ataxia are incompletely understood. Although there are no prominent tissue 
differences in gene expression nor evidence of positive selection of the Tdp1 protein (as 
reported in the Selectome database) between human and mouse (Proux et al., 2009), two 
observations suggest possible explanations for SCAN1 pathogenesis and the lack of ataxia in 
Tdp1-deficient mice. First, human Tdp1 is predominantly expressed in the cytoplasm of the 
neurons predicted to be affected in SCAN1, whereas mouse Tdp1 is predominantly 
expressed in the nucleus of the analogous neurons. Second, in vitro and cell culture 
experiments show that the p.His493Arg Tdp1 forms long lived Tdp1-DNA adducts (Hirano 
et al., 2007; Interthal et al., 2005b); therefore, development of SCAN1 may be dependent on 
this “mutagenic” property of p.His493Arg Tdp1.  
5.1 Mitochondrial dysfunction model 
The prominent cytoplasmic expression of Tdp1 in human Purkinje, dentate nucleus, anterior 
horn, and dorsal ganglion neurons suggests a cytoplasmic function for Tdp1. Given the 
mitochondrial localization of cytoplasmic Tdp1, this suggests 1) that the majority of Tdp1 in 
these neurons functions in the mitochondria and 2) that SCAN1 may be arising from 
mitochondrial dysfunction secondary to loss of mtDNA integrity. In contrast, the low 
expression of Tdp1 in the cytoplasm of these neurons in mice would suggest that Tdp1 
plays a minor role in maintenance of the mouse mitochondrial genome or that the analogous 
neurons have less mtDNA damage in mice than in humans. 
The human cerebellum contains post-mitotic neurons with a large mitochondrial 
population. Despite the non-proliferative nature of cerebellar neurons, the biogenesis of 
mitochondria and the maintenance of mitochondrial integrity are of central importance for 
survival of these neurons (Chen and Chan, 2009). The closed circular mitochondrial genome 
predisposes it to helical tension during mitochondrial replication, which is resolved by 
mtTopo I. In the nucleus, binding of Topo I to 8-oxoG rearranges the active site of Topo I 
and stabilizes it in an inactive conformation (Lesher et al., 2002). If the same occurs in 
mitochondria with mtTopo I, which encounters a much higher level of 8-oxoG, then Tdp1 
Spinocerebellar Ataxia with Axonal  
Neuropathy (SCAN1): A Disorder of Nuclear and Mitochondrial DNA Repair 
 
51 
will be critical for resolution of these lesions in mtDNA. Hypothetically, a repair process 
analogous to that in the nucleus would resolve these long-lived complexes: 1) protease 
cleavage of mtTopo I, 2) Tdp1 mediated cleavage and release of the mtTopo I peptide to 
leave an 8-oxoG 5’overhang and a 3’-phosphate, and 3) SP-BER.  SP-BER would proceed by 
PNKP removal of the 3’-phosphate and OGG1 removal of the 5’ 8-oxoG lesion, followed by 
mitochondrial polymerase-ϒ filling in the missing nucleotides and Lig3a ligating the DNA 
strand (Figure 4a).  
Based on these observations, we hypothesize that the processing of trapped or long-lived 
mtTopo I-DNA intermediates is hindered in cells from SCAN1 patients by the reduced 
catalytic activity of p.His493Arg Tdp1. Additionally, we hypothesize that mitochondria lack 
DNA repair pathways redundant for the activity of Tdp1 since 3’end processing flap 
endonucleases that could resolve mtTopo I-DNA adducts have not been detected in 
mitochondria (Liu et al., 2002). In this model, trapped or long-lived mtTopo I-DNA 
intermediates interfere with mitochondrial transcription and contribute to mtDNA damage. 
In turn, both transcriptional dysfunction and genomic instability cause mitochondrial 
dysfunction and thereby poor cellular health. Relative to other brain neurons, cerebellar 
neurons may be highly sensitive to this mitochondrial damage since they have a lower 
tolerance for mitochondrial dysfunction (Chen et al., 2007; Hakonen et al., 2008) (Figure  
4b).  
In summary, therefore, the dysfunction of mitochondrial Tdp1 may contribute to the 
pathogenesis of SCAN1. Also, the absence of ataxia in Tdp1 deficient mice may arise 
because mouse cerebellar and spinal cord neurons have a lower requirement for Tdp1 
processing of damaged mtDNA (Hirano et al., 2007). 
5.2 Tdp1 neomorph model 
The formation and accumulation of Tdp1-DNA adducts by the mutant p.His493Arg Tdp1 
causes increased DNA breaks in cells expressing this mutant Tdp1 (Hirano et al., 2007) and 
thus suggests that p.His493Arg Tdp1 acts as a mutagen. In vitro, wild type Tdp1 is the only 
identified enzyme that can remove the mutant Tdp1 from the DNA (Interthal et al., 2005a). 
However, in vivo it is possible that nuclear Tdp1-DNA adducts are processed by a DNA 
repair mechanism such as HR that is present in proliferating unaffected cells but not in 
affected quiescent neurons. Alternatively, there may not be an alternative repair pathway 
but simply replacement of cells that die from accumulated Tdp1-DNA adducts in 
proliferating tissues and a failure of replacement for non-proliferating neurons. 
As an extension of this hypothesis, one might consider that both mitochondrial dysfunction 
and the neomorphic properties of p.His493Arg Tdp1 contribute to the pathogenesis of 
SCAN1. The repair of damaged DNA is costly, and if the costs exceed cellular energy 
resources (ATP/NADH), then cell death results (Zong and Thompson, 2006). In this context, 
a mechanism that could lead to cell death is the depletion of NAD+ and ATP reserves by the 
over-activation of PARP1 due to accumulating SSBs created by Tdp1His493Arg-DNA adducts 
in the nucleus and mitochondria. In the context of compromised mitochondria, such 
depletion of cellular energy reserves, which triggers permeabilization of the outer 





(AIF) (Wang et al., 2009), would occur at a lower threshold in affected versus unaffected 
cells of SCAN1 patients (Wang et al., 2011) (Chen and Chan, 2009). In this model, the 
neurons with the least energy reserves would be most sensitive and, unlike proliferating 

















Fig. 4. A and B. 
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Fig. 4. Models for the pathobiology of SCAN1. (A) Putative Tdp1 function in the 
mitochondria. Wild type Tdp1 removes the residual peptide from stalled mtTopo I 
complexes. Interfering DNA lesions are processed by OGG1 and by PNKP or APE1. 
Religation synthesis would then proceed by mitochondrial short patch-BER. (B) The 
mitochondrial dysfunction model. In SCAN1, p.His493Arg Tdp1 (in bold) removes peptides 
derived from Topo I-DNA complexes at a severely compromised rate. This sluggish repair 
leads to a higher steady-state level of mtDNA SSBs and DSBs. To bypass the lack of Tdp1, 
error-prone repair may generate mtDNA deletions which impair mitochondrial function 
leading to cell death and SCAN1. (C) The Tdp1 neomorph model. Mutagenic p.His493Arg 
Tdp1 is trapped on DNA, and since wild type Tdp1 most efficiently repairs p.His493Arg 
Tdp1-DNA adducts, the unresolved p.His493Arg Tdp1-DNA adducts in cells from SCAN1 
patients will lead to much higher steady state levels of nuclear and mitochondrial DNA 
SSBs. This could cause neuron death both by SSB-induced programmed cell death and by 
cellular energy depletion secondary to mitochondrial dysfunction. The energy depletion 
would be accentuated by the increased energy requirement for DNA repair as exemplified 
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6. Future directions 
The discovery of Tdp1 in mitochondria places the pathobiology of SCAN1 in a new light 
although whether specific mitochondrial pathology is relevant to the pathogenesis of 
SCAN1 remains to be elucidated. To that end, the generation of Tdp1His493Arg mice will 
enable a thorough investigation of the physical and molecular characteristics of SCAN1.  
Equally important is the precise elucidation of Tdp1 function in DNA processing. 
Research in mice and yeast has deciphered much about Tdp1 function but much 
remains to be discovered. Tdp1 orthologues have been described in 29 organisms, most 
recently in the plants Arabidopsis sp. and Medicago sp., where Tdp1 repair of Topo I-
induced damage is consistent with its role in mammalian cells (Lee et al., 2010; Macovei 
et al., 2010). As the time and cost of DNA sequencing continues to decline and 
techniques for probing the genome become more accessible to biologists, the study of 
emerging model organisms will provide valuable insights into the evolutionary 
conservation of Tdp1. This approach would allow more detailed evaluation of Tdp1 
from an evolutionary perspective and enhance our mechanistic understanding. For 
example, this might enlighten us as to why the Drosophila melanogaster homologue glaikit 
appears to have a function distinct from that of the mammalian and plant Tdp1 
homologues (Dunlop et al., 2000; Dunlop et al., 2004) 
The study of SCAN1 has also defined Tdp1 as a reasonable drug target for other diseases.  
The absence of neurological disease in Tdp1 deficient mice and the adolescent onset of 
SCAN1 in humans suggest that Tdp1 could be inhibited briefly without severe adverse 
consequences. Since Tdp1 increases resistance to the Topo I poisons used as anticancer 
agents, these findings suggest that a combination therapy of Topo I poisons with Tdp1 
inhibitors might enhance the efficacy of the Topo I poisons as anticancer drugs (Marchand et 
al., 2009). 
7. Conclusion 
Mitochondrial dysfunction is not yet the sine qua non of SCAs, but it is increasingly reported 
in neurodegenerative diseases. Besides the SCAs, mitochondrial dysfunction has been 
reported as contributing to the pathobiology of aging, Alzheimer disease, Parkinson disease, 
Huntington disease and amyotrophic lateral sclerosis. Much of this work has focused on 
mitochondrial-derived reactive oxygen species; however, the contribution of mitochondrial 
fusion and fission to neuronal health and disease as well as other mitochondrial processes 
remain to be explored (Lin and Beal, 2006; Westermann, 2010). SCAN1 is emblematic of the 
interplay between the nuclear and mitochondrial genomes and how dysfunction in both 
organelles can jointly contribute to disease. This dual nuclear and mitochondrial 
pathobiology will need to be taken into consideration in experimental design as well as in 
the classification and clinical management of neurologic disorders.  
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1. Introduction 
Spinocerebellar ataxias (SCAs) are a heterogeneous group of autosomal dominant 
neurodegenerative disorders characterized by a progressive cerebellar syndrome, variably 
associated to signs of brainstem involvement, pyramidal or extrapyramidal manifestations 
and cognitive dysfunctions, among other features that confer a remarkable wide range in 
phenotypes (Harding, 1983; Durr, 2010). 
SCAs are associated with at least 31 different genetic loci, but the responsible gene is known 
in only 19 of them. Causative mutations include coding CAG expansions leading to a long 
polyglutamine (polyQ) tract in the respective proteins (SCA1, 2, 3, 6, 7 and 17), non-coding 
trinucleotide or pentanucleotide expansions (SCA8, 10, 12 and 31), as well as conventional 
mutations (SCA5, 11, 13, 14, 15/16, 20, 27 and 28) (Durr, 2010). The worldwide prevalence of 
SCAs is estimated near to 5-7 cases per 100 000 inhabitants but it can be higher in some 
regions due to foundational effects such as SCA2 in Holguín, Cuba (Velazquez-Pérez et al., 
2009a)  and  SCA3 in Azores islands, Portugal (Vale et al., 2010). 
Oculomotor disturbances are prominent features of SCA patients as result of cerebellar and 
brainstem neurodegeneration (Zee et al., 1976; Pula et al., 2010). The study of eye movement 
abnormalities give us valuable tools to search disease biomarkers because they can be easily 
accessible to clinical and/or electrophysiological evaluations and their dynamic properties 
and neurobiological basis are well known (Leigh & Kennard, 2004; Leigh & Zee, 2006; Reilly 
et al., 2008). The focus of this chapter is to review the state of the art of the eye movement 
deficits in SCAs, emphasizing in the usefulness of these features as disease biomarkers. 
2. Brief overview of eye movements 
Eye movements contribute to the clear vision stabilizing images on the retina, especially 
against movements of the head and body, capturing and keeping particular stimuli on the 
fovea and aligning the retinal images in the two eyes to guarantee the single vision and 
stereopsis. These functions can be achieved by 5 basic types of eye movements. For example, 
the image stabilization on the retina is promoted by the vestibulocular and optokinetic 
reflexes; the foveation occurs thorough the saccadic and smooth pursuit movements, 
whereas the binocular alignment is guaranteed by the vergence eye movements (Bruce & 
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Eye movements differ in many aspects, such as their velocity, reaction time, 
reflexivity/volitional degree and their neurobiological substrate (Sparks, 2002). 
Nevertheless all have generic kinematic properties and share a common final path 
represented by three cranial nerve nuclei and the three pairs of eye muscles that they control 
(Bruce & Friedman, 2002; Leigh & Zee, 2006). Cranial nerve III (oculomotor) innervates 
superior, inferior and medial rectus muscles as well as the inferior oblique muscle, whereas 
troclear (IV) and abducens (VI) nerves innervate the superior oblique and lateral rectus 
respectively (Leigh & Zee, 2006).  
Main features and neurophysiological bases of the 5 basic types of eye movements will be 
briefly addressed as follow.  
2.1 Vestibulocular reflex (VOR) 
The vestibulocular reflex (VOR) is elicited by the vestibular system in response to 
body/head rotations and consists in compensatory eye movements in opposite direction to 
body/head movement to guarantee the image stabilization on the retina (Aw et al., 1996). 
VOR depends of two neural circuits: a) Basic three neurons circuit and, b) Neural integrator 
circuit.  
In the basic three neurons circuit, the head/body rotations are detected and transduced by 
vestibular ganglion neurons in the semicircular canal. Then, the transduced information is 
projected to neurons of the vestibular nuclei, located in the pons, and from there to 
oculomotor neurons (OMN) in one of the three oculomotor nuclei. Nevertheless, the three 
neurons circuit by itself is unable to adequately stabilize the image on the retina because it 
only generates phasic innervations of the oculomotor muscles, causing the return of the eye 
back to the central position due to the pulling of elastic forces.  The neural integrator serves 
to exactly overcome this elastic force producing tonic innervations of oculomotor muscles. It 
is located in the prepositus hypoglossi and medial vestibular nuclei, which receive projections 
from the vestibular nuclei and have recurrent connections onto themselves. Some vestibular 
afferents go directly to the floculus/parafloculus cerebellar lobe, which is involved in VOR 
adaptation (Bruce & Friedman, 2002). 
2.2 Optokinetic reflex (OKR)  
When head/body rotations are very large and continued the VOR is depressed and thus it is 
complemented by the optokinetic reflex (OKR), in which the speed and direction of a full-
field image motion is computed to develop eye movements with two phases, an slow phase 
that  alternates with resetting quick phase (Tusa & Zee, 1989).  Pathway underlying OKR 
includes the nucleus of the optic tract, which receives visual motion signals from the 
contralateral eye and striate/extrastriate cortical areas. This information is send to the 
vestibular nuclei and to the inferior olivary nucleus, and then to the flocular/paraflocular 
Purkinje cells via their climbing bers (Bruce & Friedman, 2002). 
2.3 Saccadic eye movements 
Saccades are ballistic, conjugate eye movements that redirect fovea from one object of 
interest to another, allowing to explore accurately the visual scenes. For that, the saccadic 
system processes information about the distance and direction of a target image from the 
 
Eye Movement Abnormalities in Spinocerebellar Ataxias 
 
61 
current position of gaze. Saccades are the fastest eye movements, reaching up to 6000/s. 
There are close relationships between saccadic peak velocities, durations and amplitudes, 
which represent the saccadic main sequence (Bahill et al., 1975, Ramat et al., 2007).  
Behaviourally, the saccades may be classified as reexive guided saccades and intentional or 
volitional saccades. The first ones are evoked by the suddenly appearing targets, whereas 
the second ones, called also higher-order saccades, are made purposely, involve high 
cognitive processing and include voluntary, memory guided and delayed saccades as well 
as antisaccades (Müri & Nyffeler, 2008; Leigh & Kennard, 2004).   
The neural basis of saccadic eye movements system comprises some cortico-cortical and 
cortico-subcortical networks (Müri & Nyffeler, 2008). Visual information processed in the 
primary visual cortex is send to higher cortical areas, such as parietal eye field (PEF) and 
frontal eye field (FEF), which are involved in the preparation and triggering of reflexive and 
intentional saccades respectively (Pierrot-Deseilligny, et al., 2004). These cortical areas 
project their output directly or through the basal ganglia, to superior colliculus, a midbrain 
structure that identifies the target in retinotopic coordinates, generates trigger signal to the 
brainstem premotor oculomotor circuitry and encodes the magnitude and direction of the 
desired eye movement. This information is projected to the cerebellum, via a pontine pre-
cerebellar nucleus, which guarantees the saccadic accuracy. Premotor burst neurons (PBN)  
for horizontal saccades  lie within  the paramedian pontine reticular  formation  (PPRF)  
while burst neurons  for vertical  and  torsional  saccades  lie  within  the  rostral  interstitial  
nucleus  of  the  medial longitudinal fasciculus. Saccade-related cerebellar areas include the 
oculomotor vermis (lobules VI and VII) and the caudal region of the fastigial nucleus which 
send saccade commands to the contralateral PBNs leading the activation of motorneurons 
and oculomotor muscles related with the desired saccadic movement (Leigh & Zee, 2006; 
Robinson  & Fuchs, 2001;  Prsa & Their, 2011; Voogd et al., 2011).  
2.4 Smooth pursuit movements 
Smooth-pursuit eye movements enable us to maintain the image of a moving object 
relatively stable on or near the fovea by matching eye velocity to target velocity (Leigh & 
Zee, 2006). Smooth pursuit performance is optimal for target speeds ranging between 150/s 
and 300/s but pursuit velocity can reach up to 1000/s (Lencer & Trillenberg 2008; Bruce & 
Friedman, 2002). Smooth pursuit system is closely related to other oculomotor systems such 
as OKR and saccadic system. In fact, the small position errors raised when the tracking 
velocity is not properly matched to the target are corrected by saccadic movements named 
“catch up” saccades (Lencer & Trillenberg, 2007). 
Neuronal pathways for smooth pursuit movements involve a complex network of cortical 
and subcortical structures. Extrastriate visual area V5 (divided into middle temporal visual 
area (MT) and the medial superior temporal visual area (MST)) play a crucial role for motion 
perception and smooth pursuit control.  This area receives visual motion information from 
the primary visual cortex in a retinotopic and ipsilaterally organized fashion. The MT area 
encodes image motion in a retinal coordinate system whereas MST area converts the signals 
into a spatial coordinate system. The signals generated in the V5 area are projected to other 
cortical areas in the parietal and frontal lobes. Among them, the frontal eye field (FEF) is 
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perception and smooth pursuit control.  This area receives visual motion information from 
the primary visual cortex in a retinotopic and ipsilaterally organized fashion. The MT area 
encodes image motion in a retinal coordinate system whereas MST area converts the signals 
into a spatial coordinate system. The signals generated in the V5 area are projected to other 
cortical areas in the parietal and frontal lobes. Among them, the frontal eye field (FEF) is 





signals and oculomotor commands are relayed to oculomotor parts of the cerebellum, 
through the dorsolateral and medial pontine nuclei. Smooth pursuit-related areas of the 
cerebellum comprise the paraocculus, the occulus, the oculomotor vermis and the uvula, 
which control the initiation and maintenance of smooth pursuit. Finally, the cerebellar 
output is projected, via the vestibular nuclei, to the oculomotor nuclei (Lencer & Trillenberg, 
2007; Mustari et al., 2009). 
2.5 Vergence eye movements 
Vergence eye movements are disjunctive movements that provide the binocular alignment 
in response to changing xation target distances, requiring that both eyes point in contrary 
directions (Zee & Levi, 1989). Vergence movements are elicited by retinal disparity (when a 
fixation target is not on both foveae) and retinal blur (when a target is not in focus) and are 
closely related to the lens accommodation and pupillary reflexes. Although the neural basis 
of vergence eye movements are not well understood, it is known that both the retinal 
disparity and the retinal blur signals are processed by cortical visual areas such as primary 
visual cortex (V1) and an anterior region of the FEF. Additionally, it is presumed an 
important role of the oculomotor nucleus (III) for vergence movements, due to its known 
relation to lens accommodation and pupillary reflexes (Vilis, 1997; Bruce & Friedman, 2002). 
The cerebellum is involved in the processing of dynamic vergence eye movements (Sander 
et al., 2009). Cerebellar regions related with these disconjugate eye movements lie on the 
dorsal paraflocculus, and the floccular lobe, which project to the lateral portion of the 
posterior interposed nucleus (Voogd et al., 2011). 
2.6 Oculomotor disturbances  
Oculomotor disturbances can be topographically classified as peripheral or central 
disturbances. Peripheral abnormalities result from lesions in the oculomotor muscles or 
nerves, whereas the central disturbances are caused by lesions in the brainstem, cerebellum 
or other higher-level centers (Karatas, 2009). Oculomotor signs of cerebellar impairment 
include pathological nystagmus such as downbeat, rebound and periodic alternating 
nystagmus, as well as abnormal pursuit, VOR/OKR abnormalities and saccadic dysmetria 
(Robinson & Fuchs, 2001; Strupp et al., 2011). Whereas, brainstem involvement produces 
slowed vertical, torsional or horizontal saccades, ophthalmoplegia, VOR/OKR impairments 
and gaze-evoked nystagmus (Rüb et al., 2008, Strupp et al., 2011). Affectations in the basal 
ganglia can lead to reduced ability to initiate voluntary eye movements and to suppress 
unwanted saccades, in addition to decits in memory-guided saccades, eye-head 
coordination and eye-hand coordination (Hikosaka et al., 2000; Shires et al., 2010). Frontal 
cortex lesions produce prolongation of saccadic latency, impaired ability to make saccades 
to remembered target locations and errors on the antisaccade task, as well as delayed 
initiation of smooth pursuit and increase of catch up saccades (Pierrot-Deseilligny et al., 
2004; Thurtell et al., 2007; Karatas, 2009).  
3. Oculomotor findings of spinocerebellar ataxias  
3.1 Spinocerebellar ataxia type 1 (SCA1) 
The main eye movement abnormalities of SCA1 patients include saccadic dysmetria, gaze 
evoked nystagmus and depressed smooth pursuit (Matilla-Dueñas et al., 2008). Saccadic 
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hypermetria is observed in majority of the cases, appears at an early stage of the disease and 
progresses quickly (Klostermann et al., 1997; Rivaud-Pechoux et al., 1998; Buttner et al., 
1998). The overshoot of saccades may reach values greater than 30% in comparison with 
normal subjects (Buttner et al., 1998).  
Brainstem oculomotor signs such as saccadic slowing or ophthalmoparesis are observed in 
74% (Schmitz-Hübsch, et al., 2008). Reduction of saccade velocity can be detected in mildly 
affected patients and it is accentuated with the disease duration. Advanced patients may 
show ophthalmoparesis or severe saccadic slowing, so that saccadic hypermetria is less 
noticeable in comparison to early stages (Klostermann et al., 1997). Abnormal prolongation 
of saccadic latency occurs in 67% of cases (Buttner et al., 1998), whereas the execution of the 
antisaccadic task shows increased error rates, suggesting the presence of neurodegenerative 
changes in the frontal cortex (Rivaud-Pechoux et al., 1998).    
Reduced gain of smooth pursuit and OKN is noticed in 92% of SCA1 cases  with the lowest 
smooth pursuit gains in comparison to SCA2 and SCA3 patients and comparable values of 
OKN gains to SCA2 (Burk et al., 1998). The progressive saccadic slowing causes the 
diminution of catch up saccades during visual tracking, leading to decrease of the smooth 
pursuit amplitudes on advanced disease (Buttner et al., 1998, Klostermann et al., 1997). 
Regarding vestibular functions, SCA1 patients are usually characterized by reduced VOR 
gains, which distinguish this SCA subtype from SCA2 but neither from SCA3 nor SCA6 
(Burk et al., 1998; Buttner et al., 1998).  
No oculomotor abnormalities of SCA1 patients correlate with the number of CAG repeats 
(Burk et al., 1999; Rivaud-Pechoux et al.,1998), suggesting that they are not under significant 
genetic control but are more dependent on disease duration.  
3.2 Spinocerebellar ataxia type 2 (SCA2) 
The most common oculomotor sign in patients with SCA2 is a significant reduction in 
horizontal saccadic eye velocity owing to brainstem involvement. This feature called 
attention to Wadia and Swami when made the first report of SCA2 in 1971, so that they 
described the disease as “a new form of heredofamilial spinocerebellar degeneration with slow eye 
movements” (Wadia & Swami, 1971). Several clinical and epidemiological studies have 
confirmed the high frequency of this saccadic alteration in more than 80% of cases 
(Velazquez-Pérez et al., 2009a; Orozco et al., 1989; Cancel et al., 1997, Wadia et al., 1998; 
Schmitz-Hübsch, et al., 2008).  
The first electronystagmographical evaluation of SCA2 patients was conducted by Kulkarni 
& Wadia in 1975 who found a relative decrease of saccadic velocity up to 25% in comparison 
with controls (Kulkarni & Wadia, 1975). Furthermore, comparative studies of oculomotor 
phenotypes among patients with cerebellar ataxias demonstrated that saccadic slowing is 
more prominent in SCA2 patients in comparison with SCA1, SCA3, SCA6 (Burk, et al; 1999; 
Buttner et al., 1998; Rivaud-Pechoux et al., 1998) and late onset cerebellar ataxia (Rufa & 
Federighi, 2011) giving an important diagnostic value to this oculomotor feature for SCA2. 
A comprehensive electronystagmographical study developed in 82 SCA2 Cuban patients 
showed little overlap between maximal saccadic velocity (MSV) values of SCA2 patients and 
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receiver operating characteristic (ROC) yielding an area under the curve of 0.99. The most 
important finding of this work was the significant influence of the number of CAG repeats, 
but not of disease duration, on saccadic velocity (Figure 1). According to this relationship, 
patients with larger expansions showed more saccadic slowing, identifying the saccadic 
velocity as the main variable endophenotype of the SCA2, which is under strong genetic 
control and therefore it may be considered as a sensitive biomarker for the study of 
polyglutamine toxicity. Also, MSV was negatively correlated with the total score of a 
cerebellar ataxia scale suggesting its association with the severity of the cerebellar syndrome 
(Velázquez et al., 2004). Other study performed in Cuban SCA2 patients revealed a closer 
relationship between the saccadic velocity and the visuomotor learning capabilities assessed 
by a prism adaptation task (Fernandez-Ruiz, et al., 2007). 
A preliminary follow-up evaluation of saccadic slowing after one year in 30 SCA2 patients 
revealed no significant changes of MSV (Seifried et al., 2004). Nevertheless, other follow-up 
study during a larger period time it is being conducted in a large Cuban SCA2 cohort.   
The saccadic slowing appears during the presymptomatic stage of the disease only for 60° 
target amplitude, but asymptomatic subjects carrying full-penetrant CAG expansions (≥36) 
show reduced MSV values even for 30°. In fact, the MSV reduction is stronger in carriers of 
large expansions. This preclinical feature progresses insidiously and it correlates with 
predicted time to clinical manifestation, which classifies this variable as a preclinical 
biomarker of high values for diagnosis and prognosis of the disease (Velázquez-Pérez et al., 
2009b).  
The neuroanatomical basis of this disorder has been elucidated by post-mortem studies that 
demonstrated the marked loss of excitatory PBN in the PPRF (Buttner-Ennever, et al., 1985; 
Geiner et al., 2008), the structure that coordinates the horizontal saccades (Leigh & Zee, 
2006).  Early, Gierga et al, 2005 had reported a significant neuronal death in the abducens 
(cranial nerve VI) and oculomotor nucleus (cranial nerve III), which innervate the 
oculomotor muscles responsible for eye movements in the horizontal plane (Leigh & Zee, 
2006). 
Hypometric saccades to extreme gaze positions are usual in SCA2 patients (Velázquez, 
2008), nevertheless for short target amplitudes the saccade accuracy is maintained, although 
some patients can make hypermetric saccades. It has been suggested that as SCA2 patients 
having slow saccades that are no longer ballistic, visual feedback might be continuously 
available during the movement execution to guide the eye to its target rendering accurate 
short saccades (Federighi et al., 2011). 
A recent electronystagmographical study in 110 SCA2 patients demonstrated the significant 
prolongation of saccadic latency in 46% of SCA2 patients. This variable was neither 
influenced by the CAG repeats, disease duration nor ataxia score, but it was close related 
with the neuropsychological performance of frontal-executive tasks, which highlights the 
saccadic latency  as sensitive biomarker of cognitive disorders in SCA2 (Rodríguez-Labrada, 
et al., 2011a). Additionally, SCA2 patients show increased antisaccadic error rate (Rivaud-
Pechoux et al., 1998).  The delayed saccade onset and antisaccadic deficits could be 
explained by the severe gyral atrophy and neuronal loss in the frontal lobes and 
neurodegenerative changes in caudate nucleus and substantia nigra (Orozco et al., 1989; 
Durr et al., 1995; Estrada et al., 1999; Gierga et al., 2005), as well as deficits in the processing  
 




Fig. 1. Saccadic slowing in SCA2. A) Relationship of saccadic velocity and amplitudes in 
SCA2 patients. Show the significant reduction of saccadic velocity in almost all subjects. 
Dark lines represent the saccadic velocity ± 2 SD of controls. B) Influence of CAG repeat size 
on the saccadic velocity. 
of visual information (Kremlacek et al., 2011) or in the visual-spatial attention (Le Pira et al., 
2002).  
 
            (A)              (B) 
Fig. 2. Saccadic latency correlates with frontal-executive dysfunctions in SCA2 patients. 
Correlation analyses of saccadic latency with achieved categories in the Wisconsin sort card 
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Other oculomotor alterations include ofthalmoplegia, which usually appears at advanced 
disease in the 45% of the cases, although the severe saccadic slowing might overlook the 
frequency of ofthalmoplegia in SCA2. These patients have mild reduction of smooth pursuit 
gain in correspondence with the atrophy of cerebellar floculus (Ying et al., 2006) and the 
decrease of catch up saccades. The physiological and pathological nystagmus are very rare 
in SCA2 due to impaired ability to produce saccadic corrective phases. Some SCA2 patients 
have VOR responses with reduced gain (Burk et al., 1999; Rivaud-Pechoux et al., 1998; 
Buttner et al., 1998).  
Saccadic eye movements have also been used to evaluate the efficacy of therapeutical 
alternatives in Cuban SCA2 patients, such as neurorehabilitation (Rodríguez et al., 2008) and 
oral supplementation with zinc-sulphate (Velázquez-Pérez et al, 2011a). In both cases the 
saccadic latency decreased significantly after the therapies, but saccadic velocity and 
dysmetria were unchanged.  
For SCA2, the oculomotor function has not only evaluated in wake state, since the density of 
rapid eye movements (saccadic) during REM sleep was recently assessed. Both symptomatic 
and presymptomatic subjects show a marked decrease in this parameter, which is negatively 
correlated with the ataxia score in the patients (Velázquez-Pérez, et al., 2011b; Rodríguez-
Labrada et al., 2011b). These findings suggest the usefulness of saccadic density during REM 
sleep as progression marker of the disease and reflect the extension of the oculomotor 
brainstem involvement to the sleep.  
3.3 Spinocerebellar ataxia type 3 (SCA3) 
Pathological nystagmus are prominent oculomotor signs of SCA3 patients. The frequency of 
gaze evoked and rebound nystagmus is approximately 90% (Jardim et al., 2001) being 
higher than those in SCA1, SCA2 and SCA6. Square wave jerks are usually reported in 
SCA3 subjects, unlike SCA1 and SCA2 individuals (Buttner et al, 1998; Burk et al., 1998). 
This oculomotor sign results from cerebellar disease and consists in small, horizontal, 
saccade-like movements that lead the eye away from the target trajectory and, after a delay, 
bring it back onto the target (Leigh & Zee, 2006).  
Decreased VOR gain can be detected in majority of SCA3 patients and correlates with the 
CAG repeats, suggesting the pathologic involvement of the vestibular nuclei in the lateral 
brainstem. Furthermore, these patients show reduction of smooth pursuit and OKR gains 
with a presentation frequency above 70% in both cases (Buttner et al, 1998; Burk et al., 1998).  
Upon saccades, the main abnormality is saccadic dysmetria. Nevertheless, there are 
apparently conflicting data regarding the predominant type of dysmetria. Buttner et al., 
1998 reported hypermetric saccades in 86% of the cases, while Rivauld-Pechoux et al., 1998, 
observed a predominance of hypometric (56%) over hypermetric saccades (18%). The 
disagreement can be explained by differences in the clinical stage of studied patients. In fact, 
the 81% of the patients recruited by Rivauld-Pechoux and colleagues had a moderate to 
severe motor disability, which could explain the higher prevalence of saccadic hypometria. 
Different to SCA2 and SCA1, decreased saccadic velocity is not a common feature of SCA3 
patients (Burk et al., 1999; Rivaud-Pechoux et al., 1998; Buttner et al., 1998). This oculomotor 
feature appears in advanced disease, perhaps in correspondence with the degenerative 
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changes seen in the raphe interpositus nucleus (Rub et al., 2003), a key structure of the 
brainstem premotor network that contains the omnipausas neurons, a group of cells that 
play an important role in determining the size of the velocity command for saccades, beside 
their well-known role as gating saccades (Miura & Optican, 2006). Also, internuclear and 
nuclear ophthalmoplegia is observed in 53% and 10% of the cases respectively.  The latter is 
associated with a more severe disease course (Jardim et al., 2001). 
Finally, the prolongation of saccadic latency occurs late in few cases (14%) (Buttner et al., 
1998) and the performance in the antisaccadic paradigm shows an increase in the number of 
errors (Rivaud-Pechoux et al., 1998).   
3.4 Spinocerebellar ataxia type 6 (SCA6) 
Oculomotor function of SCA6 patients is characterized by signs of cerebellar and vestibular 
impairments such as horizontal and vertical nystagmus, abnormal smooth pursuit, saccadic 
dysmetria and abnormal VOR (Buttner et al., 1998; Christova et al., 2008; Bour et al., 2008). 
In comparison with other SCAs, the spontaneous downbeat nystagmus and square-wave 
jerks have the higher incidence in SCA6 subjects, whereas  gaze-evoked nystagmus, 
rebound nystagmus and periodic alternating nystagmus are common features too (Buttner 
et al., 1998; Colen et al., 2008; Kim et al., 2010).  
Patients with SCA6 have the more severe pursuit, OKN and VOR-fixed deficits among other 
polyglutamine SCAs but these oculomotor signs are not directly associated to CAG repeats 
or disease duration (Buttner et al., 1998). Vertical pursuit is impaired more than horizontal 
whereas downward pursuit more than upward (Bour et al., 2008).  
The pattern of saccadic dysmetria in SCA6 is variable since these patients can show both 
hypometric and hypermetric saccades (Buttner et al., 1998; Bour et al., 2008). Although the 
decrease of saccadic velocity is not a prominent sign in these patients, it has been reported a 
mild saccadic slowing in some subjects both for the horizontal and vertical planes (Bour et 
al., 2008). These findings suggest functional extracerebellar impairment in the saccadic 
system and therefore are opposed to the paradigm of SCA6 as a "pure cerebellar syndrome." 
In fact, the screening of non-ataxia signs reveals a 25% of brainstem oculomotor signs 
(Schmitz-Hübsch, et al., 2008). In these patients the saccadic latency is normal (Buttner et al., 
1998).  
In 2009, Christova and co-workers studied the eye movement’s abnormalities in both 
symptomatic and asymptomatic SCA6 cohorts and noticed that square-wave jerks, saccadic 
abnormalities and depressed smooth pursuit can be detected even before the disease onset. 
Among them, the square-wave jerks were the most prominent with an apparition frequency 
of 80% (Christova et al., 2008).  
3.5 Spinocerebellar ataxia type 7 (SCA7) 
The major saccadic alteration in this SCA is the slowing of saccades, together with saccadic 
dysmetria (Miller et al., 2009; Manrique et al., 2009). The decrease in saccadic velocity in 
SCA7 is associated with marked pontine atrophy that characterizes these patients from early 
stages of the disease and progresses to produce significant external ophthalmoplegia in 
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changes seen in the raphe interpositus nucleus (Rub et al., 2003), a key structure of the 
brainstem premotor network that contains the omnipausas neurons, a group of cells that 
play an important role in determining the size of the velocity command for saccades, beside 
their well-known role as gating saccades (Miura & Optican, 2006). Also, internuclear and 
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associated with a more severe disease course (Jardim et al., 2001). 
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whereas downward pursuit more than upward (Bour et al., 2008).  
The pattern of saccadic dysmetria in SCA6 is variable since these patients can show both 
hypometric and hypermetric saccades (Buttner et al., 1998; Bour et al., 2008). Although the 
decrease of saccadic velocity is not a prominent sign in these patients, it has been reported a 
mild saccadic slowing in some subjects both for the horizontal and vertical planes (Bour et 
al., 2008). These findings suggest functional extracerebellar impairment in the saccadic 
system and therefore are opposed to the paradigm of SCA6 as a "pure cerebellar syndrome." 
In fact, the screening of non-ataxia signs reveals a 25% of brainstem oculomotor signs 
(Schmitz-Hübsch, et al., 2008). In these patients the saccadic latency is normal (Buttner et al., 
1998).  
In 2009, Christova and co-workers studied the eye movement’s abnormalities in both 
symptomatic and asymptomatic SCA6 cohorts and noticed that square-wave jerks, saccadic 
abnormalities and depressed smooth pursuit can be detected even before the disease onset. 
Among them, the square-wave jerks were the most prominent with an apparition frequency 
of 80% (Christova et al., 2008).  
3.5 Spinocerebellar ataxia type 7 (SCA7) 
The major saccadic alteration in this SCA is the slowing of saccades, together with saccadic 
dysmetria (Miller et al., 2009; Manrique et al., 2009). The decrease in saccadic velocity in 
SCA7 is associated with marked pontine atrophy that characterizes these patients from early 
stages of the disease and progresses to produce significant external ophthalmoplegia in 





may precede cerebellar and retinal manifestations and are among the earliest signs of the 
disease (Oh et al., 2001). In addition, some cases have difficulties to initiate the saccadic eye 
movements and may develop gaze evoked nystagmus (Miller et al., 2009; Manrique et al., 
2009).  
3.6 Spinocerebellar ataxia type 17 (SCA17) 
The patients with SCA17 show hypometric saccades in correspondence with the marked 
reduction of Purkinje cells in the cerebellum (Hubner et al., 2007). The saccadic hypometria 
is increased with disease duration but neither with ataxia score nor the number of CAG 
repeats. In 26% of cases, there are transient saccadic decelerations and accelerations causing 
hypometric saccades with multiple steps. Clinical assessments have reported normal 
(Nakamura, 2001) or slowed saccades (Rolfs et al., 2003), although the hypometria or 
prematurely terminated saccades may conduce to the erroneous classification of slowed 
saccades. In these patients, the saccadic latency is normal, while antisaccades have a 
significant increase in the error rate (Hubner et al., 2007). 
Smooth pursuit abnormalities in SCA17 patients include decrease of initial eye acceleration, 
which appears even in the asymptomatic and mildly affected SCA17 mutation carriers, 
reduced steady state velocity and prolongation of smooth pursuit latency. Smooth pursuit 
gain decreases with the disease duration and ataxia score, whereas the latency prolongation 
correlates positively with the ataxia score. Gaze-evoked nystagmus is not a prominent 
feature in SCA17 patients (Hubner et al., 2007). 
3.7 Other spinocerebellar ataxias 
With the exception of polyglutamine expansions SCAs, the oculomotor function of 
remaining SCAs has not been systematically studied while most of data result for clinical 
assessment.  SCA5 is characterized by eye abnormalities owing to cerebellar impairments 
such as downbeat nystagmus and impaired smooth pursuit movements (Ranum et al., 1994; 
Ikeda et al., 2002). Similar features occur in SCA8, in addition to saccadic dysmetria (Day et 
al., 2000; Koob et al., 1999), and SCA10 (Zu et al., 2000; Grewal et al., 2002; Lin & Ashizawa, 
2005). SCA11 is associated with horizontal and vertical nystagmus as well as jerky pursuit 
(Worth et al., 1999), while approximately one third of SCA12 patients can develop saccadic 
slowing, abnormal smooth pursuits or pathological nystagmus (Worth et al., 1999, 
Fujigasaki et al., 2001). Besides, in subjects affected with SCA13 is usual to observe 
horizontal nystagmus (Stevanin et al., 2005; Waters & Pulst, 2008). 
Regarding SCA14, the main oculomotor disturbance is the hypermetria of downgaze and 
horizontal saccades, even from the early stages of the disease. Additionally, upwards gaze 
evoked nystagmus are common in patients with longer disease duration.  Smooth pursuit 
movements and VOR are also impaired (Yamashita et al, 2000; Brkanac et al, 2002a; Fahey et 
al., 2005). Eye movement abnormalities of SCA15/16 and SCA18 include nystagmus for all 
these SCA subtypes associated to saccadic dysmetria in the first one (Miyoshi et al., 2001; 
Brkanac et al, 2002b; Gardner et al., 2005). In addition, hypermetric saccades into downgaze 
and lateral gaze are detected in some patients with SCA20 (Knight et al., 2004). 
SCA22 patients show nystagmus and impaired smooth pursuit with intermittent corrective 
saccadic (Chung et al., 2003), while in SCA23 the ocular dysmetria and slowed saccades can 
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be noted (Verbeek et al., 2004; Verbeek, 2009).  SCA25, SCA26 and SCA27 are characterized 
by pathological nystagmus in some patients, associated with slow eye movements in SCA25, 
abnormal pursuit in SCA26 and saccadic dysmetria in SCA27 (van Swieten, et al., 2003; 
Stevanin et al. 2004; Yu et al., 2005). SCA28 patients develop gaze-evoked nystagmus at 
early disease, while subjects with advanced disease have slowed saccades and 
ophthalmoparesis with frequency estimates of 60% and 80% respectively (Cagnoli et al., 
2006). SCA29, which overlap with SCA15, is characterized by bilateral horizontal nystagmus 
(Dudding et al., 2004). In the case of SCA30, hypermetric saccades and gaze evoked 
nystagmus can be detected (Storey et al., 2009), as well as abnormal pursuit in SCA31   
(Ishikawa et al., 2004). Finally, in a new SCA subtype recently identified by Wang et al., 2010 
in two Chinese families, it was observed ocular dysmetria as main oculomotor sign.  
4. Conclusions  
Eye movement abnormalities are among the most common phenotypic manifestations of 
patients with SCAs.  The most prominent oculomotor feature is the presence of pathological 
nystagmus in almost all subtypes, which is generally associated to abnormal smooth 
pursuit, saccadic dysmetria, impaired VOR/OKR, saccadic slowing and ophthalmoplegia. 
These oculomotor phenotypes are useful, but not determinant, for the differential diagnosis 
of SCAs. For example, the early and severe saccadic slowing with rare pathological 
nystagmus distinguishes SCA2 from SCA1, SCA3, SCA6, SCA17 and other SCA subtypes, 
whereas the marked abnormalities of smooth pursuit, VOR and OKR; in association with 
pathological nystagmus and rare saccadic slowing may help to define a SCA6 phenotype. 
Nevertheless, the notable overlapping of oculomotor features between SCA subtypes 
implies the requirement of other clinical criteria or the genetic testing for sensitively 
discriminating among these diseases.     
The study of eye movement abnormalities allows the identification of several biomarkers 
useful in the clinical and research practice of SCAs. Some of the oculomotor disturbances 
precede the ataxia onset, being important preclinical markers to detect the early stages of the 
neurodegenerative process, to evaluate the genetic susceptibility of the asymptomatic 
relatives and to identify individuals close to ataxia onset for enrollment in preventive 
clinical trials and as potential outcome variables in these same trials. As most of the 
oculomotor abnormalities of SCAs are significantly accentuated with the advance of the 
disease, these can be used in monitoring clinical progression and therefore to assess the 
response to symptomatic treatments at short, medium or long term. The number of CAG 
repeats influences significantly on the saccadic slowing in SCA2 and the reduced VOR gain 
in SCA3 classifying these oculomotor features as sensitive biomarker of genetic damage, 
useful to evaluate the effect of modifying factors and therapeutic alternatives on the 
polyglutamine toxicity.  
Despite the above, still is necessary to deep more into the study of oculomotor function in 
SCAs. For example, vergence movements have not been studied, in spite of the known 
role of the cerebellum in these eye movements (Robinson & Fuchs, 2001) and the 
correspondent vergence deficits in patients with circumscribed cerebellar lesions (Sender 
et al., 2009). Moreover, further neuropathological, imaging and transcranial magnetic 
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insight on eye movement abnormalities and its potential role as therapeutic biomarkers in 
SCAs.  
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The autosomal dominant cerebellar ataxias (ADCA) are a clinically, pathologically and 
genetically heterogeneous group of neurodegenerative disorders caused by degeneration of 
cerebellum and its afferent and efferent connections. The degenerative process may 
additionally involves the ponto- medullar systems, pyramidal tracts, basal ganglia, cerebral 
cortex, peripheral nerves (ADCA I) and the retina (ADCA II), or can be limited to the 
cerebellum (ADCA III) (Harding et al., 1993).  
The most common of these dominantly inherited autosomal ataxias, ADCA I, includes many 
Spinocerebellar Ataxias (SCA) subtypes, some of which are caused by pathological CAG 
trinucleotide repeat expansion in the coding region on the mutated gene. Such is the case for 
SCA1, SCA2, SCA3/MJD, SCA6, SCA7, SCA17 and Dentatorubral-pallidoluysian atrophy 
(DRPLA) (Matilla et al., 2006).  
Among the almost 30 SCAs, the variant SCA2 is the second most prevalent subtype 
worldwide, only surpassed by SCA3 (Schöls et al., 2004; Matilla et al., 2006; Auburger, 2011). 
The disorder was first recognized in India in 1971 by Wadia and Swami, who was intrigued 
by the early and marked slowing of saccade movements, associated to the cerebellar 
syndrome (Wadia & Swami, 1971). Contemporarily, in Cuba some neurologists were 
describing many families coming from the north-east region of the country with the same 
distinct clinical picture (Vallés et al., 1978). Subsequent epidemiological surveys in this 
Cuban region, Holguín province, focusing on the causes of the highest SCA2 prevalence rate 
worldwide found evidence for a founder effect (Orozco et al., 1989; Auburger et al., 1990; 
Velázquez-Pérez et al., 2001, 2009a).  
2. Epidemiology  
The collective worldwide prevalence of SCAs is estimated at about 6 cases per 100,000 
people, although much higher gures have been reported in particular populations (Schöls 
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few existing epidemiological studies have been performed in isolated geographical regions 
with families not large enough for linkage analysis. Nevertheless, large SCA2 families have 
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SCA2 represents 87% of ADCAs in Cuba, with a national prevalence rate of 6.57 cases per 
105 inhabitants. If asymptomatic at-risk individuals are included in the prevalence analysis, 
the prevalence rate increases up to 28.51 cases per 105 inhabitants, with remarkable values in 
various eastern provinces, especially in Holguin (Figure 1A). In fact, there are regions in this 
province where the prevalence reaches higher values such as Baguanos municipality (141.7 
per 105 inhabitants) (Figure 1B) (Velázquez-Pérez et al., 2009a).  
 
Fig. 1. Epidemiological picture of SCA2 in Cuba. A) Number and prevalence (in parenthesis) 
of SCA2 mutation carriers in all Cuban provinces. B) Prevalence rates of SCA2 patients (+) 
and SCA2 mutation (*) in Holguin province, Cuba (2006–2007). 
3. Clinical features 
The clinical picture of SCA2 includes a cerebellar syndrome in all patients, characterized by 
ataxic gait, cerebellar dysarthria, dysmetria and dysdiadochokinesia (Orozco et al., 1989; 
Orozco-Diaz et al., 1990). Patients also exhibit abnormal tandem stance (95%), slow saccadic 
eye movements (91%), limited voluntary ocular movements (88%), loss of vibration sense 
(73%), areflexia or hyporeflexia (77%) after initial hiperreflexia and abnormal swallowing 
(76%) (Velazquez-Pérez et al., 2009a). 
Autonomic abnormalities (urinary dysfunction, hypohidrosis, constipation, and sexual 
dysfunction) are present in 78% of the cases and are accentuated in late stages of the disease 
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(Sánchez-Cruz, et al., 2001; Velázquez-Pérez et al., 2009a, Montes et al., 2010), together with 
dysphagia, ophthalmoplegia and distal amyotrophy. Sleep disturbances are frequent 
complaints of SCA2 patients and their relatives. The most prominent sleep disorders are 
restless legs syndrome (Trojano et al., 1998; Schöls et al., 1998; Abele et al., 2001; Irazno et al., 
2007), muscle cramps, insomnia and reduced dream recalls (Velázquez-Pérez et al., 2011a). 
Other clinical manifestations of SCA2 are the cognitive dysfunctions, which include frontal-
executive impairment, verbal short-term memory deficits as well as reduction of attention 
and concentration (Storey et al., 1999; Reynaldo-Arminan et al., 2002; Bürk et al., 1999a; 
2003). Although neuropsychological pattern of cognitive disturbances of SCA2 patients not 
necessarily resembling dementia, some studies have reported high frequency of demented 
patients (Durr et al., 1995, Burk et al., 1999a), but in the SCA2 Cuban population this 
neuropsychological state is rare (Reynaldo-Arminan et al., 2002; Orozco et al., 1989; 1990). 
Depression/anxiety/suicide attempts are found in a third of cases (Reynaldo-Arminan et 
al., 2002). In comparison to other SCAs, the frequency of slowed ocular movements, postural 
and action tremor and hyporeflexia are distinctive features of SCA2 (Schöls et al., 1997). 
Extrapyramidal manifestations are common in SCA2 patients. Myoclonuses are reported in 
13.7% whereas dystonia is present in 14.2%. Chorea may appear in approximately 7%. These 
symptoms are accentuated in patients with larger CAG repeats. Parkinsonian signs appear 
in some patients with low-range expansions containing CAA interruptions (Gwinn-Hardy 
et al., 2000; Payami et al., 2003; Lu et al., 2004; Charles et el, 2007). Among these 
manifestations, resting tremor (14,9%) and rigidity (7,9%) are the most common (Schmitz-
Hubsch, et al., 2008). Recently it was reported an unusual case of SCA2 presenting as an 
ataxia-parkinsonism-motor neuron disease syndrome in a 46-year-old Brazilian man with 40 
CAG repeats in the SCA2 gene (Braga-Neto et al., 2011).  
The age at onset varies from 3 to 79 years (mean 33). Usually, the first symptom of the 
disease is the gait ataxia (97%), followed by the cerebellar dysarthria (3%). However some 
extracerebellar manifestations may occur a decade or more before the onset of gait 
instability or dysarthria, such as painful muscle cramps in the calf, sleep disturbances, 
problems with hand writing (Globas et al, 2008), as well as autonomic alterations, consisting 
in constipation (19.4%) and pollakiuria (17.7%) (Montes-Brown et al, 2011). In the Cuban 
SCA2 population the anticipation of clinical manifestation age in successive generations is 
observed in 80% of transmissions, usually upon transmission from an affected father 
(Velázquez-Pérez et al., 2009a).  
Clinical features develop progressively with an increase in cerebellar syndrome, saccade 
slowing, and other features which confine the patients first to a wheelchair and following to 
a bed, where they die approximately 15–20 years after the initial symptoms. Nevertheless 
patients with larger CAG repeats have earlier age at onset, more saccadic slowing, axial 
tremor, pyramidal-dystonic-choreic signs, mental deficit and in general a faster progression 
to death (Filla et al 1999, Cancel et al 1997; Schöls et al., 1997; Sasaki et al., 1998; Filla et al., 
1999; Velázquez-Pérez et al., 2009a) and the total disease duration from onset to death may 
vary between 6 and 50 years (Klockgether et al., 1998; Maschke et al., 2005). Also, the female 
gender is associated with shortened survival (Klockgether et al., 1998). The main cause of 
death is bronchopneumonia (63%), followed by bronchial aspiration and cardiovascular 
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Pediatric-onset SCA2 is associated with large CAG expansions. Infantile phenotype includes 
rare symptoms such as retinitis pigmentosa, myoclonus-epilepsy, tetraparesis, 
developmental delay and facial dysmorphism (Babovic-Vuksanovic et al 1998; Rufa et al., 
2002; Tan et al., 2004; Di Fabio et al., 2011). Ramocki and coworkers describe a female child 
who met all developmental milestones until age 3 years, deterioration of expressive 
language, comprehension, memory, graphomotor skills, and dysarthria. Cranial nerve 
examination showed bilaterally restricted lateral gaze with oculomotor apraxia (Ramocki, et 
al., 2008). Abdel-Aleem and Zakiwith reported a male child with progressive 
extrapyramidal manifestations, developmental delay, slow eye movements and cognitive 
impairment, trophic changes, vasomotor instability and dysphagia (Aleem and Zakiwith, 
2008) 
4. Molecular genetics 
The underlying mutation of SCA2 consists in the unstable expansion of the trinucleotide 
repeat (CAG)8CAA(CAG)4CAA(CAG)8 within the ATXN2 gene exon 1 located on 
chromosome 12q24.1. This repeat encodes a polyglutamine (polyQ) tract in the protein 
ataxin-2 (Gispert et al., 1993; Pulst et al., 1996; Imbert et al., 1996; Sanpei et al., 1996). In 
normal individuals, the trinucleotide repeat length varies and contains between 13 and 27 
units. Intermediate expansions between 28 and 33 units may predispose the individual to an 
elevated risk for the motor neuron disease ALS or the Parkinson plus syndrome PSP (Elden 
et al., 2010; Ross et al., 2011). The prevalence of large normal alleles potentially acting as 
unstable premutation is particularly high in the Cuban province Holguín (Velázquez-Pérez 
et al., 2009a). Family planning can be aided by presymptomatic molecular genetic 
diagnostics, but care has to taken to offer psychological treatment together with the genetic 
counseling. 
Pathological alleles in SCA2 have more than 32 CAG repeats, although the repeats range 
between 32 and 36 units has incomplete penetrance (Pulst et al., 1996; Cancel et al., 1997; 
Geschwind et al., 1997). The most frequent expanded allele is 37 (72%). The expanded alleles 
have lost interrupting CAA-triplets, a factor thought to promote the length instability. 
Expansions occur in 89% and contractions in 11% of the offspring of affected patients. 
Paternal transmissions show higher variability in repeat lengths compared with the 
maternal transmissions. (Velázquez-Pérez et al., 2009a). The presence of CAA interruptions 
in expanded alleles appears to predispose to a phenotype with Parkinson or with motor 
neuron disease (Charles et al., 2007; Kim et al., 2007; Modoni et al., 2007; Corrado et al., 2011, 
Yu et al., 2011), although both CAG and CAA code for glutamine, indicating that the 
neuronal population affected by the pathogenesis is determined by RNA toxicity rather than 
protein toxicity. 
As in other polyQ diseases, in SCA2 the age at onset and symptom severity correlate 
inversely with the length of the trinucleotide repeat, which accounts for ~80% of variance, 
whereas the remaining variability suggests the existence of modier genes, genetic 
polymorphisms, epigenetic factors and unknown environmental determinants modulating 
age of onset (Velázquez-Pérez et al., 2009a). Supporting the above mentioned, long normal 
CAG repeats in the CACNA1A (Pulst et al., 2005) and RAI1 genes (Hayes et al., 2000) as well 
as the 10398G polymorphism in the mitochondrial complex I gene (Simon et al., 2007) are 
associated with earlier manifestation age, also in the Cuban SCA2 population.  
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4.1 The physiological role of ataxin-2 in cell biology 
The ataxin-2 protein (ATXN2) is a polypeptide containing 1312 amino acids encoded by 25 
exons of the SCA2/ATXN2 gene encompassed within 130 kiloBases of genomic DNA 
(Sahba et al., 1998), with at least five human isoforms produced by allelic splicing 
(Nechiporuk et al 1998; Affaitati et al., 2001; Lastres-Becker et al., 2008a) and an expression 
in many organs, but only selected neurons of the brain (Huynh et al., 1999). It is 
phosphorylated, but not glycosylated (Turnbull et al., 2004). Currently, the function of 
ATXN2 is not clear, but several lines of evidence evoke its involvement in RNA metabolism. 
For example, the protein have sequence motifs related to mRNA processing, most of ATXN2 
is associated to polyribosomes, at the rough endoplasmic reticulum (Satterfield and 
Pallanck, 2006; van de Loo et al., 2009), and this polypeptide interacts with RNA binding 
proteins such as A2BP1 and PABPC1 (Shibata et al., 2000; Ralser et al., 2005a; Satterfield and 
Pallanck, 2006).  
Interestingly, ATXN2 and its orthologues in other organisms relocalize during periods of 
cellular stress to mRNP granules where mRNA is stored during translation repression, 
promote the formation of these stress granules and inhibit cell growth (Swisher and Parker, 
2010; Nonhoff et al., 2007). Furthermore, the expression of ATXN2 is induced by specific 
stressors (Klinkenberg et al., submitted) and ATXN2 levels increase with old age (Huynh et 
al., 1999). The indirect effects of ATXN2 on RNAs appear to be mediated partially by its 
interactor DDX6, a RNA helicase (Nonhoff et al., 2007). Also the formation of P-bodies, 
mRNP granules implicated in RNA degradation, appears to depend on ATXN2, which may 
localize to these structures and influence the microRNA-mediated deadenylation of silenced 
RNAs (Nonhoff et al., 2007; Kozlov et al., 2010). There is preliminary evidence that ATXN2 
co-sediments and co-localizes with neuronal mRNPs which are responsible for the transport 
of mRNAs to synaptic sites of local protein synthesis, and indeed ATXN2 is thought to 
modulate mRNA translation similar to its yeast orthologue Pbp1 (Siddiqui et al., 2007). 
Thus, ATXN2 might be important for stimulus-dependent local mRNA translation and 
influence in this way both synaptic strength and long-term potentiation, an 
electrophysiological finding which was indeed detected in ATXN2-knock-out mice in the 
amygdala, but not in the hippocampus (Huynh et al., 2009). 
Some ATXN2 is also demonstrable at the plasma membrane, and within its protein sequence 
several proline-rich domains are able to interact with SH3-motif containing proteins. Such 
an interaction was demonstrated for endophilin A, CIN85 and Src, three components of the 
endocytosis complex that modulates trophic factor signaling through receptor tyrosine 
kinases (Ralser et al., 2005b; Nonis et al 2008). In these reports, ATXN2 was found to 
antagonize the internalization of the receptor for Epidermal Growth Factor. Interestingly, 
two other neurodegenerative disease proteins are also interactors of this complex, namely 
Huntingtin and Parkin, which was shown to ubiquitinate ATXN2 directly and to rescue 
ATXN2-toxicity (Ralser et al., 2005b; Huynh et al., 2007). Furthermore, the deficiency of 
ATXN2 in knock-out mice was observed to modulate the levels of insulin receptor, resulting 
in insulin resistance, altered fat metabolism and obesity (Kiehl et al., 2006; Lastres Becker et 
al., 2008b). Interestingly, the protein family A2D which shares sequence homology with 
ATXN2 also shows interaction with the cytoplasmic domain of the thrombopoietin and the 
erythropoietin membrane receptors which lack intrinsic tyrosine kinase activity, but is also 
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course, this physiological influence of ATXN2 on trophic signaling may be important for 
neural atrophy in SCA2. Finally, recent evidence suggests a localization and role of ATXN2 
in the nucleus, acting as interactor of the transcriptional regulator ZBRK1 (Hallen et al., 
2011). 
4.2 ATXN2 role for different diseases 
SCA2 is thought to be caused by a toxic gain-of-function of the ATXN2 protein, but it is not 
clear to which degree the physiological function of ATXN2 is enhanced and to which degree 
unspecific toxic effects such as the aggregation of polyQ domain proteins dominate in the 
pathogenesis. Since polyQ expansions in different disease proteins affect different neuronal 
populations, and since the overexpression of wild-type ATXN2 and its orthologues in lower 
species, which lack the polyQ domain completely, is neurotoxic, the specific properties of 
ATXN2 regarding expression, subcellular localization and interactors seem to be relevant in 
disease. Intermediate-length expansions of the ATXN2 trinucleotide repeat below the 
threshold of SCA2 manifestation were shown to have a pathogenic role, increasing the 
individual risk to manifest the motor neuron degeneration disease ALS (Amyotrophic 
Lateral Sclerosis) and the basal ganglia degeneration disease within the Parkinson-plus 
group of disorders PSP (Progressive Supranuclear Palsy) (Elden et al., 2010; Daoud et al., 
2011; Ross et al., 2011; Sorarù et al., 2011; Lee et al., 2011; van Damme et al., 2011). The RNA 
metabolism function of ATXN2 may explain this phenomenon, since ALS pathogenesis 
appears to be mediated mainly by altered mRNA processing (Lagier-Tourenne et al., 2010). 
ATXN2 gain-of-function also potentiates toxicity of ATXN1 and ATXN3 (the SCA1 and 
SCA3 disease proteins, respectively) and even toxicity of Tau (the frontotemporal lobar 
degeneration disease protein) in the fly model (Shulman and Feany, 2003; Al-Ramahi et al., 
2007; Lessing and Bonini, 2008; Elden et al., 2010). Conversely, reducing ATXN2 levels is 
sufficient to mitigate the neurotoxicity triggered by TDP-43, ATXN1 and ATXN3 (Al-
Ramahi et al., 2007; Lessing et al., 2008; Elden et al., 2010) in yeast and flies, indicating that 
these effects are mediated by the physiological function of ATXN2, but not by the polyQ 
domain which characterizes human ATXN2 and is not conserved until mouse. 
Large expansions of ATXN2 were reported to exert a profound effect on intracellular 
calcium levels through specific binding to the carboxy-terminal region of the type 1 inositol 
1,4,5-trisphosphate receptor (IP(3)R1), an intracellular Ca(2+) release channel (Liu et al., 
2009), an effect mediated by ATXN2 at its major localization in the cytoplasm. 
Several lines of evidence suggest that other alterations of the physiological ATXN2 function 
influence additional neuron populations and diseases. In neuroblastoma tumors, an 
upregulation of ATXN2 was found to be a decisive factor to induce apoptosis of the aberrant 
cells and spontaneous tumor remission (Wiedemeyer et al., 2003). In individuals who 
reached an age over 100 years, a single nucleotide polymorphism within ATXN2 intron 1 
contributes to the genetic signature of exceptional longevity. Moreover, in the general 
human population the same ATXN2 intron 1 polymorphism determines high blood 
pressure levels (Levy et al., 2009; Newton-Cheh et al., 2009; Sebastiani et al., 2010).  
4.3 Animal models 
Animal models have been useful tools to study the polyQ expansion diseases, in particular 
the brain tissue of early stage pathology. Specifically ATXN2 orthologues are highly 
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conserved until Saccharomyces cerevisiae, permitting high-throughput genetic screens into 
the function of ATXN2 and revealing the role of ATXN2 as a risk factor for TDP-43 toxicity 
and motor neuron degeneration (Elden et al., 2010). Again, Drosophila melanogaster studies 
demonstrated the association of dATX2 with PABP and with polysomes (Satterfield and 
Pallanck, 2006). The use of RNA interference in Caenorhabditis elegans demonstrated an 
essential role of the atx-2 gene for early embryonic development (Kiehl et al., 2000).  
Taking advantage of the mouse as an organism with genetic versatility and with similarity 
to man in brain structure, two transgenic models of SCA2 have been generated to date. The 
first one was produced by Huynh et al., 2000, who reported the use of the murine PcP2 (L7) 
promoter to direct a strong overexpression of the human ATXN2 gene with an expanded 
allele of 58 CAG repeats specifically to the cerebellar Purkinje neurons. Using the rotarod 
test, they found that the animals became ataxic at 26 and 16 weeks for the heterozygous and 
homozygous transgenic mice, respectively. Also, they described progressive incoordination 
and morphological alterations of Purkinje cells in this animal model. In 2005, Aguiar and 
coworkers (Aguiar et al., 2006) generated transgenic mouse lines overexpressing the full-
length human ATXN2 gene with 75 CAG units under the control of the human self 
promoter. A neurological phenotype was reported after 12 weeks for heterozygous and 6 
weeks for homozygous mice.  
5. Imaging 
Magnetic resonance imaging shows early cerebellar and brainstem atrophy (Figure 2) with 
marked involvement of the cerebellar cortex and the pons/inferior olive region in SCA2, in 
excellent agreement with the traditional neuropathological nomenclature of 
olivopontocerebellar atrophy (OPCA). Also, frontotemporal atrophy is observed in 
advanced disease (Bürk et al., 1996; Giuffrida et al., 1999). Voxel-based morphometry studies 
have revealed the atrophy of the cerebellar and brainstem white matter as well as the 
symmetric loss of gray matter in the cerebellar vermis (Brenneis et al., 2003; Brenneis et al., 
2005; Della Nave et al., 2008a, b, Goel et al., 2011). Positron emission tomography (PET) 
studies showed a reduced regional glucose metabolism in the cerebellum, brainstem and 
parietal cortex, which may occur years before the clinical onset of SCA2 (Inagaki et al., 2005). 
PET analyses also revealed the loss of striatal dopamine transporter function with 
nigrostriatal atrophy, similar to the pattern observed in idiopathic Parkinson’s disease 
(Boesch et al., 2004; Wüllner et al 2005; Inagaki et al., 2005). Imaging by proton magnetic 
resonance spectroscopy demonstrated the loss of choline-containing compounds in SCA2 
cerebella, suggesting the decreased production and/or the loss of cell membranes as well as 
the reduced synthesis of precursors of acetylcholine. The same study demonstrated the 
increase of lactate levels in the cerebellum suggesting an impairment of glycolysis and 
mitochondrial function (Boesch et al., 2001).  
6. Neuropathology 
The macroscopic examination of nervous structures in post-mortem samples of SCA2 patients 
shows a significant atrophy of the cerebellum, brainstem, frontal lobe, as well as pallor of 
the midbrain substantia nigra and a reduction of the cerebral and cerebellar white matter. 
Microscopically, the cerebellum is characterized by an early and marked neuronal loss in 
Purkinje cell layer with reduction in the number of dendritic arborizations and torpedo-like 
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Fig. 2. MRI scans of a SCA2 patient (age 40 years; disease duration 8 years, CAG repeat size 
39 units, SARA score 19) (A) and a healthy control (age 40 years, SARA score 0) (B). Note the 
severe atrophy of cerebellum and brainstem in the SCA2 subject.  
late stages of the disease whereas the dentate nucleus is relatively spared. Parallel fibers are 
sparse and no climbing fibers are observed in the Purkinje cell dendritic trees (Orozco et al., 
1989; Ihara et al., 1994; Estrada et al., 1999; Ying et al., 2005). In the brainstem, the most 
noteworthy microscopic findings are the marked loss of inferior olivary neurons in addition 
to the degeneration of pontine and other precerebellar brainstem nuclei (Rüb et al., 2005a; 
Lastres-Becker et al 2008a). The neuropathological evaluation of brainstem and cranial 
nerves shows that oculomotor, somatomotor, somatosensory, auditory, vestibular and 
autonomic nuclei are notably affected by neuronal loss and their associated fibers are 
atrophied and undergo demyelinization (Rüb et al., 2004a, 2004b; Rüb et al., 2006; Gierga et 
al., 2005; Hoche et al., 2008). Another important neuropathological marker of SCA2 is the 
notable reduction of neurons of the substantia nigra in the mesencephalon and the extensive 
degeneration of several thalamic nuclei, such as the reticular, fasciculosus, ventral anterior 
and posterior, lateral geniculate body and the anterior nuclei (Rüb et al., 2003a, 2003b, 
2005b). In the spinal cord, an early and progressive demyelination of the posterior and 
spinocerebellar columns together with neuronal loss in cuneate and gracile nuclei, dorsal 
roots and ganglia as well as a reduction of motor neurons, usually in the cervical level and 
the Clarke’s column, are observed (Rüb et al., 2007). Demyelination is severe (Armstrong et 
al., 2005). The selective neurodegeneration of large neurons affecting multiple regions of the 
brain with some glial inclusions is quite similar to the pattern of multiple-system atrophy 
(MSA) (Yagishita and Inoue 1997; Berciano and Ferrer 2005). Polyglutamine inclusion bodies 
appear to be much less prominent than in Huntington’s disease or in SCA3 (Huynh et al., 
2000; Uchihara et al., 2001; Koyano et al., 2002; Pang et al., 2002). Also, it is observed a 
significant loss of giant Betz pyramidal cells in the primary motor cortex. (Hoche et al., 
2010). A recent study suggested that either the age at onset or the CAG repeat expansions 
influence on the distribution pattern of SCA2 neurodegeneration (Ishida et al., 2011). 
7. Neurochemistry 
The neurochemical findings in SCA2 patients were first recognized by Orozco and co-
workers in 1989, (Orozco et al., 1989) who called attention to the significantly decrease of 
dopamine metabolites such as 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic 
acid (HVA) in cerebrospinal fluid (CSF), likely as result of neuronal depletion in the 
substancia nigra of autopsied patients. However, the mean concentration of Gamma-amino-
butyric acid (GABA), as well as metabolites of noradrenalin and serotonin were similar to 
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normal subjects. Additionally, N-acetyl-aspartate and glutamate are markedly reduced in 
these patients (Oz et al., 2010). 
A pathologically relevant biochemical finding is the significant reduction of zinc, iron and 
copper levels in the CSF and serum of Cuban SCA2 patients. The reduction of zinc levels 
could be associated with phenotypic features such as nerve conduction slowing, cognitive 
dysfunction, and immune-depression at final stages of the disease and could accentuate the 
dysfunction of cerebellar circuits, based on the important role of this element in the control 
of synapses in the cerebellum (González et al., 2006). Furthermore, most biomarkers of the 
antioxidant-prooxidant balance are significantly modified in Cuban SCA2 patients with an 
increase in malondialdehyde (MDA) as evidence of lipid peroxidation, as well as signs of 
oxidative damage to protein and DNA and significant reduction of the reduced glutathione 
(GSH). Also, the activity of glutathione S-transferase (GST), superoxide dismutase (SOD) 
and catalase (CAT) are depressed in these patients with a disruption of the balance 
CAT/SOD (Velázquez-Pérez et al, 2003; Almaguer, et al., 2005). A third interesting finding 
is the decrease of erythropoietin levels in the CSF with a compensatory increase of this 
molecule in the serum of Cuban SCA2 patients, suggesting the existence of reduced 
capabilities of neuroprotection in the nervous system (Velazquez-Pérez et al., 2011b). We 
believe that these biochemical features may contribute to the high phenotypic variability of 
SCA2 and that they could constitute potential therapeutical targets to design future clinical 
trials.  
8. Neurophysiology 
8.1 Nerve conduction and electromyography studies 
The most common electrophysiological finding in SCA2 patients is a predominantly sensory 
axonal neuropathy, expressed by the early and progressive reduction of sensory amplitudes, 
suggestive of dorsal root ganglionopathy. These alterations are associated with slowing of 
nerve conduction as sign of demyelination. The progression rate of sensory axonal 
neuropathy is notably accentuated in patients with large CAG expansion sizes. Motor nerve 
conduction parameters are usually normal, but in patients with 10-15 years of disease 
duration it is possible to observe a reduction of motor amplitudes (Kubis et al., 1999; van de 
Warrenburg et al., 2004; Velázquez-Pérez et al., 2007, 2010). Electromyographical findings 
reveal motor unit potentials (MUP) with light polyphasic alterations, increased amplitudes 
and isolated contraction pattern in the first stage of the evolution. In advanced stages of the 
disease signs of denervation can appear (fibrillations and fasciculations) and the contraction 
pattern becomes simple oscillations, indicating the loss of motor neurons in the anterior 
horn of the spinal cord (Velázquez-Pérez et al, 2009b).  
8.2 Somatosensory evoked potentials (SSEP) 
Tibial nerve SSEPs are characterized by a marked prolongation of the P40 component and 
central conduction time latencies. In the median nerve SSEP there is a latency prolongation 
of N20 and N13 components in addition to a reduction of amplitude of Erb potentials. In 
almost all cases, the SSEPs show abnormal morphology and reduced reproducibility. These 
alterations get worse quickly in patients with larger CAG repeat number and may be 
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normal subjects. Additionally, N-acetyl-aspartate and glutamate are markedly reduced in 
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A pathologically relevant biochemical finding is the significant reduction of zinc, iron and 
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could be associated with phenotypic features such as nerve conduction slowing, cognitive 
dysfunction, and immune-depression at final stages of the disease and could accentuate the 
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neuropathy is notably accentuated in patients with large CAG expansion sizes. Motor nerve 
conduction parameters are usually normal, but in patients with 10-15 years of disease 
duration it is possible to observe a reduction of motor amplitudes (Kubis et al., 1999; van de 
Warrenburg et al., 2004; Velázquez-Pérez et al., 2007, 2010). Electromyographical findings 
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8.3 Brain Stem Auditory Evoked Potentials (BSAEP) 
BSAEPs have poor reproducibility and unstable morphology in 95% of the patients, in 
addition to the increase of latency of the waves III and V and the prolongation of the I–III 
interpeak interval. These abnormalities are common in patients with disease duration above 
10 years but the abnormal reproducibility and morphology can be detected since preclinical 
stage (Velázquez-Pérez et al., 2007, 2008).  
8.4 Visual Evoked Potentials (VEP) 
VEP are frequently normal in SCA2 patients, but some patients in advances stages of the 
disease have prolonged P100 latencies with normal amplitudes. These findings reflect the 
integrity of the visual pathway in Cuban SCA2 patients, allowing us to distinguish SCA2 
from other spinocerebellar ataxias such as SCA1, SCA3 and in particular SCA7 (Velázquez-
Pérez et al., 2007, 2008).  
8.5 Event-related evoked potentials (ERPs) 
ERPs revealed prolongation of visual P300 latencies in 40% of cases with a significant 
correlation of this variable with the disease duration and clinical affectation (Kremlacek et 
al., 2011). 
8.6 Motor evoked potentials 
The study of the corticospinal tract by transcranial magnetic stimulation in SCA2 patients 
reveals an increase of central motor conduction time and motor threshold. Also, intracortical 
facilitation may be reduced and the induced cortical silent period prolonged. The 
progression of these abnormalities is dependent on the disease duration and ataxia severity. 
They probably reflect the reduced excitability of the motor cortex, disturbed conduction 
along the pyramidal tract and the loss of facilitatory influences of the cerebellum on the 
primary motor cortex (Yokota et al., 1998; Restivo et al., 2000, 2004; Schwenkreis et al., 2002) 
8.7 Electrooculography 
The main oculomotor abnormality in SCA2 is the slowing of horizontal saccadic 
movements, which is probably the result of early pontine brainstem degeneration. This 
feature is electrooculographically detectable in 99% of the patients and in several 
presymptomatic subjects. The maximal saccade velocity is negatively correlated with the 
polyQ expansion and the ataxia score, but is not significantly influenced by the disease 
duration. (Rivaud-Pechoux et al., 1998; Bürk et al., 1999b; Velázquez-Pérez et al., 2004, 2008, 
2009c). The prolongation of saccadic latency is observed in 46% of the cases, reflecting the 
cortical/subcortical involvement in SCA2. Although this saccadic feature is not directly 
influenced by the CAG repeats or the disease duration it is close related with the frontal-
executive dysfunctions, identifying it as a promising cognitive biomarker (Rodríguez-
Labrada et al., 2011a). Additionally, SCA2 patients showed saccadic dysmetria reflecting the 
cerebellar involvement (Velázquez-Pérez et al., 2008) although saccades made for short 
target amplitudes are usually accurate due to the visual feedback might be continuously 
available during the slow movements (Federighi et al., 2011). Furthermore, gain 
measurements in smooth pursuit movements and horizontal optokinetic nystagmus are 
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slightly reduced in SCA2 patients, whereas the vestibulo-ocular reflex is normal (Buttner et 
al., 1998). 
8.8 Videopolysomnography and electroencephalography 
Sleep disorders are common complaints of SCA2 patients, fundamentally towards the 
final stages of the disease. Clinically, the most prominent findings are a restless legs 
syndrome and muscle cramps, which appear in 45 % of the cases. Patients with REM 
(rapid eye movements) sleep behavior disorder; bruxism and excessive daytime 
sleepiness are scarse. The polysomnographical evaluation reveals a reduction of REM 
sleep with decreased REM density in 70% of patients. These REM sleep abnormalities 
appear before the disease onset and their progression rates depend on ataxia severity and 
disease duration. (Velazquez-Pérez et al., 2011a; Rodríguez-Labrada et al., 2011b). REM 
sleep without atonia appears in 31% of SCA2 patients and showed a significant 
correlation with the ataxia score and CAG expansions (Velazquez-Pérez et al., 2011b). 
Periodic legs movements (PLMs) are also observed, in the 38% of SCA2 patients (Figure 
3). They are directly associated with the clinical severity of the disease and their 
progression rate is notable (Velazquez-Pérez et al., 2011a). Other less prominent sleep 
abnormalities are the decrease of sleep efficiency, increase of arousal index and central 
apnea index. (Boesch et al., 2006; Tuin et al., 2006).  
 
Fig. 3. Two-minute epoch of stage 2 sleep showing periodic leg movements in a SCA2 
patient with 44 years old, 12 years of disease duration, 39 CAG repeats in the SCA2 gene 
and ataxia score in 15 units. 
The conventional EEG in SCA2 patients shows a predominantly diffuse theta activity with 
reduced reactivity to eye opening in 72 % of the cases. In the brain electrical activity 
mapping a significant increase of absolute power for the theta band with reduction of 
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(rapid eye movements) sleep behavior disorder; bruxism and excessive daytime 
sleepiness are scarse. The polysomnographical evaluation reveals a reduction of REM 
sleep with decreased REM density in 70% of patients. These REM sleep abnormalities 
appear before the disease onset and their progression rates depend on ataxia severity and 
disease duration. (Velazquez-Pérez et al., 2011a; Rodríguez-Labrada et al., 2011b). REM 
sleep without atonia appears in 31% of SCA2 patients and showed a significant 
correlation with the ataxia score and CAG expansions (Velazquez-Pérez et al., 2011b). 
Periodic legs movements (PLMs) are also observed, in the 38% of SCA2 patients (Figure 
3). They are directly associated with the clinical severity of the disease and their 
progression rate is notable (Velazquez-Pérez et al., 2011a). Other less prominent sleep 
abnormalities are the decrease of sleep efficiency, increase of arousal index and central 
apnea index. (Boesch et al., 2006; Tuin et al., 2006).  
 
Fig. 3. Two-minute epoch of stage 2 sleep showing periodic leg movements in a SCA2 
patient with 44 years old, 12 years of disease duration, 39 CAG repeats in the SCA2 gene 
and ataxia score in 15 units. 
The conventional EEG in SCA2 patients shows a predominantly diffuse theta activity with 
reduced reactivity to eye opening in 72 % of the cases. In the brain electrical activity 
mapping a significant increase of absolute power for the theta band with reduction of 
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Fig. 4. Conventional (A) and quantitative (B) EEG from a SCA2 patient with age 40 years, 10 
years of disease duration, a repeat expansion to 40 CAG in the SCA2 gene and an ataxia 
SARA score of 17.  
8.9 Other neurophysiological alterations 
The study of autonomic control of cardiovascular function by heart rate variability (HRV) in 
a large group of SCA2 patients reveals the presence of cardiovascular autonomic 
dysfunction associated to SCA2 (Pradhan et al, 2008; Montes-Brown et al., 2010). 
Additionally, SCA2 patients show a significant impairment of olfactory threshold, 
identification and discrimination capabilities. The score of the University of Pennsylvania 
smell identification test (UPSIT) is significantly reduced and it correlates positively with ataxia 
score but it is not influenced by the age, age at onset, disease duration and CAG repeats 
(Velázquez et al, 2006).  
The prism adaptation task let us identify the impaired adaptation decrement. This alteration 
is accentuated in patients with larger expansions. Also, the deterioration in the adaptation 
correlates with the motor performance and saccade velocity, suggesting that structures that 
degenerate in this disease may contribute to both adaptation and motor performance 
(Fernandez-Ruiz et al, 2007; Velázquez-Pérez et al, 2009d). 
9. Early preclinical signs 
The earliest subclinical sign appears even 15 years before the onset of ataxia by the slowing 
of horizontal saccades at 600 of target displacement, with amplitudes and latencies normal. 
This electrophysiological abnormality is accentuated in subjects with larger CAG repeats 
and reflects probably the early dysfunction or degeneration of paramedian pontine reticular 
formation (Velázquez-Pérez et al., 2009c). This alteration is followed by the reduction of 
REM sleep percentage with decreased rapid eyes movements’ density, which may precede 
the ataxia onset by 10 years although its progression during this stage is insidious 
(Rodríguez-Labrada et al., 2011b). Other preclinical alterations include decrease of sensory 
amplitudes (Velázquez-Pérez et al., 2010), increased P40 latency (Velázquez-Pérez et al., 
2007), motor performance deficits, shown by the prism adaptation task (Velázquez-Pérez et 
al., 2009d) and reduced capabilities to identify specific odors in a sensible smell 
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identification test (UPSIT). The comprehensive analysis of these early signs in SCA2 
suggests the necessity for revisit the current criteria to define the disease onset delineating 
the boundaries between presymptomatics and symptomatic states. 
10. Therapeutical options 
Till now, there is no specific treatment for SCA2. Physiotherapy and neuropsychological 
rehabilitation have palliative effects on motor and cognitive symptoms. Therefore, Cuban 
SCA2 patients receive a specialized neurorehabilitation program (Pérez-Avila et al., 2004) 
since 1998, which has been applied to more than 400 patients and has allowed some 
recovery of motor, cognitive and antioxidant functions in about 75% of the treated patients 
(Rodríguez et al., 2008).  
Regarding clinical trials, few studies have been conducted. For example, muscle cramps 
are successfully treated with magnesium and levodopa treatment alleviates the 
parkinsonian signs in SCA2 patients (Lastres-becker, 2008a), whereas severe myoclonus at 
advanced stage could be dramatically improved by piracetam (De Rosa et al., 2006). 
Recently, a randomized, double-blind, placebo-controlled pilot trial using riluzole 
resulted effective to SCA2 and other subjects with cerebellar ataxias (Ristori et al., 2010). 
Additionally, a double-blinded and placebo-controlled clinical trial with 50 mg zinc 
sulphate in 36 Cuban SCA2 patients was effective in increasing the zinc levels in serum 
and CSF of treated subjects and some benefit of this treatment for the cerebellar 
syndrome, the peripheral neuropathy and the restoration of antioxidant functions was 
apparent (Velázquez-Pérez et al., 2011c).  
Deep brain stimulation with novel patterned low-frequency stimulation (PLFS) was 
effective in localizing the tremor generator at a subthalamic-thalamic electrode position, 
suppressing a coarse postural tremor for several postoperative years in one case (Freund et 
al., 2007; Barnikol et al., 2008).  
11. Conclusions 
In conclusion, although we have learnt much since SCA2 was described as a distinct clinical 
entity (Wadia and Swami, 1971) and since its cause was identified and genetic counseling 
became available (Imbert et al 1996; Pulst et al., 1996; Sanpei et al 1996), until today we have 
only taken the first steps towards understanding the pathogenic mechanisms and validating 
neuroprotective therapies. 
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1. Introduction 
Spinocerebellar Ataxia type 3 (SCA3) or Machado-Joseph disease (MJD) is one of the most 
common polyglutamine (polyQ) diseases, which comprise a group of inherited 
neurodegenerative conditions characterized by the pathological expansion of CAG 
trinucleotide repeats in the translated regions of unrelated genes. The expansion of a (CAG) 
tract in the coding region of the causative gene MJD1, translates into an expanded 
polyglutamine tract that confers a toxic gain of function to the ataxin-3 protein. The mutant 
protein form has 55-84 consecutive glutamines, in contrast to the normal ataxin-3, which 
carries 10-51 glutamines.  
MJD is a fatal disease of the central nervous system (CNS) and a dominant 
neurodegenerative disorder of adult onset, characterized by a wide range of clinical 
symptoms, including gait and limb ataxia, peripheral neuropathy, bulging eyes, 
ophthalmoplegia, postural instability, dystonia, amyotrophy, dysarthria, nystagmus, lingual 
fasciculation’s, facial myokymia and, in some cases, parkinsonism. The expression of mutant 
ataxin-3 is widespread, although neurodegeneration in MJD has been described in particular 
brain regions such as the cerebellum, brainstem, substantia nigra, pontine nuclei and 
striatum. A hallmark of the disease is the presence of neuronal intranuclear inclusions of 
mutant ataxin-3. The genetic basis of MJD is well described, however, the molecular basis is 
still poorly understood and controversial. Several pathogenesis mechanisms have been 
proposed for MJD (as well for other polyQ diseases), which could be explored as potential 
therapeutic approaches to MJD. Decreasing the expression of mutant ataxin-3 through gene 
silencing has been shown to be one of the most promising therapeutic approaches to MJD. 
However, several others are presently under investigation, such as the inhibition of protein 
cleavage, and the induction of autophagy, as well as strategies based on neuroprotection or 
regulation of transcriptional dysfunction. The main aim of this chapter is to review the 
current knowledge about MJD/SCA3, including a short review of clinical and 
neuropathological aspects of MJD and a particular focus on the pathogenesis and potential 
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2. Machado-Joseph disease 
Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3 (SCA3) is the most common 
autosomal subtype of ataxia worldwide (Coutinho and Andrade, 1978; Rosenberg, 1992; 
Ranum et al., 1995; Schols et al., 2004). It is caused by the unstable expansion of a CAG 
repeat in the MJD1 gene, which translates into a polyglutamine tract within the ataxin-3 
protein (Takiyama et al., 1993; Kawaguchi et al., 1994). This neurodegenerative disorder of 
adult onset was named after Antone Joseph and William Machado, of Portuguese Azorean 
origin, who migrated to USA. MJD was subsequently identified in Brazil, Japan, China, 
Australia and many other countries. In the islands of the Azores, namely São Miguel and 
Flores, MJD reaches the highest prevalence (1:140 in the small island of Flores) reported 
worldwide (Sudarsky and Coutinho, 1995). 
3. Clinical and physiological features 
MJD is characterized primarily by cerebellar ataxia and pyramidal signs variably associated 
with a dystonic-rigid extrapyramidal syndrome or peripheral amyotrophy (Lima and 
Coutinho, 1980; D’Abreu et al., 2010). The clinical hallmark of MJD is progressive ataxia, a 
dysfunction of motor coordination that can affect gaze, speech, gait, and balance (Taroni and 
DiDonato, 2004). Other clinical manifestations include external progressive 
ophthalmoplegia, dystonia, intention fasciculation-like movements of facial and lingual 
muscles, as well as bulging eyes. Progressive ataxia, hyperreflexia, nystagmus, and 
dysarthria may occur early in the disease (Lima and Coutinho, 1980; Sudarsky and 
Coutinho, 1995).  
 
MJD 
type Age of onset Prevalence Symptoms 
I 5-30 years  
Limb and gait ataxia, severe dystonia, pyramidal signs, 
progressive external ophthalmoplegia. Fast progression 
of symptoms 
II ≈ 36 years The most common Ataxia, pyramidal deficits and progressive external ophthalmoplegia 
III ≈ 50 years The second most common 
Limb and gait ataxia, with marked pyramidal signs. The 
progressive external ophthalmoplegia can or not 
manifest. This type has a moderate progression and can 
evolve to one of the other types 
IV 38-47 years 
In patients with the 
fewest CAG-repeats 
expansion 
Slow progressive parkinsonism, responsive to the L-
DOPA treatment, fasciculations and peripheral 
neuropathy 
V   
Marked spastic paraplegia with or without cerebellar 
ataxia. This type is usually mis-diagnosed as hereditary 
spastic paraplegia (HSP) 
Table 1. Classification of MJD according to symptoms, prevalence and age of onset. 
Recent clinical data has demonstrated increased incidence of non-motor symptoms, which 
include cognitive and psychiatric disturbances, olfactory dysfunction, and sleep disorders 
(Rub et al., 2008). Levodopa-responsive parkinsonism symptoms resembling Parkinson’s 
disease were also reported (Gwinn-Hardy et al., 2001). MJD patients present attention and 
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executive dysfunctions, and mildly depressed mood (Klinke et al., 2010). Based on clinical 
manifestations, MJD was divided into four sub phenotypes (Riess et al., 2008), which in 
some cases during the progression of the disease can evolve from one type to the other 
(Fowler, 1984). Recently, an additional MJD type (V) has been proposed based in a 
homozygous 33-years old patient of Portuguese/Brazilian descent (Lysenko et al., 2010) 
(Table 1). 
4. Neuropathological features 
The neuropathological alterations of MJD in the brain consist of widespread neuronal 
degeneration affecting multiple neuronal systems and not confined to the cerebellum, brain 
stem, and basal ganglia (Rub et al., 2008). The neuropathology involves cerebellar systems 
(particularly dentate nucleus and pontine neurons), substantia nigra, and cranial nerve 
motor nuclei, with relative preservation of cerebellar cortex, particularly Purkinje cells and 
inferior olive (Sudarsky and Coutinho, 1995; Durr et al., 1996; Yamada et al., 2008). However 
in some cases, loss of granule and Purkinje cells was found in the cerebellum, mainly in the 
vermis (Munoz et al., 2002). A marked degeneration of Clarke’s column nuclei and 
vestibular and pontine nuclei is observed (Durr et al., 1996). Marked neuronal loss is also 
observed in the anterior horn of the spinal cord, and motor nuclei of the brainstem (Rub et 
al., 2008). Involvement of cerebellar cortex, autonomic ganglia and striatum were also 
confirmed in MJD (Yamada et al., 2001; Paulson et al., 1997b; Alves et al., 2008b). Recent 
data based on neuroimaging techniques (magnetic resonance imaging – MRI, and 
quantitative 3-D volumetry) confirmed a severe atrophy in MJD patients in the whole 
brainstem (midbrain, pons, and medulla), whole cerebellum, cerebellar hemispheres and 
cerebellar vermis, putamen and caudate nuclei (Schulz et al., 2010). Significant correlation of 
both brainstem and cerebellar atrophy with CAG repeat length, age, disease duration and 
degree of disability has also been recently reported (Camargos et al., 2011). Furthermore, an 
inverse relationship has been found in MJD patients between posture, gait and limb kinetic 
subscore (assessed by the Scale for Assessment and Rating Ataxia) and the brainstem and 
cerebellar hemispheric volumes (Jacobi et al., 2011). 
5. The MJD1 gene 
MJD is associated with an unstable expansion of a CAG tract in the coding region of the 
MJD1 gene localized on chromosome 14q32.1 (Takiyama et al., 1993; Kawaguchi et al., 1994). 
MJD1 encodes ataxin-3, a polyubiquitin-binding protein whose physiological function has 
been linked to ubiquitin-mediated proteolysis (Burnett et al., 2003; Donaldson et al., 2003; 
Doss-Pepe et al., 2003; Scheel et al., 2003; Chai et al., 2004; Durcan et al., 2011). The mutation 
results in an expanded polyglutamine tract at the C-terminus of ataxin-3 (Kawaguchi et al., 
1994; Durr et al., 1996). The CAG repeats in the MJD1 gene range from 10 to 51 in the normal 
population and from 55 to 87 in MJD patients (Cummings and Zoghbi, 2000; Maciel et al., 
2001; Gu et al., 2004; Padiath et al., 2005). This high threshold of pathogenicity is a special 
characteristic of this disorder, since in most other polyglutamine disorders trinucleotide 
repeats over 36 to 40 become pathogenic. There is an inverse correlation between the age of 
onset and the number of CAG repeats, as is the case for other polyglutamine disorders 
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6. The ataxin-3 protein 
Ataxin-3 is a modular protein with an overall molecular weight of 42 kDa, containing a 
conserved N-terminal Josephin domain (Masino et al., 2003; Scheel et al., 2003; Albrecht et 
al., 2004), followed by two ubiquitin-interaction motif (UIM) domains and the 
polyglutamine repeat region (Figure 1). Alternative splicing of the MJD1 gene has been 
shown to result in the production of different isoforms of ataxin-3 varying at the C-terminal 
portion of the protein (Goto et al., 1997), one of these containing a third UIM domain after 
the polyglutamine region (Ichikawa et al., 2001). Fifty-six alternative splicing variants of the 
ataxin-3 mRNA were recently identified, from which 50 had not been previously described, 
and 26 were only found in MJD patients (Bettencourt et al., 2010). Alternative splicing of 
ataxin-3 sequences distinct from the trinucleotide repeat may alter the properties of the 
encoded polyglutamine disease protein and thereby perhaps contribute to selective 
neurotoxicity (Harris et al., 2010). The protein is expressed in various tissues, suggesting 
that it plays an important role in eukaryotic cells (see Matos et al., 2011 for an extensive 
revision of putative ataxin-3 functions). 
 
Fig. 1. Structure of the ataxin-3 protein. Ataxin-3 is mainly composed of a highly conserved 
N-terminal domain (Josephin), encoding a predicted ubiquitin-specific protease with the 
catalytic triad of amino acids (Cys14, His119, and Asn136), a nuclear export signal (NES), 
followed by a flexible C-terminal tail with 2 or 3 ubiquitin-interacting motifs (UIM), a 
nuclear localization signal (NLS) and the polyglutamine stretch (Q(n)). Rad23 and VCP/p97, 
the two most frequently described interacting partners of ataxin-3, bind to the Josephin 
domain and the C-terminal region of the protein, respectively. 
Regarding subcellular localization, ataxin-3 has been detected both in the nucleus and in the 
cytoplasm (Paulson et al., 1997a; Trottier et al., 1998; Ichikawa et al., 2001). A putative 
nuclear localization signal (NLS) has been identified upstream the polyglutamine repeat 
region at position 282 (Tait et al., 1998; Albrecht et al., 2004), and shown to have a weak 
nuclear import activity (Antony et al., 2009). Furthermore, two nuclear export signals (NES) 
with significant activity were identified in ataxin-3: NES 77 (177-Y99) and NES 141 (E141-
E258) (Antony et al., 2009). Ataxin-3 its actively imported to and exported from the cell 
nucleus, and this nuclear export activity could also be dependent on a motif localized at is 
N-terminal region (Rodrigues et al., 2007; Macedo-Ribeiro et al., 2009), which is coherent 
with the hypothesis of the presence of a nuclear export signal (NES 174) following the 
Josephin domain (Albrecht et al., 2004). 
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Although the precise cellular role of ataxin-3 and how it is altered upon polyglutamine 
expansion is presently unknown, ataxin-3 was shown to be a polyubiquitin-binding protein 
(Donaldson et al., 2003; Doss-Pepe et al., 2003), interacting via the first two UIM domains 
with K48-linked tetraubiquitin chains (Burnett et al., 2003; Chai et al., 2004). Several lines of 
evidence suggest that ataxin-3 plays a major role in the ubiquitin proteasomal system, by 
interacting with ubiquitin and an ubiquitin-like protein called NEDD8 (Ferro et al., 2007). 
Ataxin-3 was reported to bind and hydrolyze polyubiquitin chains in vitro (Burnett et al., 
2003). Recently, it was shown that ataxin-3 deubiquitinates parkin directly (Durcan et al., 
2011). The same study argued that compared with wild-type ataxin-3, MJD-linked polyQ-
expanded mutant ataxin-3 is more active, possibly owing to its greater efficiency at DUB 
K27- and K29-linked Ub conjugates on parkin. Ataxin-3 has been also shown to be involved 
in the regulation of the proteasome by interacting with various substrates (Wang et al., 2006, 
2007; Rodrigues et al., 2009). Ataxin-3 deubiquitinating activity is thought to contribute to 
proteasomal degradation of ubiquitinated proteins by removing the poly-ubiquitin chains 
from substrates prior to digestion (Boeddrich et al., 2006; Winborn et al., 2008; Todi et al., 
2009; Scaglione et al., 2011). Ubiquitination and deubiquitination enzymes help to control 
neuronal fate determination, axonal path finding and synaptic communication and plasticity 
(see Todi and Paulson, 2011 for a review). Altogether, these data imply that ataxin-3 
modulates ubiquitin-dependent mechanisms, having an active role in the ubiquitin-
proteasome pathway. 
7. Nuclear inclusions 
In MJD, mutant ataxin-3 aggregates into intranuclear inclusions (NIIs) with many affected 
neurons exhibiting more than one inclusion body, both in and outside areas affected by 
neurodegeneration (Paulson et al., 1997b; Schimdt et al., 1998; Rub et al., 2006a, b). 
Aggregates are also found in the cytoplasm of neurons in several affected areas (Hayashi et 
al., 2003), and in axons within fiber tracts (corpus callosum, the nigrostriatal tract, the 
olivocerebellar fiber, and others) known to undergo neurodegeneration in MJD (Seidel et al., 
2010). The presence of these NIIs is a hallmark of neurodegeneration in the brains of MJD 
patients (Figure 2A), and to all the CAG repeat diseases except for the spinocerebellar ataxia 
type 6 (SCA6) (Paulson, 1999; Schols et al., 2004; Soong and Paulson, 2007). NIIs are 
eosinophilic round structures and vary in size from 0.7 to 3.7 μm. Ultra structurally, NIIs are 
non-membrane bound, heterogeneous in composition, and contain a mix of granular and 
filamentous structures. Both normal and expanded ataxin-3, and ubiquitin are components 
of NIIs of affected neurons in MJD patients (Paulson et al., 1997a), as well as other proteins, 
including heat shock proteins (HSPs) and transcription factors (Hayashi et al., 2003; Perez et 
al., 1998; Yamada et al., 2001). Ataxin-2, the protein that upon polyglutamine expansion 
causes spinocerebellar ataxia type 2 – SCA2, and the TATA box binding protein (TBP) were 
also found in NIIs of the pontine neurons of MJD patients (Uchihara et al., 2001).  
The NIIs in MJD are distributed in many neurons covering a wide range of central and 
peripheral nervous system regions, including the cerebral cortex (Figure 2B), thalamus and 
autonomic ganglia (Schilling et al., 1999). The exact role of NIIs in neuronal cell death of 
MJD patients remains unclear and controversial (Bates, 2003; Michalik and Broeckhoven, 
2003; Yamada et al., 2008). However, as NIIs are present in degenerated as well as spared 
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affected nerve cells (Rub et al., 2006b). In the other polyglutamine disorders the cytotoxicity 
of NIIs is also controversial. Several studies raised the possibility that NII formation may be 
a cellular reaction to reduce the toxic effect of mutant proteins (Klement et al., 1998; Saudou 
et al., 1998; Cummings et al., 1999). On the other hand, other studies revealed that the 
presence of transcription factors in NIIs (Yamada et al., 2001; Shimohata et al., 2000a,b), may 
induce secondarily transcriptional abnormalities in cell nuclei, resulting in slowly 
progressive neuronal degeneration. 
 
Fig. 2. Intranuclear inclusions in the striatum of Machado Joseph disease patients. (A) 
Fluorescence analysis shows ataxin-3 reaction intranuclear inclusions (green) in the neurons 
of the striatum of postmortem brain samples of MJD patients (white arrows). (B) 
Fluorescence microscopy analysis shows ataxin-3 intranuclear inclusions (green) in neurons 
of the cortex of postmortem brain samples of MJD patients (white arrows). Scale bar: 40µm. 
 




The genetic basis of MJD is well described, however, the molecular basis is still poorly 
understood and controversial. It is widely accepted that polyglutamine diseases may share 
pathogenic mechanisms. In this section several pathogenic mechanisms that could be 




Fig. 3. Mechanisms of pathogenesis in Machado-Joseph disease. Several events and 
mechanisms could contribute to pathogenesis in MJD and other polyglutamine diseases. 
The presence of mutant ataxin-3 with an expanded tract in the cellular environment, triggers 
several events that lead to neurodegeneration in selective areas of the brain. For the 
neuronal cytoxicity and dysfunction several mechanisms related to the toxicity of the 
expanded polyglutamine stretch are important such as the oligomerization and aggregation, 
the formation of toxic fragments or posttranslational modifications. Furthermore, the 
normal function of ataxin-3 in the cell could contribute to the impairment of UPS in MJD, 
and thus contribute to a dysfunction in cellular quality-control mechanisms. Other 
mechanisms could also be important to MJD pathogenesis, such as dysregulation of 
transcription, mitochondrial dysfunction, aberrant protein-protein interactions, calcium 
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Fluorescence analysis shows ataxin-3 reaction intranuclear inclusions (green) in the neurons 
of the striatum of postmortem brain samples of MJD patients (white arrows). (B) 
Fluorescence microscopy analysis shows ataxin-3 intranuclear inclusions (green) in neurons 
of the cortex of postmortem brain samples of MJD patients (white arrows). Scale bar: 40µm. 
 




The genetic basis of MJD is well described, however, the molecular basis is still poorly 
understood and controversial. It is widely accepted that polyglutamine diseases may share 
pathogenic mechanisms. In this section several pathogenic mechanisms that could be 




Fig. 3. Mechanisms of pathogenesis in Machado-Joseph disease. Several events and 
mechanisms could contribute to pathogenesis in MJD and other polyglutamine diseases. 
The presence of mutant ataxin-3 with an expanded tract in the cellular environment, triggers 
several events that lead to neurodegeneration in selective areas of the brain. For the 
neuronal cytoxicity and dysfunction several mechanisms related to the toxicity of the 
expanded polyglutamine stretch are important such as the oligomerization and aggregation, 
the formation of toxic fragments or posttranslational modifications. Furthermore, the 
normal function of ataxin-3 in the cell could contribute to the impairment of UPS in MJD, 
and thus contribute to a dysfunction in cellular quality-control mechanisms. Other 
mechanisms could also be important to MJD pathogenesis, such as dysregulation of 
transcription, mitochondrial dysfunction, aberrant protein-protein interactions, calcium 





8.1 Toxicity of the polyglutamine stretch 
A common feature of polyglutamine diseases is the deposition of insoluble intracellular 
ubiquitinated inclusions containing the misfolded disease protein (Paulson, 1999). These 
inclusions have long been suspected to be pathologic structures in polyglutamine diseases 
(Ross, 1997; Martindale et al., 1998; Yamada et al., 2000). Although this correlation is 
controversial and unclear (Bates, 2003; Michalik and Broeckhoven, 2003; Yamada et al., 
2008), the NIIs could physically impair axonal transport or nuclear function (Morfini et al., 
2005). Furthermore, the NIIs recruit other proteins, transcription factors and proteasome 
subunits (Chai et al., 1999a,b), underlying misfolding events that may be critical to 
pathogenesis (Paulson, 1999; Goti et al., 2004; Jana and Nukina, 2004; Taylor et al., 2002). 
Polyglutamine monomers of ataxin-3 acquire β-strand conformations that have been shown 
to be cytotoxic in cultured cells (Nagai et al., 2007), assembling into oligomers (Bevivino and 
Loll, 2001; Takahashi et al., 2008), both of ataxin-3 as well as other polyglutamine monomers 
(Stott et al., 1995; Lathrop et al., 1998; Tanaka et al., 2001; Thakur and Wetzel, 2002), and can 
also simultaneously dissociate into monomers (Schaffar et al., 2004). Thus, it seems that β-
stranded polyglutamine monomers are important for pathogenesis in MJD and other 
polyglutamine diseases, however its contribution to neurotoxicity is still controversial. 
In several neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, 
prion diseases, and polyglutamine diseases, including MJD, oligomers of causative proteins 
have been proposed to be the most toxic structures (Walsh et al., 2002; Kayed et al., 2004) 
and candidates for a pathogenic intermolecular structure. Polyglutamine oligomers, in 
particular, have been shown to induce greater toxicity than polyglutamine monomers or 
inclusion bodies in differentiated neurons (Takahashi et al., 2008). This and other findings 
support the hypothesis that polyglutamine oligomers may have a crucial role in cytotoxicity 
(Poirier et al., 2002; Sanchez et al., 2003; Kayed et al., 2003; Ross and Poirier, 2005; Behrends 
et al., 2006). 
The proteolytic cleavage of mutant protein may produce smaller toxic fragments containing 
an expanded polyglutamine tract, in this way facilitating the entry of cytoplasmic 
polyglutamine proteins into the nucleus. These toxic cleavage fragments upon release 
undergo the conformational change required for aggregation formation (Wanker, 2000; Ross 
et al., 2003). The misfolded expanded fragments may interact with full-length ataxin-3, 
possibly inducing a misfolding event in the polyQ tract of ataxin-3, which facilitates its 
stable incorporation into the fibrillar aggregates (Ikeda et al., 1996; Haacke et al., 2006). The 
proteolytic fragment has been proposed to be a product of caspase enzymes (Wellington et 
al., 1998; Berke et al., 2004), of autolytic cleavage (Mauri et al., 2006) or of calpains (Haacke 
et al., 2007). This toxic fragments hypothesis was also proposed for other polyglutamines 
diseases (Walsh et al., 2005), namely Huntington disease (Goldberg et al., 1996; Schilling et 
al., 2006) and spinocerebellar ataxia type 7 (SCA7) (Young et al., 2007; Takahashi-Fujigasaki 
et al., 2011). The mutant ataxin-3 mjd1a putative–cleavage fragment was identified in 
permanent clones of a transfected cell line (Yamamoto et al., 2001), transgenic mice and MJD 
patient’s brains (Goti et al., 2004). Nevertheless, some controversy remains as other studies 
failed to identify the proteolytic fragments of ataxin-3 (Cemal et al., 2002; Berke et al., 2004; 
Chou et al., 2006). Recently, it was reported that the presence of a 259 N-terminal ataxin-3 
fragment (without the polyglutamine stretch) was sufficient to induce MJD neurological 
phenotype in mice (Hubener et al., 2011). 
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The toxicity of causative gene products in MJD and other polyglutamine diseases has been 
proposed to be influenced not only by the polyglutamine stretch but also by the post-
translational modification of amino acid residues outside the polyglutamine stretch, 
including phosphorylation (Fei et al., 2007; Tao et al., 2008; Mueller et al., 2009), acetylation 
(Li et al., 2002; Evert et al., 2006; Chou et al., 2011), ubiquitination (Matsumoto et al., 2004; 
Jana et al., 2005; de Pril et al., 2007), and sumoylation (Ueda et al., 2002; Shen et al., 2005). 
These modifications might result in aberrant interactions with other proteins or modification 
of the properties of causative proteins, including the stability or tendency to form toxic 
structures. 
8.2 Protein interactions 
The importance of expanded polyglutamine protein in disease progression is important, 
however, the toxicity of expanded polyglutamine protein does not fully explain the selective 
neuronal degeneration in MJD and in other polyglutamine diseases. Mutant ataxin-3 is 
widely expressed in the brain (Paulson et al., 1997a), even in areas with no significant 
neuronal degeneration. Thus, the normal function of ataxin-3 or interactions with other 
proteins in each neuronal subpopulation might explain its selective toxicity (Takahashi et 
al., 2010). Normal ataxin-3 is found in nuclear inclusions of different polyglutamine 
diseases, particularly in spinocerebellar ataxia type 1 – SCA1, SCA2, Dentatorubral-
pallidoluysian atrophy, (Uchihara et al., 2001) and in neuronal intranuclear hyaline 
inclusion disease (Takahashi et al., 2001). It is also found in Marinesco bodies under stressful 
conditions and aging in human and non-human primates brains (Fujigasaki et al., 2000; 
Fujigasaki et al., 2001; Kettner et al., 2002).  
Ataxin-3 recruitment to inclusions raises the possibility that normal ataxin-3 and ubiquitin-
mediated pathways may be involved in cellular reactions against stress and misfolded 
proteins (Fujigasaki et al., 2001). In a Drosophila model normal ataxin-3 suppressed the 
neurotoxicity of mutant ataxin-3 by an ubiquitin-mediated mechanism in association with 
the proteasome (Warrick et al., 2005). However in a MJD lentiviral rat model the 
overexpression of normal ataxin-3 did not mitigate the mutant ataxin-3 induced 
neurodegeneration and even aggravated inclusion generation (Alves et al., 2010).  
Several studies have revealed the importance of protein-protein interactions in 
understanding the normal function of the disease-causing protein (Steffan et al., 2001; 
Yoshida et al., 2002; Chen et al., 2004; Goehler et al., 2004; Ravikumar et al., 2004; Kaytor et 
al., 2005; Tsuda et al., 2005). Recently, the normal activity of ataxin-2 was shown to be 
important to MJD neurodegeneration, suggesting that toxicity of one polyglutamine disease 
protein could be modulated by the normal activity of another (Lessing and Bonini, 2008). 
The protein-protein interaction and alteration of the activity of causative proteins was also 
reported for other neurodegenerative disorders and is therefore an important subject of 
research (Lim et al., 2006; Zoghbi and Orr, 2009; Elden et al., 2010). 
8.3 Dysregulation of transcription 
Expanded polyglutamine proteins tend to accumulate in the nucleus, where the high 
concentration of solutes creates favorable conditions for interaction with transcriptional 
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affected by polyglutamine expansion, such as ataxin-1 or ataxin-2 either interact or function 
as transcription factors (Fernandez-Funez et al., 2000; Lim et al., 2006; Lastres-Becker et al., 
2008) suggesting that transcriptional dysregulation may be a central feature of the 
neurodegenerative mechanism in the polyglutamine disorders (Steffan et al., 2001; Nucifora 
et al., 2001; Minamiyama et al., 2004; La Spada et al., 2001; Hughes et al., 2001; Yamada et al., 
2000; Lim et al., 2008; Godavarthi et al., 2009; Yamanaka et al., 2008, Riley and Orr, 2006). 
Accordingly, the transcription factor TBP and transcription co-factor CBP were shown to be 
incorporated into nuclear inclusions of polyglutamine-expanded ataxin-3 (McCampbell et 
al., 2000). Thus, it is possible that mutant polyglutamine ataxin-3 causes transcriptional 
dysregulation and resulting neurotoxicity. Downregulation of mRNA levels of genes 
involved in glutamatergic signaling and signal transduction, but no neurological phenotype, 
were reported in a MJD transgenic mouse expressing ataxin-3 with 79 CAG repeats in brain 
regions affected in the disease. This suggests the involvement of transcriptional abnormality 
in initiating the pathological process of MJD, with expanded ataxin-3 disrupting the normal 
pattern of gene transcription and contributing to cerebellar dysfunction and ataxia (Chou et 
al., 2008). 
8.4 Ubiquitin-proteasome system dysfunctions 
Cells produce a large amount of misfolded proteins, thus protein degradation systems like 
the UPS or autophagy are crucial to maintain cellular function and viability. A dysfunction 
in the UPS leads to the accumulation of misfolded proteins, resulting in dysfunction and cell 
death in neurons. The normal function of ataxin-3 has been linked to protein surveillance 
pathways (Chai et al., 2004). Ataxin-3 acts as polyubiquitin-binding protein, recruiting poly-
ubiquitinated substrates through a carboxy-terminal cluster of ubiquitin interaction motifs 
(Burnett et al., 2003; Raoul et al., 2005). A loss of mutant ataxin-3 function could affect the 
UPS and in that way enhance neuronal degeneration and death. Moreover, mutant ataxin-3 
nuclear inclusions are ubiquitinated and contain proteasome components, suggesting that 
the UPS may be disrupted by expanded protein (Paulson et al., 1997b; Chai et al., 1999b). 
8.5 Autophagy impairment 
There are strong evidences that proteins with a mutant polyglutamine tract are inefficiently 
degraded by the UPS but could be degraded by macroautophagy, a mechanism with a 
crucial role in degradation of insoluble aggregate-prone proteins and essential for neuronal 
survival (Cuervo, 2004a, b; Williams et al., 2006). Recently, our group has shown that 
important autophagy proteins are sequestered by mutant ataxin-3 inclusions in an MJD 
lentiviral model and abnormally accumulate in MJD patient’s brain (Nascimento-Ferreira et 
al., 2011). As it happens with the UPS system a disruption in the autophagy system could 
enhance neurodegeneration and cell death induced by mutant ataxin-3. Accordingly, 
impairments in the autophagy pathway have been reported in other neurodegenerative 
diseases (Shibata et al., 2006, Pickford et al., 2008; Crews et al., 2010), as well as a decrease of 
activity with ageing (Cuervo, 2004b; Vellai, 2009). 
8.6 Mitochondrial dysfunction 
There is growing evidence that mitochondrial dysfunction may play important roles in 
neurodegeneration (Knott et al., 2008), and could be implicated in the pathogenesis of MJD 
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(Yu et al., 2009) and other polyglutamine diseases (Browne et al., 1997; Panov et al., 2002; 
Cui et al., 2006). In addition, mitochondrial dysfunction has been implicated in ageing, 
which is a major risk factor of progressive neurodegenerative diseases. Oxidative stress is 
induced by reactive oxygen species (ROS) or free radicals, and increasing with age, and 
possibly diminished capacity to deal with oxidative stress may cause modification of 
cellular macromolecules and lead to cell damage. 
8.7 Impairment of axonal transport 
The function and survival of neurons demands continuous axonal transport of mRNA and 
proteins. Several studies suggest that axonal transport disturbance is an attractive 
hypothesis that could explain the vulnerability of neurons (Gunawardena et al., 2003; 
Szenbenyi et al., 2003; Caviston et al., 2007). However, currently there is no sufficient 
evidence to confirm this hypothesis in polyglutamine diseases. Recently, the presence of 
inclusions in axons was identified in several brain regions of MJD patients affected by 
neurodegeneration (Seidel et al., 2010). It was hypothesized that the presence of axonal 
inclusions could be detrimental to axonal transport mechanisms and thereby contribute to 
degeneration of nerve cells in MJD. 
8.8 Dysregulation of intracellular Ca2+ homeostasis 
Intracellular Ca2+ homeostasis is important for the function and survival of neurons, and it 
has become clear that cellular Ca2+ overload, or perturbation of intracellular Ca2+ 
compartmentalization, can cause cytotoxicity and trigger either apoptotic or necrotic cell 
death (Orrenius et al., 2003). Several studies proposed that deranged Ca2+ signaling might 
play an important role in Huntington’s disease (Tang et al., 2003; 2005; Bezprozvanny and 
Hayden, 2004; Wu et al., 2006). Abnormal Ca2+ homeostasis has been reported in 
mitochondria isolated from lymphoblast’s from patients and from brains of the YAC72 HD 
mouse model (Hodgson et al., 1999; Panov et al., 2002). This Ca2+ role could also be 
important in other polyglutamine diseases, as it is generally assumed that many of these 
diseases share a common pathogenic mechanism (Cummings and Zoghbi, 2000; Gusella and 
MacDonald, 2000; Zoghbi and Orr, 2000; Gatchel and Zoghbi, 2005). Accordingly, recent 
evidence suggests that abnormal neuronal Ca2+ signaling might also contribute to 
pathogenesis in SCAs (Bezprozvanny, 2009; Kasumu and Bezprozvanny, 2010). In MJD, data 
also suggest that deranged neuronal Ca2+ signaling plays a significant role in pathology 
onset and progression (Chen et al., 2008). Mutant ataxin-3 has been shown to specifically 
bind to and activate an intracellular calcium channel, similar to huntingtin. Moreover, long-
term feeding of MJD-transgenic mice with a Ca2+ stabilizer (dantrolene) alleviated age-
dependent motor coordination deficits and prevented neuronal loss in pontine nuclei and 
substantia nigra regions (Chen et al., 2008). 
9. Therapeutic strategies in MJD 
Expansion of the polyglutamine tract of ataxin-3 initiates a cascade of events that include 
the accumulation of insoluble inclusions and culminates in degeneration of specific 
neurons. The strategies that can be used to treat MJD or other polyglutamine diseases can 
be grouped into five main approaches: i) reducing the levels of expanded proteins, ii) 
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clearance mechanisms, iv) targeting a specific cellular mechanism and v) promoting 
neuroprotection (Figure 4). 
 
Fig. 4. Potential therapeutic strategies to Machado-Joseph disease. Expansion of the 
polyglutamine tract of ataxin-3 initiates a cascade of events that culminates with the 
accumulation of insoluble inclusions and degenerations in selected neurons. The strategies 
that can be used to treat MJD or other polyglutamine diseases can be grouped into five 
approaches: i) reducing the levels of expanded proteins (using gene silencing by RNAi-
based strategies), ii) preventing mutant ataxin-3 cleavage, oligomerization and aggregation 
(inhibiting proteolysis, using aggregation inhibitors or preventing the nuclear transport), iii) 
activation of the clearance mechanisms (upregulation of UPS and autophagy), iv) targeting a 
specific cellular mechanism (increase transcription, stabilize Ca2+ homeostasis or inhibit 
oxidative stress) and v) neuroprotection strategies (using drugs, proteins or factors to 
protect neurons). 
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9.1 RNA interference-based therapeutics 
Although several approaches could be envisioned to treat MJD and other polyglutamine 
diseases, the most direct solution to counter these diseases pathogenesis is to reduce the 
expression of the mutant allele (Kim and Rossi, 2007). RNA interference (RNAi) is a 
powerful tool for selective knockdown of gene expression. Gene silencing by RNAi has been 
successfully used to downregulate the expression of mutant genes and rescue phenotype in 
various neurodegenerative diseases, including Huntington’s disease (Harper et al., 2005; 
Rodriguez-Lebron et al., 2005; DiFiglia et al., 2007, van Bilsen et al., 2008; Lombardi et al., 
2009; Pfister et al., 2009), familial forms of amyotrophic lateral sclerosis (ALS) (Raoul et al., 
2005; Ralph et al., 2005; Azzouz, 2006), SCA1 (Xia et al., 2004), and MJD (Miller et al., 2003; 
Alves et al., 2008a, 2010; Hu et al., 2009).  
However, a major problem of gene silencing may be the lack of discrimination between 
normal and mutant forms of the causative protein. In some diseases partial silencing of 
normal protein could be tolerated; for example in HD transgenic animal models silencing of 
mutant huntingtin and 75% of endogenous protein led to behavioral enhancement 
(Boudreau et al., 2009). However, it has been reported that in cellular MJD models absence 
of wild-type ataxin-3 leads to cytoskeletal disorganization and increased cell death 
(Rodrigues et al., 2010). This would suggest that for some polyglutamine disorders it might 
be prudent to preserve the wild-type protein, as prolonged full knockdown of normal 
protein function could be harmful. This would demand specific targeting of the mutant 
allele for RNAi.  
It was first demonstrated in cell models that RNAi species could be engineered to 
specifically silence the causative genes while preserving the wild-type, which differed in a 
single nucleotide (Miller et al., 2003). More recently, our group showed both in vitro and in a 
rat model of MJD that lentiviral-mediated silencing of the mutant human ataxin-3 was 
efficient and selective, allowing preservation of wild-type ataxin-3 (Alves et al., 2008a). 
Specific silencing has also been later reported to SNPs targeting ataxin-7 in SCA7 
(Scholefield et al., 2009) and huntingtin in Huntington’s disease (Zhang et al., 2009; Hu et al., 
2009). This allele-specific silencing of ataxin-3 significantly decreased the severity of the 
neuropathological abnormalities associated with the disease by targeting a single nucleotide 
polymorphism (SNPs) that is present in more than 70% of the patients with MJD (Stevanin 
et al., 1995; Gaspar et al., 1996). These data support the therapeutic potential of RNAi for 
MJD. However, this therapy would benefit ~70% of MJD patients at best. Whether silencing 
not discriminating between wild type and mutant alleles would be safe and effective was 
recently investigated, by either overexpressing or silencing wild-type ataxin-3 in a rat model 
of MJD. It was shown that (i) overexpression of wild-type ataxin-3 did not protect against 
MJD pathology, (ii) knockdown of wild-type ataxin-3 did not aggravate MJD pathology and 
that (iii) non-allele-specific silencing of ataxin-3 strongly reduced neuropathology in a rat 
model of MJD. These findings indicate that therapeutic strategies involving non-allele-
specific silencing to treat MJD patients may also be safe and effective (Alves et al., 2010). 
9.2 Preventing the cleavage of ataxin-3 
In MJD, it was proposed that production of a cleavage fragment of mutant ataxin-3 





clearance mechanisms, iv) targeting a specific cellular mechanism and v) promoting 
neuroprotection (Figure 4). 
 
Fig. 4. Potential therapeutic strategies to Machado-Joseph disease. Expansion of the 
polyglutamine tract of ataxin-3 initiates a cascade of events that culminates with the 
accumulation of insoluble inclusions and degenerations in selected neurons. The strategies 
that can be used to treat MJD or other polyglutamine diseases can be grouped into five 
approaches: i) reducing the levels of expanded proteins (using gene silencing by RNAi-
based strategies), ii) preventing mutant ataxin-3 cleavage, oligomerization and aggregation 
(inhibiting proteolysis, using aggregation inhibitors or preventing the nuclear transport), iii) 
activation of the clearance mechanisms (upregulation of UPS and autophagy), iv) targeting a 
specific cellular mechanism (increase transcription, stabilize Ca2+ homeostasis or inhibit 
oxidative stress) and v) neuroprotection strategies (using drugs, proteins or factors to 
protect neurons). 
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of MJD. It was shown that (i) overexpression of wild-type ataxin-3 did not protect against 
MJD pathology, (ii) knockdown of wild-type ataxin-3 did not aggravate MJD pathology and 
that (iii) non-allele-specific silencing of ataxin-3 strongly reduced neuropathology in a rat 
model of MJD. These findings indicate that therapeutic strategies involving non-allele-
specific silencing to treat MJD patients may also be safe and effective (Alves et al., 2010). 
9.2 Preventing the cleavage of ataxin-3 
In MJD, it was proposed that production of a cleavage fragment of mutant ataxin-3 





Haacke et al., 2006). Thus, blocking the proteases involved in ataxin-3 cleavage and 
decreasing the concentration of the cleavage fragment bellow a critical level in the brain 
could be an effective strategy for MJD treatment. This approach has been used for other 
neurodegenerative diseases, including Alzheimer (Citron, 2004) and Huntington’s diseases 
(Ona et al., 1999; Gafni et al., 2004) and therefore could also be a therapeutic strategy for 
MJD (Tarlac and Storey, 2003). Nevertheless, the natures of the protease and of the cleavage 
fragment still need investigation. 
9.3 Acceleration of the degradation of misfolded proteins 
The acceleration of the proteolysis mechanisms (UPS and autophagy machinery) could 
promote mutant ataxin-3 degradation and probably prevent or delay the MJD progression. 
Overexpression of chaperones has been shown to aid in the handling of misfolded or 
aggregated polyglutamine-expanded ataxin-3 and suppress polyglutamine aggregation with 
a parallel decrease in toxicity (Chai et al., 1999b). Thus the induction of such molecular 
chaperones can be envisaged as a strategy for therapy of polyglutamine diseases (Nagai et 
al., 2010; Robertson et al., 2010). Accordingly, the use of chemical chaperones such as the 
organic solvent dimethyl sulfoxide – DMSO, cellular osmolytes glycerol, trimethylamine N-
oxide – TMAO, and ectoine reduce aggregate formation and cytotoxicity induced by 
truncated expanded ataxin-3 (Yoshida et al., 2002), alters subcellular localization of 
inclusions and reduces apoptotic cell death induced by mutant ataxin-3 (Furusho et al., 
2005). 
It was also shown that overexpression of UPS-related factors or proteins (e.g. E64 or CHIP) 
increase ubiquitination and degradation rate and decrease aggregation and cell death 
(Matsumoto et al., 2004; Jana et al., 2005; Miller et al., 2005). Therefore, overexpression of 
these proteins could be a molecular approach for therapy of MJD. It was shown that CRAG 
(guanosine triphosphatase) acts as an activator of promylocytic leukaemia protein-
associated ubiquitin ligase and leads to the degradation of polyQ through the ubiquitin-
proteasome pathway (Qin et al., 2006). Because the expression levels of CRAG decrease in 
the adult brain (Qin et al., 2006), it was suggested that a reduced level of CRAG could 
underlie the onset of polyglutamine diseases. In fact, lentiviral-mediated overexpression of 
CRAG in Purkinje cells of a transgenic mice model extensively cleared polyQ aggregates 
and re-activated dendritic differentiation, resulting in a striking rescue from ataxia 
(Torashima et al., 2008). It was also suggested that the activity of normal ataxin-3 could 
provide a therapeutic approach to MJD, enhancing the cellular pathways in which it 
participates (Warrick et al., 2005). However, in a lentiviral-based rat model for MJD as well 
as in double-transgenic mice, the overexpression of normal ataxin-3 did not decrease the 
pathological abnormalities induced by mutant ataxin-3 (Alves et al., 2010; Hübener et al., 
2010). 
Another possible therapeutic approach to MJD and to other polyglutamine diseases could 
be the up-regulation of autophagy, leading to a selective clearance of the mutant protein. 
Rapamycin, an activator of the autophagy pathway alleviated neurodegeneration in 
Drosophila and in a transgenic mouse model of HD. However, this drug failed to prolong life 
span in a mouse model (Ravikumar et al., 2004). In MJD, it was recently shown that the 
administration of a rapamycin esther improves motor coordination in a transgenic model of 
MJD (Menzies et al., 2010). The rapamycin esther reduced the number of aggregates in the 
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brains of transgenic mice and decreased the levels of cytosolic soluble mutant ataxin-3, 
while endogenous wild-type protein levels remained unaffected.  
Recently, our group showed that lentiviral-mediated overexpression of beclin-1, a crucial 
protein in early and late steps of autophagy, led to a stimulation of autophagic flux, mutant 
ataxin-3 clearance and overall neuroprotective effects in neuronal cultures and in a 
lentiviral-based rat model of MJD (Nascimento-Ferreira et al., 2011). The same study found 
an abnormal expression of endogenous autophagy markers, accumulation of 
autophagosomes and decreased levels of beclin in the brain of MJD patients. Overall, these 
data suggest that up-regulation of UPS or autophagy can be a therapeutic option for MJD 
and for other polyglutamine diseases. 
9.4 Inhibition of nuclear transport  
It has been shown that ataxin-3 translocates to the nucleus, and that the polyglutamine 
expansion is not essential for this transport (Tait et al., 1998). The resulting presence of 
ataxin-3 in the nucleus has been shown to drastically aggravate the pathology in Machado-
Joseph disease (Bichelmeier et al., 2007). Therefore, inhibition of nuclear transport may slow 
the disease progression, and might be sufficient to ameliorate the disease symptoms, and 
thus could be explored as therapeutic approach for MJD (Breuer et al., 2010). 
9.5 Prevention of protein misfolding, oligomerization and aggregation 
Protein misfolding, oligomerization, and formation of insoluble inclusions represent a 
common physiological response to pathogenic proteins. Thus, different research groups 
have developed high-throughput screening assays aiming at the discovery of molecules 
with selective binding affinities for polyglutamine expanded proteins, with the ability to 
modulate their pathogenic properties and potential therapeutic applications (Desai et al., 
2006; Lansbury and Lashuel, 2006). Several compounds have been identified as potential 
inhibitors of polyglutamine aggregation (Heiser et al., 2000, 2002; Apostol et al., 2003; 
Sanchéz et al., 2003; Tanaka et al., 2005; Wolfgang et al., 2005; Herbst and Wancker, 2006). 
The prevention of aggregation and oligomerization by polyglutamine disease can also be 
promoted by modulation of molecular chaperones (Nagai et al., 2010; Roberston et al., 2010). 
The Hsp90 inhibitor geldanamycin suppresses aggregation of polyQ-expanded mutant 
huntingtin through induction of endogenous molecular chaperones (Sittler et al., 2001). In 
MJD Drosophila models, it was shown that the administration of a less toxic derivative of 
geldanamycin suppresses polyQ-induced neurodegeneration through the induction of 
multiple endogenous molecular chaperones (Fujikake et al., 2008). 
Another therapeutic approach involves the use of small peptides or molecules with the 
ability to modulate protein folding, stabilize proteins in their native conformation, and 
prevent or inhibit aggregation (Tanaka et al., 2005). Several compounds proved to be 
suitable in preventing polyglutamine proteins aggregation, mainly for Huntington Disease 
(Table 2). In a screening of 16,000 compounds a small molecule (IC50) that inhibits 
polyglutamine aggregation in HD neurons and suppresses neurodegeneration in vivo was 
found (Zhang et al., 2005). In a MJD Drosophila model a tandem repeat of the polyglutamine 
binding peptide QBP1, which preferentially binds to polyglutamine stretches, has been 
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binding peptide QBP1, which preferentially binds to polyglutamine stretches, has been 





recently a high-content chemical and RNAi screening in a Drosophila primary neuronal 
culture of HD model identified several compounds that suppress mutant huntingtin 
aggregate formation (Schulte et al., 2011).  
 
Compound Disease tested Study 
Geldanamycin Huntington Disease Sittler et al., 2001 
17-(allylamino)-17-
demethoxygeldanamycin (17AAG) Machado-Joseph Disease Fujikake et al., 2008 
Congo red Huntington Disease Frid et al., 2007 
C2-8 Huntington Disease Chopra et al., 2007 
Trehalose Huntington Disease Tanaka et al., 2005 
GW5074 Huntington Disease Schulte et al., 2011 
Juglone Huntington Disease Schulte et al., 2011 
Radicicol Huntington Disease Schulte et al., 2011 
Rapamycin Huntington Disease Schulte et al., 2011 
Rapamycin esther Machado Joseph disease Menzies et al., 2010 
Camptothecin Huntington Disease Schulte et al., 2011 
Etoposide Huntington Disease Schulte et al., 2011 
Ouabain Huntington Disease Schulte et al., 2011 
Proscillaridin A Huntington Disease Schulte et al., 2011 
Ethacrynic acid Huntington Disease Schulte et al., 2011 
IC50 Huntington Disease Zhang et al., 2005 
Table 2. Compounds that have shown to prevent or inhibit polyglutamine proteins 
aggregation. 
9.6 Targeting transcriptional dysfunction 
Polyglutamine-expanded ataxin-3 (as other polyglutamine expanded proteins) has been 
shown to repress transcription. Ataxin-3 acts through distinct mechanisms involving both the 
polyglutamine-containing C-terminus and the N-terminus of ataxin-3 (Li et al., 2002). 
Transcriptional dysregulation has been suggested to play a central role in neurodegenerative 
mechanisms of the polyglutamine disorders (Chou et al., 2008). The overexpression of 
transcription factors that interact with polyglutamine diseases reduces the cytotoxicity of 
mutant proteins (Dunah et al., 2002; Taylor et al., 2003). Moreover, it was shown that the use of 
several reagents that increase transcription reduce the toxicity of expanded polyglutamine 
(Steffan et al., 2001; Ferrante et al., 2003, 2004; Hockly et al., 2003; Gardian et al., 2005; 
Shimohata et al., 2005). Recently, it was shown that regulation of transcriptional activity 
through an inhibition of histone hypoacetylation (Chou et al., 2011) might be a promising 
therapeutic intervention for MJD. Histone acetylation, which is controlled by histone 
acetyltransferase and histone deacetylase (HDAC), plays an important role in regulating 
transcriptional activity (Kurdistani et al., 2004). The H3 and H4 histones were hypoacetylated 
in the cerebellum of MJD transgenic mice, which displayed transcription downregulation and 
ataxic symptoms. Daily administration of a HDAC inhibitor (sodium butyrate) reversed 
histone hypoacetylation and transcriptional downregulation in the cerebellum of the MJD 
transgenic mice, delaying the onset of ataxic symptoms, ameliorated the neurological 
phenotype and improved the survival rate of the mice (Chou et al., 2011). 
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9.7 Targeting the calcium homeostasis 
It has been shown that deranged calcium signaling might play an important role in MJD 
pathology (Chen et al., 2008). The same study found that feeding a MJD transgenic mice 
with dantrolene, a clinically relevant stabilizer of intracellular Ca2+ signaling, improved 
motor performance and prevented neuronal cell loss in pontine nuclei and substantia nigra 
regions. Therefore, calcium-signaling stabilizers such as dantrolene may be considered as 
potential therapeutic drugs for the treatment of MJD patients. 
9.8 Targeting mitochondrial dysfunctions 
Several studies have shown that administration of antioxidants ameliorates motor deficits 
and prolongs survival in transgenic mouse model of HD (Ferrante et al., 2002). Moreover, 
drugs that improve transcriptional regulation of genes necessary for energy metabolism also 
improve HD motor phenotype (Hathorn et al., 2011). In MJD, evidences point to a role of 
mitochondrial dysfunction in MJD pathogenesis (Yu et al., 2009). Decreased mitochondrial 
DNA copy numbers were found in mutant cells stably transfected with ataxin-3 with 78 
CAG repeats and in MJD patients, compared to normal controls. Furthermore, 
mitochondrial DNA depletion was higher in MJD patients compared with that in normal 
individuals. Overall, mutant ataxin-3 may influence the activity of enzymatic components to 
remove O2* and H2O2 efficiently and promote mitochondrial DNA damage or depletion, 
which leads to dysfunction of mitochondria (Yu et al., 2009). Therefore, therapies targeting 
mitochondrial dysfunction in MJD should be further investigated. 
9.9 Neuroprotection 
The possibility of administration of drugs or molecules with neuroprotective properties in 
neurodegenerative diseases has also been explored. Many research groups have 
investigated the use of neurotrophic factors for therapy of polyglutamine disorders over the 
last decade (Bensadoun et al., 2000; de Almeida et al., 2001; Zala et al., 2004; Xie et al., 2010). 
In HD the BDNF supply to striatal neurons is compromised. Therefore delivery of this factor 
has been investigated as a replacement therapy for the missing factor (Zuccato et al., 2001). 
BDNF replacement was later shown to enhance the motor phenotype (Canals et al., 2004), 
and BDNF overexpression prevented loss and atrophy of striatal neurons and motor 
dysfunction (Xie et al., 2010), both in in HD transgenic mice. 
Studies in mouse models of Alzheimer’s and Parkinson’s diseases found that caffeine could 
alleviate pathological signs and behavior deficits in these neurodegenerative disease 
paradigms, by antagonizing A2A adenosine receptors (Arendash and Cao, 2010; Prediger, 
2010; reviewed in Cunha and Agostinho, 2010). Moreover, administration of caffeine and 
other stimulants in orexin/ataxin-3 transgenic narcoleptic mice induced an increase in 
motor activity but the effects on neuropathology remain to be investigated (Okuro et al., 
2010) and should be further investigated in MJD models.  
Several evidences suggest that neuroprotective compounds could be also explored as a 
therapeutic strategy in MJD and the drug ability of some of these compounds may 
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neurodegenerative diseases has also been explored. Many research groups have 
investigated the use of neurotrophic factors for therapy of polyglutamine disorders over the 
last decade (Bensadoun et al., 2000; de Almeida et al., 2001; Zala et al., 2004; Xie et al., 2010). 
In HD the BDNF supply to striatal neurons is compromised. Therefore delivery of this factor 
has been investigated as a replacement therapy for the missing factor (Zuccato et al., 2001). 
BDNF replacement was later shown to enhance the motor phenotype (Canals et al., 2004), 
and BDNF overexpression prevented loss and atrophy of striatal neurons and motor 
dysfunction (Xie et al., 2010), both in in HD transgenic mice. 
Studies in mouse models of Alzheimer’s and Parkinson’s diseases found that caffeine could 
alleviate pathological signs and behavior deficits in these neurodegenerative disease 
paradigms, by antagonizing A2A adenosine receptors (Arendash and Cao, 2010; Prediger, 
2010; reviewed in Cunha and Agostinho, 2010). Moreover, administration of caffeine and 
other stimulants in orexin/ataxin-3 transgenic narcoleptic mice induced an increase in 
motor activity but the effects on neuropathology remain to be investigated (Okuro et al., 
2010) and should be further investigated in MJD models.  
Several evidences suggest that neuroprotective compounds could be also explored as a 
therapeutic strategy in MJD and the drug ability of some of these compounds may 
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1. Introduction 
Spinocerebellar Ataxia 12 (SCA12) is a rare disease that was first identified in a family in the 
United States. Patients suffered from classical spinocerebellar ataxia symptoms with an age 
of disease onset ranging from 8-55 years. A trinucleotide (CAG) repeat expansion was 
confirmed in all the affected individuals. The CAG expansion mapped to the 5’ untranslated 
region (UTR) of the PPP2R2B gene. This gene encodes a regulatory subunit, B of the 
heterotrimeric protein phosphatase 2A (PP2A). The function of this particular PP2A 
complex is not well understood, and the underlying molecular mechanism of SCA12 
remains unclear. Additional pedigrees have been identified throughout the world but 
SCA12 remains a rare disease. In this chapter we will discuss the clinical manifestation of 
the disease and the known functions of the PP2A regulator B. 
2. Molecular genetics and Incidence 
SCA12 is defined as an autosomal dominant cerebellar ataxia (ADCA) of otherwise 
unknown cause concurrent with a CAG repeat expansion within chromosome 5q31-33 
upstream of the PPP2R2B gene (Holmes et. al., 1999). The PPP2R2B gene product, termed 
Bβ, is a neuron specific regulatory subunit of the heterotrimeric PP2A (Strack et. al., 1998). 
PP2A has been shown to play an essential role in many cellular functions (Janssens & Goris, 
2001). The CAG repeat expansion associated with SCA12 was first identified through an 
unbiased repeat expansion detection study and found to occur within the noncoding region 
of the PPP2R2B gene (Holmes et. al., 1999). The nonpathalogical range of allele expansion is 
quite large (7-45 repeats) and is highly dependent on ethnic background (Fujigasaki et. al., 
2001; Holmes et. al., 1999). The lower extreme of the range of pathological allele expansion 
has been established as 51 repeats. As is common to all ADCA disorders, inheritance of 
SCA12 follows an autosomal dominant pattern wherein a CAG repeat expansion of 
pathological length in just one allele is sufficient to induce the SCA12 disease state. Unlike 
other neurodegenerative diseases associated with a CAG repeat expansion, such as 
Huntingon disease, the number of CAG repeats associated with SCA12 does not correlate 
with the age of disease onset (Srivastava et. al., 2001). In addition, nondirectional vertical 
instability in the length of the expanded allele has been observed, however its clinical 
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pathological repeat expansions in both alleles; however, due to the young age of this patient, 
it is unclear what effect homozygosity will have on the disease phenotype (Bahl et. al., 2005).  
The world-wide incidence of SCA12 is quite low. Nonetheless, SCA12 has been identified across 
the globe in independent populations. The results of ADCA population screens that have 
examined the CAG repeat of the PPP2R2B gene are summarized below (Table 1), regardless of 
whether a SCA12 pathological CAG repeat expansion was identified. The well characterized 
SCA12 patient populations will hereafter be referred to as the American, Indian, Italian and 
Chinese cohorts when referencing the work by Holmes, et. al. (1999) and O’Hearn, et. al. (2001); 
Fujigaski, et. al. (2001), Srivastava, et. al. (2001) and Bahl, et. al. (2005); Brusco et al. (2002) and 
Brussino, et. al. (2010); and Jiang, et. al. (2005-1), Jiang, et. al. (2005-2) and Wang, J., et. al. (2011). 
 
Table 1. Summary of SCA12 descriptions available in the primary literature. 
3. Clinical features 
At present, SCA12 confirmed by genetic testing remains a very rare illness. However, as 
genetic testing, including whole genome sequencing, becomes common practice, the true 
incidence of SCA12 may prove to be much higher among previously categorized ADCA 
patients of unknown cause. Indeed, among a cohort of ADCA patients in India the incidence 
of SCA12 has proven to be much higher than in other geographical locales (Bahl et. al., 2005; 
Srivastava et. al., 2001). Given this observation, those who encounter ADCA patients should 
be aware of SCA12 and develop an index of suspicion informed by careful history taking, 
detailed neurological examination and deliberate laboratory testing.  
As SCA12 has only been recognized as a distinct pathology for the last decade and, at 
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appreciation for the natural history of the disease is still evolving. By careful consideration 
of those cases that have been well characterized in the American, Indian, Italian and Chinese 
cohorts, a clinical picture of the SCA12 patient will be developed here. The descriptions 
provided here are intended to inform the clinician who encounters ADCA patients of 
unknown cause and to guide clinical decision-making. 
3.1 Patient reported history of illness 
Early in the course of the disease the prototypical SCA12 patient will present with postural 
and action tremor of the upper limbs. Age of onset of this tremor is highly variable with a 
range between 8 and 55 years, but seems to cluster primarily between the third and fifth 
decade of life (Brussino et. al., 2010; Fujigasaki et. al., 2001; Holmes et. al., 1999; O'Hearn et. 
al., 2001; Srivastava et. al., 2001). The first manifestations of the action tremor of the upper 
limbs have been described by patients as difficulty with activities requiring fine motor 
coordination, such as writing, as well as difficulties with activities requiring gross motor 
coordination such as attempting to hold and purposefully manipulate objects like a cup 
(Fujigasaki et. al., 2001; O'Hearn et. al., 2001). Observers describe the tremor as slowly 
progressive in nature with an increase in amplitude and involvement of the head and neck 
have been observed over the course of a decade (O'Hearn et. al., 2001). The action tremor of 
the upper limbs as the harbinger of the disease is unique to SCA12 and differentiates SCA12 
from other ADCA disorders (Schols et. al., 2004; Teive, 2009). This tremor is not, however, 
universal among SCA12 patients, and its absence does not rule out SCA12 (Srivastava et. al., 
2001; Wang, J et. al., 2011). Presentation of the upper limb action tremor is very similar to 
that of essential tremor and has previously been misdiagnosed as such early in the SCA12 
course (O'Hearn et. al., 2001). Differentiating the SCA12 associated upper limb action tremor 
from isolated essential tremor requires an appreciation of the complete constellation of 
SCA12 associated symptoms as well as a family history consistent with ADCA.  
3.2 Neurological examination 
The time elapsed since disease onset has been reported to directly correlate with the number 
of neurological abnormalities (O'Hearn et. al., 2001). The examination of an SCA12 patient 
should therefore be informed by the patient reported history. To fully characterize the 
constellation of symptoms associated with SAC12 early in the course of the disease, care 
should be taken to elicit mild neurological abnormalities that may otherwise be subclinical 
in nature. Characterizing the gross neurological deficits present late in the course of the 
disease can serve to chart disease progression.  
3.2.1 Motor skills deficits 
As indicated above, the action tremor associated with SCA12 is one of the earliest hallmarks 
of the disease. Action tremor features include postural and kinetic properties, as well as a 
low frequency (3 Hz)(O'Hearn et. al., 2001), and are similar to a tremor subset associated 
with cerebellar lesion termed “cerebellar postural tremor”(Hallett, 1991). As such, the 
postural features of the tremor can be elicited in the clinical setting by asking the patient to 
maintain their arms in an outstretched position and observing for limb tremor. The kinetic 
features of the tremor can be assessed by having the patient engage in a goal-directed 
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completely while the upper limbs are at rest and not maintaining position against the force 
of gravity. 
Loss of motor coordination due to cerebellar dysfunction associated with SCA12 manifests 
when the patient engages in a number of activities. During finger-to-nose testing, rather 
than smooth, rapid, accurate movements, the SCA12 patient will display slow, hesitant, 
inaccurate movements consistent with upper limb dysmetria. Further, the SCA12 patient has 
been reported to be unable to engage in rapid alternating movements (dysdiadochokinesia) 
such as alternating between turning the palms or the back of the hand face up (O'Hearn et. 
al., 2001). Motor deficits also disrupt speech and can result in dysarthria (O'Hearn et. al., 
2001; Srivastava et. al., 2001). 
Parkinsonain features have also been described in SCA12 patients from the American 
Cohort. These manifest as paucity of spontaneous movements, mild bradykinesia, upper 
limb rigidity and postural anteroflexion (O'Hearn et. al., 2001).  
A great deal of heterogeneity has been observed in the symptoms of SCA12 patients from 
different ethnic backgrounds. Unique to the Indian cohort, facial myokymia has also been 
described in a small number of SCA12 patients (Srivastava et. al., 2001). Although the 
proband of the Chinese cohort developed generalized ataxia during the third decade of life, 
action tremor has not been observed (Wang, J et. al., 2011). 
3.2.2 Gait abnormalities 
The ataxic gait of the SCA12 patient has been described as being very similar to that observed 
in other diseases with cerebellar dysfunction. The SCA12 patient maintains stability by 
adopting a broad based stance. Parkinsonian features have also manifest in the gait among 
individuals of the American Cohort (O'Hearn et. al., 2001). Initiation of movement is delayed. 
Steps have been described as hesitant, small and slow. When turning, the SCA12 patient has 
been described as engaging in an “en bloc” approach. A mild ataxic phenotype can be 
exaggerated by having the patient maintain a tandem gait, wherein the patient walks in a 
straight line with the heel of the front foot touching the toes of the back foot at each step. 
3.2.3 Cranial nerve assessment 
With the exception of oculomotor nerve (CNIII) abnormalities, the cranial nerves are largely 
intact and function without deficit in the SCA12 patient. Horizontal nystagmus has been 
described and may represent an early manifestation of the disease (Fujigasaki et. al., 2001; 
Holmes et. al., 2003; O'Hearn et. al., 2001; Srivastava et. al., 2001). In addition slow saccades 
and broken pursuit have been described in SCA12 patients from the Indian cohort 
(Fujigasaki et. al., 2001; Srivastava et. al., 2001).  
3.2.4 Assessment of reflexes 
Diffuse hyperreflexia has been described for SCA12 patients from the American, Indian and 
Italian cohorts (Brussino et. al., 2010; Fujigasaki et. al., 2001; O'Hearn et. al., 2001; Srivastava 
et. al., 2001). A return of primitive reflexes in the otherwise mature SCA12 patient has also 
been described. These reflexes include an extensor plantar response (positive Babinski sign), 
grasp reflex, rooting reflex and glabellar blink reflex (Myerson sign).  
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3.2.5 Mental Status 
Psychiatric disorders have been reported to occur concurrently with SCA12. Anxiety and 
depression have been reported in members of the American cohort, but not the Indian or 
Italian cohorts (Brussino et. al., 2010; O'Hearn et. al., 2001; Srivastava et. al., 2001). Whether 
these disorders result as a direct consequence of the SCA12 disease process or represent an 
individual response to the presence of the disease is unclear. Paranoid delusions have also 
been reported in one SCA12 patient (O'Hearn et. al., 2001). A decline in cognition has been 
described in SCA12 patients two to three decades after initial onset of the disease (Fujigasaki 
et. al., 2001; O'Hearn et. al., 2001).   
 
Fig. 1. Neuroradiologic images from two patients with spinocerebellar ataxia type 12. (A,B) 
Coronal computed tomography of the proband at age 62 years reveals cerebellar and diffuse 
cerebral cortical atrophy. (C) (sagittal), (D) (coronal): T-1 weighted magnetic resonance 
images of a 59-year-old affected woman also shows cerebellar and cortical atrophy. 
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3.3 Neuroimaging studies 
Computerized tomography (CT) and magnetic resonance imaging (MRI) studies of 
symptomatic SCA12 patients reveal that mild to moderate cerebellar and cortical atrophy 
is a near universal finding of the disease (Brussino et. al., 2010; Fujigasaki et. al., 2001; 
O'Hearn et. al., 2001; Srivastava et. al., 2001; Wang, J et. al., 2011). An example of these 
findings from imaging studies performed on members of the American cohort of SCA12 
patients is shown (Figure 1). The cerebellar vermis appears to be more vulnerable to 
atropy than the cerebellar hemispheres (O'Hearn et. al., 2001). Atrophy of subcortical 
structures has not been described. Additional characterization by single-proton emission 
computed tomography (SPECT) revealed metabolic deficiencies in atrophic cortical areas; 
however, the value of this test is uncertain in the symptomatic patient (Fujigasaki et. al., 
2001). Proton magnetic resonance spectroscopy has been used to demonstrate 
neurometabolic and microstructural changes in the SCA12 patient (Brussino et. al., 2010), 
and this technique represents a noninvasive method that may longitudinally describe the 
asymptomatic SCA12 patient.  
3.4 Genetic testing 
Genetic testing for the presence of CAG repeat expansion is available. The reader is directed 
to the GeneTests Laboratory Directory available online (http://www.ncbi.nlm. 
nih.gov/sites/GeneTests/lab) for a list of available testing centers. The small sample size of 
affected individuals currently identified has left the question of penetrance of the disease 
open. Therefore, a great deal of care should be exercised when interpreting the results of a 
genetic test from an asymptomatic patient. 
3.5 Medical management 
Currently, management of SCA12 is limited to providing symptomatic relief for the action 
tremor. Treatment of the SCA12 action tremor is very similar to that provided for essential 
tremor. A reduction in tremor amplitude has been achieved with beta-blockers and 
barbiturates (O'Hearn et. al., 2001). When appropriate, pharmacological relief for symptoms 
associated with the disease such as depression and anxiety should be offered to the SCA12 
patient.  
4. PPP2R2B gene regulation and protein function 
4.1 PP2A and B regulatory subunit 
Protein phosphorylation is the most common posttranslational modification of proteins, and 
it plays a role in nearly every cellular function. The addition of phosphate is mediated 
through a large group (>500) of enzymes called kinases and requires ATP as a substrate. The 
reverse reaction is mediated by a smaller number of protein phosphatases in which, in most 
cases, specificity is provided through the formation of multimeric protein complexes. One of 
the most abundant protein phosphatase is PP2A, which is an essential, ubiquitously 
expressed phosphatase that targets phospho-serine and phospho-threonine. PP2A exists as a 
heterotrimer composed of one member of four diverse families of regulatory subunits (B), a 
scaffolding subunit (A) and a catalytic subunit (C) (Figure 2). Humans express 4 families of 
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regulatory subunits termed B, B’, B’’, and B’’’, which determine both cellular localization 
and substrate specificity (Slupe et. al., 2011). The B family, also known B55, consists of 4 
distinct genes () that encode proteins containing a highly conserved core WD40 
domain, which has propeller like structure, with over 90% amino acid identity among the 
family members (Figure 2B). The B regulatory subunit is encoded by the PPP2R2B gene, 





Fig. 2. Models of PP2A/Bα prepared from PDB 3DW8. The subunits of the heterotrimeric 
complex are color coded with the catalytic subunit (C) in blue, the scaffold subunit (A) in 
gray, and the regulatory subunit (B) in green. A, “top-down” view of the heterotrimer 
suface. B, “end-on” view of the heterotrimer ribbon diagram. C, Close of view of the PP2A 
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4.2 Gene structure and expression 
The exon arrangement of the PPP2R2B gene is highly conserved among mammals and 
spread over more than 500,000 base pairs (Dagda et. al., 2003; Schmidt et. al., 2002). Exon 1.1 
and 1.2 are alternatively expressed first exons containing the ATG start site for the splice 
variants B1 and B2, respectively. These first exons, which contain the unique amino-
termini, are spliced to common exons 2-9 that encode the WD40 domain found in all the B 
family of regulatory subunits (Figure 3) (Dagda et. al., 2003). At the mRNA level, B1 and 
B2 are expressed prominently in brain tissue, and B1 can also be found in the testis 
(Dagda et. al., 2003). At the protein level, western blot analysis indicates that the B1 is 
exclusively expressed in brain tissue and not in the testis, despite the high mRNA 
expression in that tissue. Closer analysis of specific brain regions has shown high levels of 
the B1 protein throughout the brain (Strack et. al., 1998).  
4.2.1 Transcriptional regulation 
The CAG trinucleotide repeat expansion associated with the SCA12 disease is situated just 
upstream of the transcriptional start site of the B1 specific exon 1.1. A recent study 
identified the apparent transcriptional regulators for basal expression of the B1 promoter 
and the effect of the CAG repeat on basal expression (Lin et. al., 2010). Luciferase assays 
using deletions of the B1 promoter and chromatin immunoprecipitation assays reveal that  
 
Fig. 3. Schematic representation of PPP2R2B gene structure, splice variant transcripts and 
proteins. The gene structure shows the CAG repeat expansion location, the B1 (exon 1.1; 
red) and B2 N-terminal coding sequences (exon 1.2; green). Transcripts and proteins 
indicate the B1 (red) and B2 (green) splice variant specific transcripts and encoded 
proteins. Modified from Dagda et. al. (2003). 
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CREB1, SP1 and TRAP4 bind to and regulate the B1 promoter. Higher luciferase activity is 
seen in neuronal cell lines and correlates well with the known B1 neuronal expression. 
Interestingly, increasing the size of the CAG repeat in the Bβ1 promoter increased the 
promoter activity two-fold. The increased activity is specific to the expansion of the CAG 
and not a result of changing the spacing of promoter since no change is seen in an AT 
expansion control (Lin et. al., 2010). A normal length CAG repeat does appear to be 
important for basal promoter activity since decreasing the number of CAG repeats reduced 
the promoter activity (Chen et. al., 2009). Independent studies conducted in Japan and 
Taiwan found that patients suffering from Alzheimer’s disease had an increased likelihood 
of having a reduced number of CAG trinucleotide repeats compared to healthy control 
subjects (Chen et. al., 2009; Kimura et. al., 2011). Overall, these studies have identified 
important aspects of the PPP2R2B transcriptional regulation and help to discriminate 
between the role of the CAG repeat in providing basal transcriptional activation and the 
pathological effects of increasing or decreasing the trinucleotide repeat number. 
A recently identified Japanese autosomal dominant cerebellar ataxia raises more uncertainty 
about the role of PPP2R2B gene in SCA12. The disease locus for this new ataxia included the 
PPP2R2B gene but contained no CAG expansion (Sato et. al., 2010). Additionally, all exons 
and intron/exon borders were sequenced for the entire PPP2R2B gene, including the both 
first exons (1.1 and 1.2), and no mutations were discovered. Several neuronally expressed 
genes are within the identified locus and may contain the genetic insult resulting in the 
ataxia (Sato et al 2010). This does raise the possibility that some of the effects of the CAG 
expansion in the PPP2R2B gene may be mediated through dysregulation of other nearby 
genes and not just changes in Bgene expression. 
4.2.2 PPP2R2B regulation and cancer 
Another important form of regulation of B1 occurs in colorectal cancer (CRC) wherein 
developed cell lines show a decrease or complete absence of B1 expression (Tan et. al., 
2010). Furthermore, gene array comparisons of matched patient-derived mucosa controls 
and CRC tumors indicate a significant decrease in B1 expression in 90% of the tumors. The 
loss of B1 expression is mediated through hypermethylation of a CpG island that occurs in 
the B1 promoter. Aberrant methylation of the PPP2R2B gene also appears to be important 
in breast cancer, as seen in recent reports (Dejeux et. al., 2010; Muggerud et. al., 2010). 
Finally, an intronic SNP of the PPP2R2B gene, with unknown functional consequence, is 
correlated with improved prognosis in a breast cancer cohort (Vazquez et. al., 2011). These 
studies clearly indicate that regulation of the PPP2R2B gene is important in multiple cancers 
and may provide additional insight into the function of the PPP2R2B gene. 
4.3 Protein function 
The B1 and B2 splice variants encode proteins that share a common WD40 repeat domain 
that mediates the recruitment of the A and C subunits of PP2A to make a functional trimeric 
protein phosphatase. The B1 and B2 proteins differ only in the first 21 and 24 amino acids, 
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4.3.1 B1 protein function 
B1 has a cytoplasmic distribution and overexpression in cultured primary neurons does 
not change the morphology, survival or sensitivity to toxic treatments (Figure 4) (Dagda et. 
al., 2008). Overexpression of B1 in a neuroblastoma cell line does result in increased 
autophagy (Cheng et. al., 2009). In CRC the loss of B1 following methylation of the CpG 
island leads to aberrant phosphorylation of several proteins, including the oncogene c-myc. 
Reexpression of B1 in a colorectal cell line decreases xenograft growth (Tan et. al., 2010). 
This represents the first described pathway regulated specifically by a B1 containing PP2A 
trimer. Since some of the proteins regulated by B1 in CRC are also expressed in neuronal 
tissues, it may be of interest to examine whether the B1-mediated changes in 
phosphorylation also play a role in SCA12.  
4.3.2 B2 protein function 
The B2 N-terminus encodes a mitochondrial targeting sequence that results in recruitment 
of the trimeric PP2A enzyme to the outer mitochondrial membrane (OMM) (Dagda et. al., 
2003). In primary hippocampal neurons, PP2A-mediated phosphatase activity at the OMM, 
through recruitment by B2, results in mitochondrial fragmentation and increased basal 
death and sensitivity to neurotoxic insults (Figure 4) (Dagda et. al., 2005; Dagda et. al., 2008). 
Expression of B2 mutants, that either do not target to the OMM or cannot recruit the A and 
C subunits, prevents the mitochondrial fragmentation and increased neuronal death (Figure 
4) (Dagda et. al., 2008). Epitasis experiments indicate that the PP2A/B2-mediated 
mitochondrial fragmentation precedes and is obligatory to the increased neuronal cell death 
(Dagda et. al., 2008). An additional study, utilizing neuroblastoma cells, confirmed the 
increased sensitivity of cells expressing B2 but implicated an increase in autophagy as the 
culprit in the increased cell death (Cheng et. al., 2009).  
Mitochondrial dysfunction is a hallmark of several neurodegenerative diseases, including 
Alzheimer disease. It can therefore be postulated that the CAG trinucleotide repeat 
expansion, which is known to increase B1 promoter activity, amplifies both B1 and B2 
expression. The B2 upregulation may lead to increased mitochondrial fragmentation and 
increasing mitochondrial dysfunction in SCA12. Indeed, several other ataxias involve 
mitochondrial dysfunction. In patients suffering from SCA7, both liver and skeletal muscle 
biopsies show abnormal mitochondria (Han et. al., 2010). Heterozygous knockout mice for 
AFG3L2, a mitochondrial-targeted AAA-protease, develop abnormal mitochondria with 
decreased function and are a model of SCA28 (Maltecca et. al., 2009). Finally, in clinical trials 
pharmacological treatments with idebenone, an antioxidant thought to counteract 
mitochondrial dysfunction, have shown some promise in treatment of the genetic 
neurological disorder Friedreich ataxia (Marmolino, 2011). These examples highlight some 
of the ataxias associated with mitochondrial dysfunction and exemplify why mitochondrial 
dysfunction could be an important aspect of SCA12. 
4.4 Animal models of SCA12  
While characterization of the PPP2R2B gene products has suggested possible pathogenic 
mechanisms, animal models of SCA12 are urgently needed to test the predictions of the in  
 














Fig. 4. Mitochondrial targeting of PP2A/B2 is neurotoxic. Hippocampal neurons were 
transfected with the indicated GFP fusion proteins (om, outer mitochondrial; WT, wild-
type) and scored for apoptotic nuclei. B2 mutants that block mitochondrial localization 
(R6A) or AC dimer recruitment (RR168EE) also block apoptosis induction. Modified from 
Dagda et. al. (2008). 
vitro studies discussed above. A recently developed fly model of SCA12 does display some 
neuropathies that may be homologous to the human disease (Wang, YC et. al., 2011). In this 
model, Drosophila overexpresses the human B2 or tws, the fly homolog of B, which 
results in a dramatic increase in neuronal apoptosis and, for the highest level of tws, a 
decrease in fly life span. Overexpression of tws results in mitochondrial fragmentation and 
dysfunction, observed as an increase in reactive oxygen species (ROS) production. 
Expression of superoxide dismutase 2 or antioxidants treatments reduces ROS production 
and attenuates the effects of tws overexpression. How the neuropathies and their reversal  
by pharmacological treatments seen in the fly SCA12 model relate to the human disease 
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The CAG trinucleotide repeat expansion that occurs in the PPP2R2B gene is now well 
established as the cause of the autosomal dominant SCA12. This is a rare disease that 
shows a classical ataxia phenotype. The CAG repeat occurs in the promoter of a 
neuronally expressed protein, B1, and expansion of the CAG results in increased B1 
promoter activity. Aberrant expression of B1 also correlates with several cancers. 
Expression of another neuronal splice variant of PPP2R2B, B2, increases neuronal death, 
but its role in SCA12 remains unknown. Despite the identified PPP2R2B gene functions, 
the underlying molecular basis of the SCA12 disease is not known. Animal models are 
needed to address the complexity of SCA12 and develop potential therapeutic treatments. 
The fly model of SCA12 does show mitochondrial dysfunction and recapitulates some 
neuron specific cell death (Wang, YC et. al., 2011); however, the development of a 
mammalian model system will likely be required to understand the molecular basis of 
SCA12 pathogenesis. 
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1. Introduction 
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) (OMIM #270550) was 
originally found among inhabitants of the Charlevoix-Saguenay region of Quebec 
(Bouchard et al., 1978). ARSACS patients in Quebec show uniform phenotypes characterized 
by early-onset spastic ataxia, peripheral neuropathy, retinal hypermyelination, hand or foot 
deformities, and normal mentality. In 2000, the SACS gene, which is responsible for 
ARSACS, was identified in Quebec patients (Engert et al., 2000). Since then, ARSACS has 
been reported worldwide, especially in the Mediterranean area (El Euch-Fayache et al., 2003; 
Criscuolo et al., 2004; Grieco et al., 2004; Richter et al., 2004) and Japan (Ogawa et al., 2004; 
Takiyama, 2006). More SACS gene mutations were also identified in other areas (Takiyama, 
2007; Ouyang et al., 2008; Vermeer et al., 2008; Gerwig et al., 2010). Meanwhile, ARSACS in 
non-Quebec patients, especially in Japanese ones, showed marked clinical heterogeneity, 
i.e., there were patients without spasticity (Shimazaki et al., 2005; Hara et al., 2007; 
Shimazaki et al., 2007), without retinal hypermyelination (Hara et al., 2007), and with 
decreased mentality (Shimazaki et al., 2005; Yamamoto et al., 2005; Shimazaki et al., 2007; 
Hara et al., 2005). The clinical spectrum of the sacsinpathies will expand with the 
identification of more SACS gene mutations (Gomez, 2004).  
We herein review the epidemiology, genetics, clinical phenotypes, radiological and 
pathological findings in ARSACS cases carrying mutations of the SACS gene. 
2. Epidemiology 
2.1 Quebec 
ARSACS is the most common of all inherited spastic ataxias, 320 affected patients having 
been identified in Quebec (Bouchard et al., 1998). In Quebec, most of the patients’ families 
originate from the Charlevoix and Saguenay-Lac-St. Jean (SLSJ) regions. These regions have 
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ancestors who settled first in the Charlevoix region back in the seventeenth and early 
eighteenth centuries. ARSACS affects 1/1519 individuals in Charlevoix and 1/1952 in the 
Saguenay-Lac-St. Jean region, where the carrier frequency was estimated to be 1/22 for the 
1941-1985 period (De Braekeleer et al., 1993). 
2.2 Non-Quebec 
SACS gene identification has enabled us to find ARSACS patients worldwide outside 
Quebec: Tunisia (El Euch-Fayache et al., 2003) in 2003, Italy (Criscuolo et al., 2004; Grieco et 
al., 2004)in 2004, Japan (Ogawa et al., 2004) in 2004, and Turkey (Richter et al., 2004) in 2004. 
More cases were then reported in Spain (Criscuolo et al., 2005), France (Anheim et al., 2008), 
Belgium (Ouyang et al., 2008), the Netherlands (Vermeer et al., 2008), Germany (Gerwig et 
al., 2010), Maritime Canada (Guernsey et al., 2010), and Morocco and eastern Europe (Baets 
et al., 2010). In eastern France, ARSACS was identified in two index patients among 102 
autosomal recessive cerebellar ataxia (ARCA) ones (Anheim et al., 2008), meanwhile among 
43 Dutch ARCA patients, 16 with mutations in the SACS gene were identified (Vermeer et 
al., 2008). In Japan, 17 Japanese ARSACS families have been discovered on SACS gene 
analysis so far (Ogawa et al., 2004; Hara et al., 2005; Shimazaki et al., 2005; Yamamoto et al., 
2005; Ouyang et al., 2006; Yamamoto et al., 2006; Okawa et al., 2006; Hara et al., 2007; 
Takado et al., 2007; Shimazaki et al., 2007; Kamada et al., 2008; Tsugawa et al., 2009; Haga et 
al., 2011; Miyatake et al., 2011; Komure et al., 2006). ARSACS might be the second most 
frequent ARCA next to ataxia with oculomotor apraxia 1 (AOA1) in Japan. Figure 1 shows 
the geographical distribution and numbers of ARSACS families with SACS gene mutations 
in Japan. We could not find apparent regional accumulation of ARSACS families in Japan. 
Table 1 lists the previously identified SACS gene mutations that we could confirm in the 17 
Japanese ARSACS families. The mutations were unique ones for each family except for one 
missense mutation (W3248R) found in two unrelated families.  
 
Fig. 1. Regional distribution of ARSACS families in Japan.  
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ARSACS families show a nationwide distribution in Japan. The numbers in circles are the 
numbers of families identified in the regions.  
Amino acid substitutions Exon family references 
W3248R 10 2 Ogawa, 2004, Takiyama, 2006 
K2931fsX2952 10 1 Hara, 2005 
F1054S 10 1 Shimazaki, 2005 
G1734fsX1736 10 
1 Yamamoto, 2005 
S2058fsX2076 10 
V1231del 10 
1 Komure, 2006 
P3559L 10 
Q1345X 10 1 Okawa, 2006 
R4325X 10 1 Yamamoto, 2006 
C395fsX407 8 
1 Ouyang, 2006 
D687fsX713 8 
R2119X 10 1 Hara, 2007 
L308F 8 1 Takado, 2007 
D1996fsX1999 10 1 Shimazaki, 2007 
N161fsX175 7 
1 Kamada, 2008 
L802P 10 
G1257X 10 
1 Tsugawa, 2009 
R3788fsX3820 10 
Y138X 6 
1 Haga, 2011 
K1755fsX1775 10 
R3636X 10 1 (unpublished) 
S4007F 10 1 Miyatake, 2011 
 
Table 1. Previously identified SACS gene mutations in Japanese patients. 
3. Genetics 
3.1 Gene structure and pathological mutations 
The SACS gene was originally reported to consist of a single gigantic exon spanning 
12,794bp encoding an 11,487bp open reading frame (ORF), which represents the largest exon 
and the largest ORF within an exon found in any vertebrate (Engert et al., 2000). Recently, 
eight new exons located upstream of the gigantic one were found (Ouyang et al., 2006). 
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MAR-2011). The SACS gene comprises ten exons with a 13,737 bp ORF encoding 4579 amino 
acids (Figure 2A).  
The SACS gene is predicted to encode a 520-kDa multidomain protein, sacsin. The region 
near the C-terminus exhibits sequence similarity to the J-domain (DnaJ motif) of heat shock 
protein (HSP) 40 proteins (Parfitt et al., 2009), and the higher eukaryote and prokaryote 
nucleotide-binding (HEPN) domain (Grynberg, Erlandsen, and Godzik, 2003) (Figure 2B). A 
ubiquitin-like domain was identified at the N-terminus of sacsin (Parfitt et al., 2009)(Figure 
2B). A sacsin repeating region (SRR) is present in triplicate at the N-terminus of sacsin 
(Anderson, Siller, and Barral, 2010). A xeroderma pigmentosum complementation group C-
binding (XPCB) domain (Kamionka and Feigon, 2004) upstream of the DnaJ domain is also 
predicted.  
 
Fig. 2. Primary structure of the SACS gene (A) and domain organization of the sacsin 
protein (B). UBL: ubiquitin-like domain; SRR: sacsin repeating region; XPCB: XPC-binding 
domain; DnaJ: DnaJ motif (adopted from (Kozlov et al., 2011)). 
Seventy-four mutations have been reported as pathological ones in the SACS gene (Baets et 
al., 2010). After publication of that report, we verified the table and found seven additional 
mutations in exons 6 and 10 of the SACS gene in Japanese  patients (Table 1) (Komure et al., 
2006; Tsugawa et al., 2009; Haga et al., 2011; Miyatake et al., 2011). As far as we know, at 
least 81 mutations have been found worldwide to date. Most of the mutations are predicted 
to generate truncated sacsin proteins, and are located in the largest exon, 10. Seventeen 
mutations were found in exons 4, 6, 7, 8 and 9. On copy number variation (CNV) analysis, 
an intragenic SACS deletion of exons 3-5 was identified (Baets et al., 2010). Two types of 
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large deletions of the whole SACS gene and adjacent genes have been reported (Breckpot et 
al., 2008; Terracciano et al., 2009; McMillan et al., 2009).  
3.2 Normal sacsin function 
Sacsin is highly expressed in neurons, especially in cerebral corticospinal neurons and 
cerebellar Purkinje cells (Parfitt et al., 2009). The subcellular localization of sacsin in a 
cultured neuroblastoma-derived cell line was predominantly cytoplasmic and overlapped 
with that of mitochondrial protein heat shock protein (HSP) 60 (Parfitt et al., 2009). 
Because sacsin contains a functional J-domain (DnaJ motif), it has been proposed to act as 
a co-chaperone of the HSP70 chaperone system (Parfitt et al., 2009). The N-terminal 
segment of sacsin containing the ubiquitin-like (UbL) domain and the first sacsin 
repeating region (SRR) exhibits molecular chaperone activity and ATP-hydrolyzing 
activity (Anderson, Siller, and Barral, 2010, 2011). The UbL domain can interact with the 
20 S proteasomal subunit (Parfitt et al., 2009). The HSP70 chaperone machinery is an 
important component of the cellular response to aggregation prone mutant proteins, and 
the UbL domain protein is a part of the quality control machinery that regulates protein 
aggregation. Overall, the main function of sacsin, like other molecular chaperones, is 
probably to prevent protein misfolding and aggregation. Sacsin prevents polyglutamine-
expanded ataxin-1 toxicity (Parfitt et al., 2009). The XPCB domain interacts with ataxin-3, 
which is involved in spinocerebellar ataxia type 3 (Kamionka and Feigon, 2004). HEPN 
may stabilize nucleotide binding in complexes formed with the DnaJ domain (Grynberg, 
Erlandsen, and Godzik, 2003). Recently, the structure and function of the HEPN domain 
were determined, it being shown that it dimerizes and has a high affinity binding site for 
GTP, but it does not have GTPase activity (Kozlov et al., 2011).  
3.3 Pathogenesis of ARSACS 
Although the molecular mechanism underlying ARSACS remains unclear, the autosomal 
recessive transmission and truncating nature of most SACS mutations suggest the loss of 
sacsin function might cause development of this disease. Several functional alterations of 
sacsin proteins have been reported. An aspartate to tyrosine mutation (D168Y), located in 
the first SSR domain, abrogates its ATP-hydrolyzing activity (Anderson, Siller, and Barral, 
2010). An asparagine to aspartate mutation (N4549D) in the HEPN domain of the sacsin 
protein disrupts dimerization and correct protein folding (Kozlov et al., 2011). Premature 
termination of other mutations and loss of the HEPN domain might lead to ARSACS 
disease.  
4. Clinical phenotypes 
4.1 Original Quebec phenotype 
ARSACS is clinically characterized by early-onset spastic ataxia, axonal and 
demyelinating neuropathy, and hypermyelination of retinal nerve fibers (Bouchard et 
al., 1978; Bouchard, 1991). Unsteadiness of gait is usually the initial symptom. None of 
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beyond 18 months of age) (Bouchard et al., 1978; Bouchard, 1991). The disease 
progression becomes most obvious in the late teens or early twenties, and the mean age 
for patients becoming wheelchair-bound is 41 years in Quebec patients (Bouchard, 
1991). Concerning Quebec patients, ataxia, dysarthria, nystagmus, Babinski sign, 
hyperreflexia, spasticity, and retinal striations are noted in all of them. Distal 
amyotrophy of the feet is present in all patients after 20 years old (Bouchard, 1991), and 
pes cavus is noted in most Quebec patients. With these clinical features, ARSACS is 
clinically homogeneous in Quebec patients. Bouchard described progressive signs and 
early non-progressive ones of ARSACS in a review of this disease (Bouchard, 1991). The 
progressive signs are mostly spastic ataxia of the four limbs, slurred and dysrhythmic 
speech, discrete to severe distal amyotrophy, and absent ankle jerks after 25 years of 
age. The early non-progressive signs are increased deep tendon reflexes, a bilateral 
abnormal plantar response, marked saccadic alteration of smooth pursuit, and 
prominent myelinated fibers radiating from the disc on the retina.  
4.2 Non-Quebec atypical phenotypes 
The mean ages at onset are 5.4 and 4.5 years old in Japanese and Tunisian patients, 
respectively (Takiyama, 2007), while the ages at onset range from one to 1.5 years old in 
Quebec ones (Bouchard, 1991). Thus, the age at onset in these non-Quebec patients seems to 
be later than that in Quebec patients. According to a recent report from Belgium, the disease 
onset was over 20 years in five patients and as late as 40 years in one patient (Baets et al., 
2010).  
Although ataxia is noted in all non-Quebec ARSACS patients, one report stated that the 
cerebellar features were very mild in two patients (Baets et al., 2010). Other core clinical 
features of ARSACS, i.e., dysarthria, nystagmus, distal amyotrophy, Babinski sign, 
hyperreflexia, and pes cavus, are noted in most non-Quebec patients, which are similar to in 
Quebec patients.  
Non-Quebec patients, however, show some atypical features in comparison with Quebec 
ones. First, although spasticity is a core clinical feature of ARSACS, we found that two 
patients in a Japanese family with ARSACS lacked spasticity in the legs and showed 
areflexia or hyporeflexia (Shimazaki et al., 2005). In Quebec and Tunisian patients, spasticity 
becomes progressively worse during the disease course and is prevalent in older patients, 
and tendon reflexes remain preserved throughout the disease, except for ankle jerks 
(Bouchard et al., 1978; El Euch-Fayache et al., 2003). Since we did not observe the two above 
patients in their childhood, we were not able to determine whether or not their spasticity 
had decreased during the disease course or had been absent from the onset (Shimazaki et al., 
2005). The cases without spasticity, this depended on the fact that the neuromuscular 
manifestations were severe enough to diminish muscle tone and masked spasticity, and the 
planter responses were extensor, demonstrating that pyramidal tract sign was present. 
Recently, however, we observed another ARSACS patient whose spasticity had 
disappeared, probably due to the progressive peripheral nerve degeneration in the disease 
course of 29 years (Shimazaki et al., 2007). Thus, we should recognize that there is a rare 
ARSACS phenotype without spasticity, and the SACS gene should be analyzed even in 
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cases of early-onset cerebellar ataxia without spasticity. After that, several reports on 
spasticity-lacking ARSACS patients were published (Hara et al., 2007; Baets et al., 2010; 
Miyatake et al., 2011). 
Second, intellectual impairment is sometimes found in non-Quebec patients. The verbal IQ 
was 58, 88, 100, and 66 (mean: 78.00) in the four Japanese patients we examined (Takiyama, 
2006). Similarly, mental retardation and dementia have been found in Italy (Criscuolo et al., 
2004), Japan (Hara et al., 2005), and Turkey (Richter et al., 2004). Meanwhile, the verbal IQ 
(mean: 92.67) of Quebec patients is considered to be within normal limits, and a number of 
ARSACS patients have completed the secondary and university levels of education 
(Bouchard, 1991). Thus, intellectual impairment seems to be variable in ARSACS. Since the 
mode of inheritance of ARSACS is autosomal recessive, genes other than SACS might 
influence the intellectual impairment. 
Defects in conjugate pursuit ocular movements, decreased or absent vibration sense in the 
toes, hand deformities, and urinary or fecal incontinence are rather frequently noted in 
Quebec (Bouchard, 1991) and non-Quebec patients (El Euch-Fayache et al., 2003; Takiyama, 
2006). Cardiovascular evaluation revealed mitral valve prolapse in a majority of Quebec 
patients examined (Bouchard, 1991). 
Very recently, the disease initially presented with symptoms mainly orienting toward 
peripheral neuropathy in several patients, and there was one patient who did not exhibit 
any clinical or electrophysiologic signs of peripheral neuropathy (Baets et al., 2010).  
4.3 Ophthalmologic findings 
Although increased visibility of myelinated retinal nerve fibers is a hallmark of ARSACS in 
Quebec patients (Bouchard, 1991), there have been a considerable number of non-Quebec 
patients without this characteristic sign for ARSACS (El Euch-Fayache et al., 2003; Grieco et 
al., 2004; Criscuolo et al., 2004; Richter et al., 2004; Hara et al., 2005; Yamamoto et al., 2005; 
Ouyang et al., 2006; Okawa et al., 2006; Yamamoto et al., 2006; Hara et al., 2007; Baets et al., 
2010). Thus, retinal hypermyelination is a variable feature in non-Quebec patients. It is, 
however, very useful for suspecting a diagnosis of ARSACS, especially in an unusual 
phenotype without spasticity (Shimazaki et al., 2005). In a case without retinal 
hypermyelination, ARSACS resembles conditions referred to as early onset cerebellar ataxia 
with retained tendon reflexes (EOCA) (Chio et al., 1993), Friedreich ataxia with retained 
reflexes (De Castro et al., 1999), and several clinical descriptions of hereditary spastic 
paraplegia such as SPG7 (Wilkinson et al., 2004),  SPG21 (Simpson et al., 2003), SPG27 
(Meijer et al., 2004), and SPG30 (Klebe et al., 2006). 
Recently, Desserre et al. have reported that the retinal nerve fiber layer was thickened, as 
shown using optical coherence tomography (OCT), and that the retina did not show 
hypermyelinated areas on funduscopy (Desserre et al., 2011). Likewise, Vingolo et al. 
reported that four patients with ARSACS showed myelinated fibers on funduscopy, and 
also increased thickness of the retina on OCT, which is a finding not characteristic of 
persistent myelination of the retina (Vingolo et al., 2011). It is possible that persistent 
myelination of the retina, a general common finding, was present in those patients without 
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5.1 Brain MRI findings 
Some reports have mentioned that characteristic MRI findings in ARSACS are superior 
cerebellar vermian atrophy and cervical spinal cord atrophy (Bouchard et al., 1998; 
Takiyama, 2007). Recently, MRI of five patients in Quebec revealed linear hypointensity in 
T2- and Fluid-Attenuated Inversion Recovery (FLAIR) images of the pons (Martin et al., 
2007). Thereafter, the same findings have been reported in only one patient in each of the 
Netherlands (Van Damme et al., 2009), France (Anheim et al., 2010), and Italy (Terracciano et 
al., 2010). 
We recruited six ARSACS patients with SACS mutations in four Japanese families. Brain 
MRI was performed in all six patients. Brain MRI in the six patients showed superior 
cerebellar vermian atrophy. In addition, not only pontine linear hypointensity but also 
middle cerebellar peduncle hypointensity was observed in T2-weighted and FLAIR images 
(Shimazaki et al., in press) (Table 2). These areas showed isointensity in T1-weighted 
images. Figure 3 shows representative brain MRI findings in patients 3 (A) and 2 (B). In 
patient 3, T2*-weighted images were obtained showing no abnormal findings in the pons 
and middle cerebellar peduncles (Figure 3, A-1).  
We found the characteristic MRI findings in the six Japanese ARSACS patients, who all 
exhibited linear hypointensity in the pons, and a hypointense area in the middle cerebellar 
peduncles in T2-weighted and FLAIR images (Shimazaki et al., in press). A middle 
cerebellar peduncle hypointense area has not previously been reported in ARSACS patients, 
although pontine linear hypointensity was originally reported in five Quebec patients 
(Martin et al., 2007). Furthermore, as far as we know, hypointensity in these portions has not 
been described as a MRI finding in spinocerebellar ataxias and hereditary spastic 
paraplegias.  
We thought these hypointense areas were close to the location of the pontocerebellar fibers. 
We could find low intensity in the middle cerebellar peduncle (MCP) because the 
pontocerebellar fiber runs from the middle pons to the cerebellum through the MCP. We 
can detect low MCP intensity in an Italian case (Terracciano et al., 2010). We think an 
abnormal MCP signal is not specific for Japanese patients. 
The hypointensity in the pons and middle cerebellar peduncle might be specific findings for 
ARSACS cases even in non-Quebec ones with clinical heterogeneity (Shimazaki et al., 2012). 
Thus, pontine and middle cerebellar peduncle T2 hypointensity detectable on MRI should 
prompt us to perform SACS gene analysis even in such atypical early-onset cerebellar ataxia 
cases.  
5.2 Spinal MRI findings 
In Quebec cases, the cervical cord is small and flat (Bouchard, 1991). In our cases, upper 
cervical cord and medulla oblongata atrophy was not observed in three of the six patients 
for whom cervical MRI was performed (Shimazaki et al., 2012). Upper cervical atrophy is 
not a constant feature of ARSACS. In thirteen Belgium cases, cervical spinal cord atrophy 
was observed on MRI in only one case (Baets et al., 2010).  
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Case 1 2 3 4 5 6 
Age at exam, 
gender 
47, F 43, M 46, M 37, M 33, M 57, F 
Age at onset 6 6 3 8 7 3 
Cerebellar 
ataxia 
++ + ++ + ++ ++ 
Hyperreflexia + + + - - - 
Leg spasticity + + + - - - 




+ + + + + + 
Peripheral 
neuropathy 
+ + + + + + 
Mental 
impairment 
NE +(WAIS-R) +(WAIS-R) NE +(WAIS-R) +(MMSE) 
Amino acid 
substitutions
 W3248R  W3248R W3248R   F1054S

















- - + + + - 
Upper cervical 
cord atrophy 




+- NE +- + + + 
 
Table 2. Clinical, genetic and MRI findings in the ARSACS patients. NE: not examined; 
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Case 1 2 3 4 5 6 
Age at exam, 
gender 
47, F 43, M 46, M 37, M 33, M 57, F 
Age at onset 6 6 3 8 7 3 
Cerebellar 
ataxia 
++ + ++ + ++ ++ 
Hyperreflexia + + + - - - 
Leg spasticity + + + - - - 




+ + + + + + 
Peripheral 
neuropathy 
+ + + + + + 
Mental 
impairment 
NE +(WAIS-R) +(WAIS-R) NE +(WAIS-R) +(MMSE) 
Amino acid 
substitutions
 W3248R  W3248R W3248R   F1054S

















- - + + + - 
Upper cervical 
cord atrophy 




+- NE +- + + + 
 
Table 2. Clinical, genetic and MRI findings in the ARSACS patients. NE: not examined; 







Fig. 3. Representative brain MRI findings in two ARSACS patients. T2-weighted and FLAIR 
images of patient 3 (A-2a, 2b, 4a, and 4b) and patient 2 (B-1, 2a, 2b, 4a, and 4b) showed 
hypointensity in the pons (arrowheads) and bilateral middle cerebellar peduncles (arrows). 
Sagittal sections (A-3 and B-3) revealed superior cerebellar vermian atrophy in all patients. 
A T2* image of patient 3 (A-1) disclosed no remarkable low intensity in the pontine 
tegmentum or cerebellar peduncles (Shimazaki et al., 2012). 
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5.3 SPECT findings  
Single photon emission computed tomography (SPECT) of the brain with three-dimensional 
stereotactic surface projection (3D-SSP) analysis for five cases showed decreased blood flow 
in the upper cerebellar vermis in three cases (Shimazaki et al., 2007; Shimazaki, Nakano, and 
Takiyama, 2008) (Figure 4). Meanwhile, early onset cerebellar ataxia with retained tendon 
reflexes (EOCA) and Friedreich’s ataxia often show a reduction in the parietotemporal 
cortex blood flow as well as cerebellar hypoperfusion (De Michele et al., 1998), this being a 
different feature from in ARSACS. 
 
Fig. 4. 123I-IMP SPECT with three-dimensional stereotactic surface projection (3D-SSP) 
analyses of cases 4, 5, and 6.  
The results showed decreased blood flow in the superior cerebellar vermis and cerebellar 
hemisphere.  
6. Neuropathology 
6.1 Postmortem autopsy and comparison with the characteristic brain MRI findings    
The pathological findings in ARSACS patients have only been reported in a 21-year-old man 
(Bouchard, 1991) and a  59-year-old man (Richter et al., 1996). The former report of a young 
man described no findings regarding pontocerebellar fibers, but mentioned a small 
corticospinal tract and normal pontine nuclei in the pons (Bouchard, 1991). A T2* image of 
patient 3 disclosed no remarkable low intensity in the pontine tegmentum or cerebellar 
peduncles. These findings suggest that T2 hypointensity in the pons and cerebellar 
peduncles is not reflected by iron deposition in these portions. However, a second autopsy 
on the 59-year-old man revealed the presence of swollen thalamic and cerebellar cortical 
neurons (Bouchard et al., 1998). Most of these neurons had dense, lipofuscin-like granules 
within their lysosomes, and the authors suggested that ARSACS may be a lysosomal storage 
disease (Richter et al., 1996). In neuronal ceroid lipofuscinosis, MRI can often reveal 
hypointensity of the thalamus and putamen in T2-weighted images, which may reflect the 
storage of lipofuscin and the increase in the viscosity in these neurons (Autti, Joensuu, and 
Aberg, 2007). Therefore, the linear hypointensity of the pons that was found among 
ARSACS patients can also be explained by possible storage of lipofuscin-like materials. 
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6.2 Nerve and muscle biopsy 
Sural nerve biopsy revealed severe axonal degeneration and loss of large myelinated fibers 
(Peyronnard, Charron, and Barbeau, 1979; Bouchard, 1991; El Euch-Fayache et al., 2003; 
Takiyama, 2006). These findings in Quebec and non-Quebec patients are consistent with an 
axonal neuropathy associated with demyelinating features. 
Muscle biopsy disclosed typical and obvious neurogenic atrophy, i.e., grouped atrophy in 
the studied patients (Bouchard, 1991; El Euch-Fayache et al., 2003).  
7. Neurophysiology 
7.1 Peripheral nerve conduction studies 
The peripheral nerve conduction study in Quebec patients revealed an axonal neuropathy 
with absent sensory action potentials and low motor conduction velocity (Peyronnard, 
Charron, and Barbeau, 1979; Bouchard, 1991). We have presented the peripheral nerve 
conduction data for cases 4 and 5 (Shimazaki et al., 2005). In each patient, the motor nerve 
conduction velocity was mildly reduced in the ulnar and median nerves, and moderately in 
the posterior tibial nerves. Each compound muscle action potential (CMAP) was markedly 
decreased. In case 5 (patient 1 of (Shimazaki et al., 2005)), a CMAP was not evoked in the 
common peroneal nerves. No sensory nerve action potential was evoked in any of the 
extremities. These data indicate not only a severe to moderate axonal neuropathy but 
dysmyelinating neuropathy complicated by secondary axonal degeneration as in Quebec 
and Tunisian patients (Peyronnard, Charron, and Barbeau, 1979; El Euch-Fayache et al., 
2003). 
7.2 Motor and sensory evoked potentials 
Central pathway conduction studies including ones on somatosensory evoked potentials, 
brainstem auditory evoked potentials, and pattern reversal visual evoked potentials were 
performed in 67 Quebec patients (De Lean, Mathieu, and Bouchard, 1989). The findings that 
showed marked delays revealed widespread processes of demyelination in the primary 
sensory neurons as well as in the central nervous system (Bouchard, 1991). The central 
sensory and motor pathways were markedly impaired that could be attributed to 
myelinopathies, and there were high incidences of asymptomatic auditory and visual 
pathway involvement (Bouchard, 1991). 
Electronystagmography showed horizontal gaze nystagmus in all Quebec patients with 
marked impairment of smooth ocular pursuit and optokinetic nystagmus, and defective 
fixation suppression of caloric nystagmus (Dionne et al., 1979). Recently, both the masseter 
and blink reflexes were found to be abnormal in two ARSACS patients (Garcia et al., 2008), 
whereas the masseter reflex was preserved but a bilateral delay of the late response of the 
blink reflex was observed in Friedreich’ ataxia patients.  
8. Therapy and management 
Spasticity, the main feature of ARSACS during childhood, is rather mild in most patients. In 
the teens, however, the  spasticity increases in the lower limbs and patients often present a 
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spastic gait with evolving pes cavus (Bouchard et al., 2007). Physical therapy and use of oral 
medications such as baclofen to control spasticity in the early phase of the disease may 
prevent tendon shortening and joint contractures. When spasticity becomes significant, 
intrathecal baclofen may be considered. The most effective surgical procedures were triple 
arthrodesis with percutaneous lengthening of the Achilles tendon, and adductor and psoas 
tenotomies combined with neurectomy of the obturator nerve for perineal hygiene in a 
retrospective study of 26 patients who received surgical orthopaedic treatment (Bouchard 
and Langlois, 1999).  
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1. Introduction 
The aim of this work has been to review the neurochemical alterations described in the 
cerebellar ataxias, and to enumerate the attempts made at their pharmacological treatment. 
As will be shown, little use has been made of the neurochemical information available, and 
the therapeutic trials have been far from successful.  
The predominant (though not exclusive) reference to degenerative ataxias is due to the 
fact that the specificity of the affected cell populations should allow anticipation of 
more or less specific neurochemical alterations. This information could be used to look 
for therapeutic strategies, given the absence of curative treatments for the majority of 
ataxic disorders. This review covers only the pharmacologic attempts performed to treat 
ataxic symptoms, and is not exhaustive in terms of nosology, genetics or congenital 
errors of metabolism. The neurochemical basis of some non-degenerative ataxias that 
demonstrate favourable responses to pharmacological treatment are also reviewed. An 
outline of the physiological neurotransmission in the cerebellum opens this chapter 
(Table 1).  
2. Neurotransmission in the cerebellum  
The cerebellum is made up of four pairs of nuclei located in the deep white matter that 
covers the fourth ventricle, and is surrounded by a superficial layer of grey matter. The 
cerebellar cortex has a very uniform cellular structure and great cell density. 
In the cortex of the cerebellum, there are several types of inhibitory interneurons that utilize 
-aminobutyric acid (GABA) as neurotransmitter. These are Golgi cells (that coexpress 
GABA with glycine), stellate cells, basket cells and Lugaro cells.  
Purkinje cells are also GABAergic; they are the only ones whose axons exit the cortex of the 
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Purkinje cells are also GABAergic; they are the only ones whose axons exit the cortex of the 






The excitatory amino acid glutamate is used in the cerebellar cortex by granule cells and 
unipolar brush cells. The axons of the granule cells constitute the parallel fibres of the 
molecular layer.  
Most of the afferent fibres of the cerebellum are excitatory and use glutamate as main 
neurotransmitter. The climbing fibres that leave the contralateral inferior olive and synapse 
with the Purkinje cell dendrites are mostly glutamatergic, in addition to using aspartate and 
homocysteic acid. The mossy fibres are more numerous and originate in a number of areas, 
such as the pontine nuclei, reticular formation, spinal cord, deep cerebellar nuclei (as 
collaterals to the nuclear axons) and unipolar brush cells. They reach the dendrites of the 
granule cells in the so called glomerular structures. The great majority of mossy fibres use 
glutamate; a small proportion, acetylcholine (afferents from the vestibular nuclei and others 
from the cerebellar nuclei) and peptides such as enkephalins, cholecystokinin, 
corticotrophin, or calcitonin gene related peptide (CGRP). Part of the climbing and mossy 
fibres which originate in precerebellar structures, emit a collateral ramification that reaches 
the deep cerebellar nuclei on their trajectory toward the cortex. The efferent nuclear fibres 
are excitatory, with the exception of those destined for the inferior olives, which have an 
inhibitory function.  
In addition to the mossy and climbing fibres, there is a group of beaded fibres that use 
monoamines as neurotransmitters, and reach the three layers of the cerebellar cortex.   
 
Table 1. Neurotransmitters in the cerebellum (references 1-7). 
Origin in vestibular nuclei Acetylcholine 
Origin in hipothalamus Histamine 
Origin in reticular formation Serotonin 
Origin in locus ceruleus Noradrenaline 
Golgi cells (coexpressed with GABA) Glycine 
Golgi cells 





Mossy fibers                    
Climbing fibers  
Granule cells 
Parallel fibers 
Unipolar brush cells 
Glutamate 
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A contingent of noradrenergic fibres stems from the locus ceruleus, and there seems to be a 
group of dopaminergic afferents of indeterminate origin. Serotonergic fibres originate at the 
paramedian and lateral reticular nuclei, the periolivary reticular formation and the lateral 
tegmental region; it has not been possible to demonstrate connections between the raphe 
nuclei and the cerebellar cortex. Some histaminergic fibres reach the cerebellar cortex from 
the hypothalamus.  
Nitric oxide (NO) is a non-synaptic neurotransmitter present in the cerebellar cortex, mostly 
generated in the soma and parallel fibres of the granule cells. This substance spreads 
through the cell membranes and acts on glial cells and some neurons, stimulating the 
synthesis of cyclic guanosine-monophosphate. Basket and unipolar brush cells also 
synthesise NO, although not so Purkinje cells (1-7).  
In conclusion, neurotransmission in the cerebellum implicates the amino acids glutamate 
and GABA, which establish an equilibrium between excitatory and inhibitory phenomena  
(Table 1).   
Figures of the anatomy of the cerebellum and its connections, and of the neurochemical 
organization of the cerebellar cortex may be found the works of Colin et al (5), and Ottersen 
et al (1). 
3. Neurochemistry and pharmacological therapy of the cerebellar ataxias  
The abundance of neurotransmitters in the cerebellum complicates the task of determining 
which among them are implicated in disease pathogenesis. In addition, neurochemical data 
about many diseases is fragmentary. This section reviews the available neurochemical 
information (Table 2) and attempts at pharmacological treatment (Table 3) of the following 
conditions:  
1. Cortical cerebellar atrophies  
2. Atrophies of the cerebellar cortex and afferent fibres from the brainstem 
(olivopontocerebellar atrophies, OPCA). 
3. Spinocerebellar atrophies. 
4. Degenerations of the dentate nucleus and efferent tracts of the cerebellum.  
5. Episodic ataxias. 
4. Cortical cerebellar atrophies  
The cortical cerebellar atrophy (CCA) of idiopathic etiology constitutes a relatively 
straightforward neurochemical model: the loss of Purkinje cells in the cerebellar vermis (8) 
causes a selective decrease of the concentration of GABA in the dentate nuclei (9) and 
cerebrospinal fluid (CSF) (10-13), with no reduction in that of glutamate (9), homovanillic 
acid (HVA), 5-hydroxiindolacetic acid (5-HIAA), or the noradrenergic metabolite 3-
methoxy-4-hydroxyphenylglycol (MHPG) (14). Reduced consumption of glucose in the 
cerebellum has been determined by positron emission tomography (PET) (15). This 
condition presents as a late-onset, pure cerebellar syndrome (8). Autosomal dominant 
spinocerebellar ataxias (SCA) that exhibit a progressive and isolated cerebellar syndrome 
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Cortical cerebellar atrophy Decreased content of GABA in the dentate nuclei and CSF. 
Oivopontocerebellar 
atrophy  
Decreased levels of GABA and glutamate in the cerebellar cortex, and of 
GABA in the dentate nuclei. Decreased concentration of dopamine and 
HVA in putamen, caudate and nucleus accumbens.  
CSF: decreased levels of GABA and glutamate  
Friedreich's ataxia  Decreased glutamate concentration in the grey substance and dorsal 
columns in the lumbar spinal cord.  
Low glutamate and GABA concentrations in the cerebellar cortex.  
Machado-Joseph disease  Decreased HVA in CSF.  
Dentatorubral-
pallidoluysian atrophy  
Decreased GABA and substance P in globus pallidus and substantia nigra, 
and of choline-acetyltransferase in putamen and caudate nucleus.  
Reduced GABA in CSF.  
Episodic ataxia type 6  Defective glutamate uptake  
Table 2. Neurochemistry of the cerebellar ataxias. 
 
Cortical cerebellar atrophy  Anticholinesterase drugs: physostigmine (13,53)  
Serotonergic drugs: L-5-hydroxytryptophan (38-41), buspirone (43-47), 
tandospirone (48) 
Serotonergic antagonists: ondansetron (49)  
Peptides: TRH (51,52)  
GABAergic drugs: gabapentin (25), pregabalin (31) 
NMDA agonists: D-cicloserine (54)  




Anticholinesterase drugs: physostigmine (53,94)  
Serotonergic drugs: L-5-hydroxytryptophan (40,91), buspirone (46)  
Dopaminergic drugs: amantadine (89)  
Peptides: TRH (52)  
Cholinergic drugs: lecithin (95), L-acetylcarnitine (99)  
GABAergic drugs: vigabatrin (90), gabapentin (103), zolpidem (101)  
Glucocorticoid drugs: betamethasone (105)  
Glutamatergic drugs: ramified amino acids (100)  
Riluzole (102) 
Friedreich's ataxia  Cholinergic drugs: L-acetylcarnitine (99)  
Serotonergic drugs: L-5-hydroxytryptophan (40,91) 
Tandospirone (48) 
Dopaminergic drugs: amantadine (89,115)  
GABAergic drugs: vigabatrin (116)  
Peptides: TRH (52)  
Iron chelators: deferiprone (133) 
Antioxidant agents: idebenone (118-121,123, 126,127)  
Erythropoietin (131, 132) 
Machado-Joseph disease  Tetrahydrobiopterin (140)  
Trimethoprim-sulfametoxazole (141,145)  
Serotonergic drugs: buspirone (92), fluoxetin (120), tandospirone (147, 48)  
Antiepileptic drugs: lamotrigine (146)  
Antiarrhythmic drugs: mexiletine (148) Riluzole (102) 
Episodic ataxia type 1  
Episodic ataxia type 2  
Episodic ataxia type 3  
Episodic ataxia type 4  
Episodic ataxia type 5  
Acetazolamide, phenytoin (156)  
Acetazolamide (161)  
Acetazolamide (164)  
Dimenhydrinate (166)  
Acetazolamide (169)  
Table 3. Pharmacological therapy of the cerebellar ataxias. Boliographic references are in 
brackets.  
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A deficiency of GABA in the cerebellum may lead to cerebellar ataxia, as suggested by 
abnormal GABAergic neurotransmission in the presence of antibodies directed against the 
enzyme glutamic decarboxylase (GAD) (16), and the coexistence of ataxia with the 
aforementioned antibodies (17-19). Anti-GAD antibodies are present in juvenile neuronal 
ceroid-lipofuscinosis, a disorder that may associate ataxia (20), and a selective vulnerability 
of GABAergic neurons has been found in other lysosomal disorders (21). Besides, an 
amelioration of ataxia was achieved with the use of GABAergic drugs in a case of adult 
GM2 gangliosidosis (22), and administration of gabapentin improved motor coordination in 
potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1) 
knockout mice, which exhibit a decreased content of GABA in the cerebellum (23).  
The pharmacological trials in CCA are reviewed in the following section.  
An open-label trial of gabapentin reported a substantial clinical improvement, and 
statistically significant differences in the scores of some items selected from the International 
Cerebellar Ataxia Rating Scale (ICARS) (24). Ten patients were initially given a single dose 
of 400 mg of gabapentin, followed by doses between 900 and 1600 mg per day during four 
weeks. Every patient experienced an improvement in ataxia, and in three, gait became 
normal (25). Gabapentin interacts with the 2- subunit of the P/Q type voltage-dependent 
calcium channels (VDCC) (26), stimulates GABAergic neurotransmission by presynaptic 
mechanisms (27) and increases the concentration of GABA in the brain of healthy adults 
(28). More recently, gabapentin treatment decreased ICARS scores by more than 10% in 11 
patients with SCA 6 (caused by an abnormal expansion in CACNA1A, 19p13, that encodes 
the 1A subunit of the P/Q-type VDCC), indicating that the drug could be beneficial in this 
disease (29).  
Pregabalin, a molecule closely related to gabapentin, improved the scores in the Scale for the 
Assessment and Rating of Ataxia (SARA) (30) in a single blind, placebo controlled trial that 
included two patients with CCA (31).  
A patient with cortical cerebellar ataxia was administered piracetam in a single-blind trial. 
Piracetam (a derivative of GABA that binds to H3–glutamate sites) improved tandem gait 
and gait ataxia in a dose of 60 g per day, and the authors concluded that this drug might 
have an anti-ataxic effect when used in high doses (32). Subsequently, 60 g per day of 
piracetam was given to a group of two patients with hereditary CCA, and six with other 
hereditary ataxias (excluding Friedreich ataxia, FRDA), in an open-label trial. The reduction 
obtained in the mean total score of ICARS (from 39.4±17, to 30.9±14.9), and in that of the 
posture and gait item, reached statistical significance (33).  
Chan-Palay et al induced ataxia in animals through thiamine deprivation, and found a loss 
of serotonergic fibres in the nervous system (34). As a consequence, the authors suggested 
that a deficiency of serotonin might constitute the neurochemical basis for ataxia in humans 
(35). Anyway, neither a deficiency of serotonin nor atrophy of structures that could cause 
serotonergic denervation have been demonstrated in humans with CCA. The modulating 
effect of serotonin on GABAergic neurotransmission could explain some of the results 
reported below (36,37).   
In two studies on the serotonergic precursor L-5-hydroxytryptophan, improved stance and 
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GABAergic drugs: gabapentin (25), pregabalin (31) 
NMDA agonists: D-cicloserine (54)  




Anticholinesterase drugs: physostigmine (53,94)  
Serotonergic drugs: L-5-hydroxytryptophan (40,91), buspirone (46)  
Dopaminergic drugs: amantadine (89)  
Peptides: TRH (52)  
Cholinergic drugs: lecithin (95), L-acetylcarnitine (99)  
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Episodic ataxia type 1  
Episodic ataxia type 2  
Episodic ataxia type 3  
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Table 3. Pharmacological therapy of the cerebellar ataxias. Boliographic references are in 
brackets.  
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A deficiency of GABA in the cerebellum may lead to cerebellar ataxia, as suggested by 
abnormal GABAergic neurotransmission in the presence of antibodies directed against the 
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calcium channels (VDCC) (26), stimulates GABAergic neurotransmission by presynaptic 
mechanisms (27) and increases the concentration of GABA in the brain of healthy adults 
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patients with SCA 6 (caused by an abnormal expansion in CACNA1A, 19p13, that encodes 
the 1A subunit of the P/Q-type VDCC), indicating that the drug could be beneficial in this 
disease (29).  
Pregabalin, a molecule closely related to gabapentin, improved the scores in the Scale for the 
Assessment and Rating of Ataxia (SARA) (30) in a single blind, placebo controlled trial that 
included two patients with CCA (31).  
A patient with cortical cerebellar ataxia was administered piracetam in a single-blind trial. 
Piracetam (a derivative of GABA that binds to H3–glutamate sites) improved tandem gait 
and gait ataxia in a dose of 60 g per day, and the authors concluded that this drug might 
have an anti-ataxic effect when used in high doses (32). Subsequently, 60 g per day of 
piracetam was given to a group of two patients with hereditary CCA, and six with other 
hereditary ataxias (excluding Friedreich ataxia, FRDA), in an open-label trial. The reduction 
obtained in the mean total score of ICARS (from 39.4±17, to 30.9±14.9), and in that of the 
posture and gait item, reached statistical significance (33).  
Chan-Palay et al induced ataxia in animals through thiamine deprivation, and found a loss 
of serotonergic fibres in the nervous system (34). As a consequence, the authors suggested 
that a deficiency of serotonin might constitute the neurochemical basis for ataxia in humans 
(35). Anyway, neither a deficiency of serotonin nor atrophy of structures that could cause 
serotonergic denervation have been demonstrated in humans with CCA. The modulating 
effect of serotonin on GABAergic neurotransmission could explain some of the results 
reported below (36,37).   
In two studies on the serotonergic precursor L-5-hydroxytryptophan, improved stance and 





them (38,39). However, in a double-blind placebo crossover study of 13 patients with CCA, 
seven with OPCA, and 19 with FRDA, no improvement in ataxia was observed (40), 
although the inclusion of different diseases in the mentioned trials prevented a clear 
assessment of the effect of L-5-hydroxytryptophan on CCA. In addition, this drug was 
administered to six patients with CCA in an open-label study, without finding changes in 
the amplitude of voluntary movement or in the latency of electromyographic activity in 
antagonist muscles, showing that L-5-hydroxytryptophan was not an effective therapeutic 
agent for CCA (41).  
The drug buspirone stimulates the serotonergic 5-HT1A receptor. It is currently used as an 
anxiolytic (42), so this effect must be ruled out in its assessment as a treatment for CCA (43-
47). Trouillas et al studied the effect of buspirone on CCA in an open-label (42) and in two 
placebo-controlled studies (44,45). They defined their results as “a progressive modulation, 
rather than a radical transformation of ataxic symptoms” (43,45), referring to the limited and 
delayed improvement achieved. Lou et al (46) used buspirone in an open-label study in 14 
patients with CCA and six with OPCA; the drug was administered in accordance with the 
severity of the ataxia. The authors found that buspirone was effective in cases of mild or 
moderate ataxia, though they did not individualize its effect on any of the two disorders. 
Andrade-Filho et al (47) noted improvement in 11 patients with CCA, with the addition of 
buspirone to other anti-ataxic and antiepileptic drugs. However, the methodology 
employed in this work did not make clear the aetiology of the ataxias, nor did it measure 
accurately the effectiveness of the drug.  
The serotonergic agonist tandospirone was given during four weeks to 5 patients with SCA 
6, 5 with SCA 1, 6 with SCA 2, 14 with Machado Joseph disease (MJD), and 9 with 
multisystem atrophy. This was an open-label, non blinded trial, and obtained reductions in 
the ICARS scores of the SCA 6 (p 0.043) and MJD (p 0.005) subgroups that reached statistical 
significance. It must be remarked, however, that the two tables in this article mentioned 
different values for the pre-treatment mean ICARS score of the cerebellar-multisystem 
atrophy subgroup, that the discussion incorporated results not specified in the 
corresponding section, and that the value of probability (p<0.0001) for the reduction of 
ICARS scores after treatment with tandospirone for the entire group, was out of proportion 
with the results of p for every subgroup of patients (48). 
A double-blind, placebo controlled study of the serotonergic antagonist ondansetron 
showed worsening of the knee-heel manoeuvre in 15 patients with CCA (49).   
Thyrotropin-releasing hormone (TRH) increases noradrenaline turnover, facilitates 
cholinergic transmission, and adjusts GABAergic neurotransmission (50). Although its 
intravenous administration had no effect on one patient with familial CCA (51), a study of 
patients with CCA, OPCA and FRDA showed an amelioration of postural instability (52). 
Obviously, the risk of hyperthyroidism prevents the prolonged use of this potentially 
beneficial agent.   
The use of the anti-cholinesterase drug physostigmine in two double-blind, placebo 
controlled studies in patients with CCA, obtained no improvement in ataxia. The authors of 
both articles concluded that physostigmine was not effective in the treatment of this disease 
(13,53).   
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The amino-acid D-cycloserine, a partial agonist of the N-metil-D-aspartate (NMDA) 
glutamate receptor, was used in a placebo controlled trial in two patients with CCA, two 
with SCA 6 (53), 10 patients with multisystem atrophy and one with degenerative 
spinocerebellar ataxia. Mild improvements were found in some items of ICARS, and it was 
suggested that activation of NMDA receptors could lead to symptomatic improvement in 
spinocerebellar ataxia (54).  
Finally, the use of acetazolamide in three patients with SCA 6 was found to have no effect 
on ataxia (55). Nevertheless, an open-label study of 9 patients with SCA 6 treated with 500 
mg per day of acetazolamide, achieved a statistically significant improvement in ICARS 
scores and in the results of posturographic analysis (56).  
Some forms of CCA have a non-degenerative etiology. Chronic abuse of ethanol may cause 
loss of neurons with GABA-A receptors, especially in the Purkinje cell layer, and vermian 
atrophy. Abstention from alcohol has been proposed to halt progression of ataxia (57).  
Cerebellar paraneoplastic degeneration is a remote consequence of cancer. It is characterised 
histologically by loss of Purkinje cells and the presence of perivascular and leptomeningeal 
inflammatory infiltrates (58). An autoimmune cause is invoked by the presence of 
antibodies directed against epitopes common to the tumour and: 1) Purkinje cells (Yo, Tr) 
(59,60), 2) Hu and Ri nuclear proteins (60), 3) Tr dendritic protein (61), 4) P/Q-type VDCC 
(62,63), and 5) mGluR1 type glutamate metabotropic receptors (64). The latter are capable of 
altering both the acute and plastic response of Purkinje cells, causing cerebellar dysfunction 
(64). Antineoplastic treatment is recommended, or immunotherapy in its defect (60).  
5. Olivopontocerebellar atrophies 
The olivopontocerebellar atrophies comprise a heterogeneous group of disorders 
(degenerative diseases, prionopathies, hereditary errors of metabolism and mitochondrial 
encephalopathies) whose histological substrate is: 1) loss of neurons in the inferior olive and 
ventral portion of the pons; 2) loss of mossy and climbing fibres, and 3) atrophy of the 
cerebellar cortex (65). There is depletion of Purkinje and granule cells in the cerebellar 
cortex, especially in the hemispheres (8). This expresses clinically a global cerebellar 
syndrome, accompanied by additional neurological signs. It may be sporadic or familial; 
familial cases are associated with a greater frequency of medullar signs (with the exception 
of spasticity), dystonia and oculomotor abnormalities (65). Autosomal dominant 
spinocerebellar ataxias in which OPCA constitutes the pathological or radiological substrate 
are SCA 1, 2, 7, 12 and 13 (66).  
A fourth part of sporadic OPCA cases develop multisystem atrophy (which associates 
parkinsonism and autonomic failure) (66,67). Analysis of pathological material has shown 
immunoreactive inclusions to alpha-synuclein in oligodendrocytes (68) and neurons (69) in 
this disease. However, this is not the case with SCA1 or SCA2 (disorders caused by 
expansion of CAG triplets in 6p22.3 and 12q24.13), in which olivopontocerebellar atrophy 
constitutes the pathological basis (66). The frequency of associated lesions (locus coeruleus, 
red nucleus, substantia nigra, dentate, hypoglossal and dorsal motor nuclei, nucleus 
ambiguus, etc) with those described, blurs the nosological limits of OPCA (70).  
Neurochemical studies in OPCA have demonstrated an important decrease of GABA 
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The content of glutamate in the cerebellum varied between an important reduction and 
normality, in different sources (9,71,72). Kanazawa et al established correlation in brains 
with OPCA, between: 1) the content of glutamate in the anterior vermis, and the density of 
granule cells; 2) the concentration of glutamate in the posterior vermis and the cerebellar 
hemispheres, and the cellular density of the inferior olive; 3) the content of GABA in the 
dentate nuclei, and the density of Purkinje cells (9). 
In an autoradiographic receptor study, Albin and Gilman found a statistically significant 
reduction in the density of GABA, benzodiazepine (BZD) and glutamate receptors in the 
cerebellar cortex of OPCA brains, compatible with loss of granule and Purkinje cells (73). A 
PET study found diminished flumazenil binding in the brainstem and cerebellum, 
confirming the deficiency of GABA observed in OPCA (74).  
A study of a patient with sporadic OPCA found IgM antibodies directed against the 
glutamate receptor subunit GluR2. Antibodies were demonstrated on Purkinje cells, basal 
portion of the pons and inferior olive, by immunohistochemical methods. The antibodies 
were shown to be able to depolarise neurons in vitro, a fact that pointed to excitotoxicity of 
autoimmune origin in the genesis of the disease (75). 
A low activity of the enzyme glutamate dehydrogenase was previously considered a 
biochemical hallmark of OPCA (76), although later studies demonstrated a lack of specificity 
of this metabolic alteration (77,78). 
PET studies have shown decreases in dopamine and HVA levels in the striatum in familial 
(79) and sporadic (80) OPCA. The density of dopamine D2 receptors was normal in the 
putamen and caudate nuclei in one parkinsonian patient who exhibited OPCA at autopsy, 
demonstrating the possibility of presynaptic parkinsonism in this disease (81).  
A reduced acetylcholinesterase activity and a low density of muscarinic receptors in the 
cerebellar cortex were found in familial OPCA, suggesting that cholinergic denervation was 
a major neurochemical anomaly in this variant (82,83). Nevertheless, choline-
acetyltransferase activity in mossy fibres (1,3) was greater in familial OPCA than in control 
cases (82), disproving the previously mentioned proposal. 
In CSF, in addition to a low content of GABA (9-11), a low glutamate level was found in 
sporadic OPCA (11), as well as low levels of HVA, thiamine and MHPG in hereditary OPCA 
(84-86), with those of tryptophan and 5-HIAA in normal ranges (85). 
In addition, a decrease in the levels of pontine and cerebellar N-acetylaspartate (reflecting 
neuronal loss), was found by high field proton magnetic resonance spectroscopy (1H MRS) 
in patients with SCA 2 and cerebellar multisystem atrophy. An increase in myoinositol, that 
points to involvement of glial cells, was also found in multisystem atrophy (87). 
To summarise, deficiencies of GABA, glutamate, dopamine and possibly noradrenaline, are 
present in the nervous system of OPCA patients, although no deficiencies of serotonin or 
acetylcholine have been documented (79,85).  
In an ataxia-telangiectasia (AT) brain with cerebellar, inferior olive and dentate nuclei 
atrophy, the contents of GABA and glutamate in the cerebellar cortex, and of GABA in the 
dentate nuclei, were lower than those in controls (88). These neurochemical findings were 
similar to those in hereditary OPCA (71), and demonstrate that the neurochemical 
abnormalities of the ataxias are independent of the underlying condition.  
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The neurochemical complexity of OPCA makes successful pharmacological therapy 
difficult. As outlined below, a large number of clinical trials have been done, in an attempt 
to find a remedy. 
A double-blind placebo controlled study using amantadine hydrochloride in 30 patients 
with OPCA without akinesia, obtained improvements in simple and movement reaction 
times in response to visual and auditory stimuli, that reached statistical significance. The 
beneficial results were attributed, either to a dopaminergic effect of the drug, or to blockade 
of NMDA receptors, an effect similar to that exercised by memantine (89). 
In a group of 14 patients (one with sporadic OPCA, four with familial OPCA and nine with 
FRDA), a double-blind comparative trial of vigabatrin (an irreversible inhibitor of GABA-
transaminase) with placebo, yielded no apparent benefit (90). 
A previously mentioned trial (40) did not find improvement in ataxia with L5-
hydroxytryptophan in a group that included seven patients with OPCA. This conclusion 
was shared by Currier et al, using the same drug in a group that included three patients 
with OPCA (91). 
A group of 20 patients (5 with SCA 2, 2 with SCA 3, 4 with FRDA, and the remaining with 
other degenerative ataxias) was given buspirone at doses of 60 mg per day, in a double-
blind, placebo-controlled, cross-over trial; buspirone was not superior to placebo in the 
amelioration of ataxia (92). The potential effects of oestrogen on neuroprotection, and of 
buspirone on ataxia, were combined in an open-label study with 18 OPCA patients. The 
participants were allocated either to buspirone, 15 mg/day, or to buspirone and oestrogen, 
0.625 mg/day. No statistically significant differences were found in ICARS scores, 
compared with baseline, in any group, although a trend of improvement in gait speed and 
knee-tibia test was observed in the first one, suggesting that oestrogen was not beneficial in 
cerebellar dysfunction (93). The work of Lou et al, using buspirone in seven patients with 
OPCA and 14 with CCA, has been detailed earlier (46). 
In another previously mentioned study, the administration of physostigmine to 10 patients 
with OPCA and nine with CCA gave no apparent benefit (53), although this drug was found 
to have a favourable effect when used in a heterogeneous group that included three cases of 
OPCA (94). 
The administration of the cholinergic precursor lecithin to 11 patients with OPCA induced a 
clinical worsening coincident with elevated plasma choline levels (95). Results obtained with 
choline chloride (96) and physostigmine, led Harding (97) and Manyam (13) to conclude 
that cholinergic drugs were not effective to treat cerebellar ataxias, probably because no 
deficit in cholinergic neurotransmission has been confirmed in these diseases (50). In spite of 
this, a double-blind, placebo controlled analysis of the cholinomimetic agent L-
acetylcarnitine obtained a mild improvement in the coordination items of ICARS, in a group 
of 14 patients with sporadic and hereditary OPCA (98), and in another group of 11 patients 
with FRDA (99). 
Based on the hypothesis that stimulation of glutamate metabolism could favour its 
neurotransmission in the cerebellum, and so prevent excitotoxic damage, Mori et al gave 
branched amino-acids to a group of 16 patients (five with sporadic OPCA, and 11 with 
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placebo (100). Starting with an ICARS score average of 42.44  16.60, reductions of 2.92  
3.35 were obtained with a 1.5g dose, and of 4.31  4.57 with a 3g dose. These modest results 
were nevertheless statistically significant, though the effect on patients with OPCA could 
not be individualized. 
The favourable effect of TRH in a group of patients with several types of ataxia (including 
12 with OPCA) has been referred to already (52). 
In four out of five patients with SCA 2, an improvement of ataxia and intention tremor was 
observed after administration of zolpidem in single doses of 10 mg. In one patient, a SPECT 
scan verified normalization of a previously diminished Tc99exametazime binding. The 
drug’s beneficial effect was attributed to reversion of a phenomenon of diaschisis (101).  
In a randomized, double-blind, placebo-controlled trial, 40 patients (4 with SCA 2, 6 with 
multisystem atrophy, 8 with FRDA, and others with degenerative and acquired ataxias) 
were assigned to riluzole (100 mg/day) or placebo, during 8 weeks. The number of patients 
with a 5-point drop in ICARS compared to baseline (primary endpoint of the study) was 
significantly higher in the riluzole group after 4 and 8 weeks of treatment, with a mean 
change of – 7.05 [± 4.96] points in the total score, versus 0.16 [± 2.65] with placebo (102). 
Gabapentin was found to improve gait in a patient with sporadic OPCA, and dysarthria and 
oscillopsia in another (103). Duhigg described an unexpected regression of ataxia in a 
patient with OPCA that received 30 mg/day of propranolol (104).  
Finally, inhaled betamethasone led to improvement in the ataxia of a patient with infantile 
AT (105), whilst pregabalin in combination with tiagabine ameliorated ataxia in a patient 
with adult-onset AT (106). 
6. Spinocerebellar atrophies 
The most frequent and severe spinocerebellar atrophy is Friedreich’s ataxia. FRDA has 
autosomal recessive inheritance, and an early onset. It is associated with scoliosis, pes cavus, 
cardiomyopathy, dysarthria, deep tendon areflexia, loss of vibration sense and extensor 
plantar responses (107). The lesions are located mainly in the spinal cord, where 
macroscopic atrophy, loss of fibres in the dorsal columns, dorsal and ventral spinocerebellar 
bundles, and direct and crossed corticospinal tracts, are present. Neuronal loss is found in 
the gracilis and cuneatus nuclei, Clarke’s dorsal nuclei and in the dorsal root ganglia. The 
dorsal roots are atrophic, and there is depletion of myelinated fibres in the sensory nerves. 
Neuronal depopulation and loss of iron in the dentate nuclei, as well as atrophy of the 
superior cerebellar peduncles are also found, while the cerebellar cortex is preserved 
(8,97,108). Hypertrophic changes are present in the heart, with increased connective tissue 
and loss of cardiomyocytes (108).  
The genetic anomaly in FRDA is an abnormal expansion of a GAA triplet in the first intron 
of the FXN gene on chromosome 9q13, that inhibits the transcription of the mitochondrial 
protein frataxin. Its deficiency interferes with the synthesis of iron-sulphur complexes, and 
with iron transport. These cause an accumulation of reactive iron in the mitochondria, 
interfere with oxidative phosphorylation and allow the formation of toxic oxygen radicals 
(109).    
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Neurochemical studies in FRDA have demonstrated low concentrations of glutamate and 
glycine in the grey matter of the lumbar cord and of glutamate in the dorsal columns, which 
reflect the loss of corticospinal and sensory glutamatergic fibres (110,111). There was also a 
reduction in the concentrations of glutamate and GABA in the vermis and the cerebellar 
hemispheres (112).   
HVA and 5-HIIA CSF levels were reduced in patients with FRDA (85); this was not the case 
with CSF levels of GABA and homocarnosine (113), nor with the density of BZD receptors in 
the brain (114).  
Pharmacological therapy has only achieved partially favourable results in FRDA. As 
previously mentioned, the results of trials with L-hydroxytryptophan (40,94), physostigmine 
(53), TRH (52), vigabatrin (91), riluzole (102) and buspirone (92), in groups that included 
patients with several types of ataxia, did not permit individualization of the effect of these 
drugs on FRDA. 
Botez et al did not find improvement in ataxia when treating a group of 27 patients with 
FRDA with amantadine hydrochloride (90). The same result was reported by Filla et al, in a 
double-blind cross-over trial using amantadine hydrochloride in 12 patients with FRDA 
(115). No benefit was obtained, either, in an open-label assay of vigabatrin in nine patients 
with FRDA (116).  
Idebenone (a government-supported drug for treatment of FRDA in Canada, among other 
countries) is a synthetic analogue of coenzyme Q10 with powerful antioxidant properties, 
whose effectiveness on the ataxia and cardiomyopthy of FRDA is currently being 
investigated. 
A positive effect of idebenone on the cardiomyopathy of FRDA reported in a preliminary 
trial (117) was confirmed in a randomized placebo-controlled trial with 29 patients, in which 
a reduction of the thickness of the interventricular septum and posterior wall of the left 
ventricle, that reached statistical significance, was evidenced by echocardiography (118). 
Another study found that six (among eight) patients with FRDA exhibited an important 
reduction of cardiac hypertrophy (119), although no improvement in ataxia was noticed in 
any of these trials. 
In a study with an examination period that ranged from 6 to 84 months, Ribat et al observed 
that ataxia and cardiac ejection fraction deteriorated in 88 patients with FRDA while 
receiving 5 mg/kg per day of idebenone (in spite of finding decreased cardiac hypertrophy 
by echocardiography), as well as in 16 non-treated patients (120). An increase in 
interventricular septum and left posterior wall thickness was observed in patients without 
previous myocardiopathy, who received 5 mg/kg per day of idebenone. The authors 
concluded that idebenone did not prevent the development of myocardiopathy, although no 
worsening was found in patients with known cardiac disease (121). 
The phase 3 Idebenone Effects on Neurological ICARS Assessments (IONIA) study 
randomized 70 ambulatory FRDA patients aged 8 to 18, with ICARS scores between 10 and 
54, to placebo and idebenone at doses of 10-20, and 30-54 mg/kg per day. No improvement 
in left ventricular hypertrophy or cardiac function could be demonstrated over a six month 
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Artuch et al (123) reported a statistically significant amelioration in cerebellar function, 
compared with baseline evaluation, in paediatric patients with FRDA receiving idebenone. 
Recently, emphasis has been placed on the use of high doses of idebenone in an effort to 
improve ataxia in FRDA (124,125); accordingly, a randomized, double-blind, placebo-
controlled phase 2 six-month trial (National Institutes of Health Collaboration with Santhera 
in Ataxia [NICOSIA]) of this drug at doses of 5, 15 and 45 mg/kg per day, was performed 
on 48 ambulatory FRDA patients aged between 8 and 18, with ICARS scores between 10 and 
54. Increasing doses of idebenone were associated with reductions in ICARS scores in a 
dose-dependent manner, even though overall statistically significant differences were not 
obtained; thus concluding that high doses of idebenone might be necessary to attain 
beneficial effects on neurological function (126).  
In contrast, the “neurological” arm of the IONIA trial achieved a minimal mean reduction in 
ICARS scores, which did not reach statistical significance when compared to placebo (127). 
The drug mitoquinone (an antioxidant derived from idebenone), which is active in the 
mitochondrion though not so in the cytosol, is expected to be an effective therapeutic agent 
in FRDA (128) 
A double-blind study of 5-hydroxytryptophan and placebo in 19 patients with FRDA (129), 
and of an open-label study of amantadine in 16 (130), only gave slightly positive results. A 
similar benefit was obtained in a previously mentioned study that used L-acetylcarnitine in 
11 patients with FRDA (100). 
It was demonstrated recently that human recombinant erythropoietin (rhuEPO) increased 
frataxin in lymphocytes from patients with FRDA, in vitro; this effect was independent from 
the EPO receptor (131). Thus, a persistent and significant increase in frataxin levels was 
found in peripheral blood lymphocytes of seven (among 10) patients with FRDA who 
received 5.000 units of rhuEPO subcutaneously, three times a week during 8 weeks; 
reductions in the urinary oxidative stress marker 8-hydroxi-2’-deoxyguanosine excretion, 
and in SARA scores, were also found (132). The same favourable results (that reached 
statistical significance) were replicated in a study involving 8 patients with FRDA, who 
received 2.000 units of rhuEPO three times a week during six months; unfortunately, the 
design of the trial could not rule out a placebo effect of the drug (133). 
More specific therapeutic approaches for FRDA are under investigation, such as the histone 
deacetylase inhibitors, which impair abnormal DNA transcription in FRDA; peroxisome 
proliferator-activated receptor gamma agonists, that enhance cell antioxidant activity and 
frataxin levels; deferiprone (a mitochondrion-specific iron chelator) reduced iron content in 
the dentate nuclei (as measured by MRI), and improved neuropathy and gait ataxia in the 
youngest patients among 9 adolescents with FRDA (134); gene-based strategies, as the use of 
viral vectors that express frataxin, which corrected sensitivity to oxidative stress in FRDA 
fibroblasts (128,135); and finally, pluripotent stem cells induced from FRDA fibroblasts were 
able to differentiate into neurons and cardiomyocytes (136).  
An isolated deficiency of vitamin E, caused by mutations in the gene that encodes the alpha-
tocopherol transfer protein in 8q13, can present with an identical phenotype to FRDA. The 
neurological manifestations stabilise or may partially revert with administration of vitamin 
E (137).  
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7. Degenerations of the dentate nucleus and efferent tracts of the cerebellum 
This section deals about about Machado-Joseph disease and dentatorubral-pallidoluysian 
atrophy (DRPLA). 
MJD, also designated SCA3, is caused by an unstable expansion of a CAG triplet in the 
ataxin 3 gene in14q32.1, and exhibits dominant transmission (138). The lesions are found in 
the dentate nuclei and superior cerebellar peduncles, and respect the cerebellar cortex, 
striatum, inferior olive and corticospinal tracts. The pontine nuclei are sometimes affected. 
The dorsal columns, spinocerebellar tracts and Clarke’s dorsal nuclei degenerate in the 
spinal cord (110). Associated lesions may be present in the anterior horns, oculomotor and 
subthalamic nuclei, substantia nigra, medial longitudinal fascicle, and peripheral nerves. 
Among the manifestations of MJD, ataxia is related to lesions in the dentate or pontine 
nuclei; oculomotor disorders, to those in the brainstem; and parkinsonism, to those in the 
substantia nigra. The frequent spasticity cannot be explained by the aforementioned 
findings (138).  
Neurochemical abnormalities in MJD consist of a reduced CSF concentration of HVA, even 
in cases without apparent parkinsonism (85,139). Concentrations of 5-HIAA and MHPG 
were reduced in CSF in one patient with MJD (136), although these changes were not found 
in every instance (85,139).  
Attempts at pharmacological therapy in MJD are outlined below.   
Based on the finding that trimethoprim increased the concentration of tetrahydrobiopterin 
(THB) in CSF in MJD, Sakai et al administered 1 mg/kg of THB and placebo to five patients 
for 10 day periods, in a crossover scheme. They reported a statistically significant 
improvement in the performance of some timed tests of motor function, though deglutition 
and tendon hypereflexia were not modified (140).  
A double-blind, placebo-controlled, crossover trial of trimethoprim-sulfamethoxazole (TS) 
in 20 patients with SCA3, employed: 1) a clinical scale of ataxia and other non-cerebellar 
symptoms; 2) posturographic analysis; 3) the Schoppe motor performance test; and 4) 
achromatic and colour discrimination visual sensitivity tests. After six months of TS 
administration, none of the patients showed improvement in any of the enumerated tests. 
No differences were noted in sub-group analysis according to age, sex, duration of illness, 
phenotype, age at onset, or number of CAG triplets (141). These categorical results contrast 
with the more favourable outcomes obtained in a study that included eight patients with 
MJD (142), and with three other reports of individual patients (143-145) that received TS. 
The reason for the differing results could lie in the absence of molecular diagnosis in the 
latter studies, or in other methodological differences (141).  
An open-label study on the use of the antidepressant drug fluoxetine involved doses of 20 
mg per day given to 13 patients with MJD. In spite of a statistically significant improvement 
according to the Montgomery-Asberg depression rating scale, the EDSS and UPDRS scales 
showed no differences in motor function. The study concluded that serotonergic stimulation 
was not effective in the treatment of MJD (146).  
Buspirone, at a dose of 60 mg per day, did not improve ataxia in a group of 20 patients that 





Artuch et al (123) reported a statistically significant amelioration in cerebellar function, 
compared with baseline evaluation, in paediatric patients with FRDA receiving idebenone. 
Recently, emphasis has been placed on the use of high doses of idebenone in an effort to 
improve ataxia in FRDA (124,125); accordingly, a randomized, double-blind, placebo-
controlled phase 2 six-month trial (National Institutes of Health Collaboration with Santhera 
in Ataxia [NICOSIA]) of this drug at doses of 5, 15 and 45 mg/kg per day, was performed 
on 48 ambulatory FRDA patients aged between 8 and 18, with ICARS scores between 10 and 
54. Increasing doses of idebenone were associated with reductions in ICARS scores in a 
dose-dependent manner, even though overall statistically significant differences were not 
obtained; thus concluding that high doses of idebenone might be necessary to attain 
beneficial effects on neurological function (126).  
In contrast, the “neurological” arm of the IONIA trial achieved a minimal mean reduction in 
ICARS scores, which did not reach statistical significance when compared to placebo (127). 
The drug mitoquinone (an antioxidant derived from idebenone), which is active in the 
mitochondrion though not so in the cytosol, is expected to be an effective therapeutic agent 
in FRDA (128) 
A double-blind study of 5-hydroxytryptophan and placebo in 19 patients with FRDA (129), 
and of an open-label study of amantadine in 16 (130), only gave slightly positive results. A 
similar benefit was obtained in a previously mentioned study that used L-acetylcarnitine in 
11 patients with FRDA (100). 
It was demonstrated recently that human recombinant erythropoietin (rhuEPO) increased 
frataxin in lymphocytes from patients with FRDA, in vitro; this effect was independent from 
the EPO receptor (131). Thus, a persistent and significant increase in frataxin levels was 
found in peripheral blood lymphocytes of seven (among 10) patients with FRDA who 
received 5.000 units of rhuEPO subcutaneously, three times a week during 8 weeks; 
reductions in the urinary oxidative stress marker 8-hydroxi-2’-deoxyguanosine excretion, 
and in SARA scores, were also found (132). The same favourable results (that reached 
statistical significance) were replicated in a study involving 8 patients with FRDA, who 
received 2.000 units of rhuEPO three times a week during six months; unfortunately, the 
design of the trial could not rule out a placebo effect of the drug (133). 
More specific therapeutic approaches for FRDA are under investigation, such as the histone 
deacetylase inhibitors, which impair abnormal DNA transcription in FRDA; peroxisome 
proliferator-activated receptor gamma agonists, that enhance cell antioxidant activity and 
frataxin levels; deferiprone (a mitochondrion-specific iron chelator) reduced iron content in 
the dentate nuclei (as measured by MRI), and improved neuropathy and gait ataxia in the 
youngest patients among 9 adolescents with FRDA (134); gene-based strategies, as the use of 
viral vectors that express frataxin, which corrected sensitivity to oxidative stress in FRDA 
fibroblasts (128,135); and finally, pluripotent stem cells induced from FRDA fibroblasts were 
able to differentiate into neurons and cardiomyocytes (136).  
An isolated deficiency of vitamin E, caused by mutations in the gene that encodes the alpha-
tocopherol transfer protein in 8q13, can present with an identical phenotype to FRDA. The 
neurological manifestations stabilise or may partially revert with administration of vitamin 
E (137).  
 
Neurochemistry and Neuropharmacology of the Cerebellar Ataxias 
 
185 
7. Degenerations of the dentate nucleus and efferent tracts of the cerebellum 
This section deals about about Machado-Joseph disease and dentatorubral-pallidoluysian 
atrophy (DRPLA). 
MJD, also designated SCA3, is caused by an unstable expansion of a CAG triplet in the 
ataxin 3 gene in14q32.1, and exhibits dominant transmission (138). The lesions are found in 
the dentate nuclei and superior cerebellar peduncles, and respect the cerebellar cortex, 
striatum, inferior olive and corticospinal tracts. The pontine nuclei are sometimes affected. 
The dorsal columns, spinocerebellar tracts and Clarke’s dorsal nuclei degenerate in the 
spinal cord (110). Associated lesions may be present in the anterior horns, oculomotor and 
subthalamic nuclei, substantia nigra, medial longitudinal fascicle, and peripheral nerves. 
Among the manifestations of MJD, ataxia is related to lesions in the dentate or pontine 
nuclei; oculomotor disorders, to those in the brainstem; and parkinsonism, to those in the 
substantia nigra. The frequent spasticity cannot be explained by the aforementioned 
findings (138).  
Neurochemical abnormalities in MJD consist of a reduced CSF concentration of HVA, even 
in cases without apparent parkinsonism (85,139). Concentrations of 5-HIAA and MHPG 
were reduced in CSF in one patient with MJD (136), although these changes were not found 
in every instance (85,139).  
Attempts at pharmacological therapy in MJD are outlined below.   
Based on the finding that trimethoprim increased the concentration of tetrahydrobiopterin 
(THB) in CSF in MJD, Sakai et al administered 1 mg/kg of THB and placebo to five patients 
for 10 day periods, in a crossover scheme. They reported a statistically significant 
improvement in the performance of some timed tests of motor function, though deglutition 
and tendon hypereflexia were not modified (140).  
A double-blind, placebo-controlled, crossover trial of trimethoprim-sulfamethoxazole (TS) 
in 20 patients with SCA3, employed: 1) a clinical scale of ataxia and other non-cerebellar 
symptoms; 2) posturographic analysis; 3) the Schoppe motor performance test; and 4) 
achromatic and colour discrimination visual sensitivity tests. After six months of TS 
administration, none of the patients showed improvement in any of the enumerated tests. 
No differences were noted in sub-group analysis according to age, sex, duration of illness, 
phenotype, age at onset, or number of CAG triplets (141). These categorical results contrast 
with the more favourable outcomes obtained in a study that included eight patients with 
MJD (142), and with three other reports of individual patients (143-145) that received TS. 
The reason for the differing results could lie in the absence of molecular diagnosis in the 
latter studies, or in other methodological differences (141).  
An open-label study on the use of the antidepressant drug fluoxetine involved doses of 20 
mg per day given to 13 patients with MJD. In spite of a statistically significant improvement 
according to the Montgomery-Asberg depression rating scale, the EDSS and UPDRS scales 
showed no differences in motor function. The study concluded that serotonergic stimulation 
was not effective in the treatment of MJD (146).  
Buspirone, at a dose of 60 mg per day, did not improve ataxia in a group of 20 patients that 





Another open-label study used 10 to 30 mg per day doses of tandospirone. Seven out of 10 
patients with MJD had their ICARS scores slightly improved, with additional mitigation of 
symptoms potentially caused by 5-HT1 receptor dysfunction (insomnia, anorexia, 
depression and cold lower extremities). The authors concluded that MJD manifested 
symptoms derived from these receptors, and recommended further tests with tandospirone 
in this disease (147). An open-label trial of tandospirone in 39 patients (14 with MJD among 
them) has already been commented on (48). 
The antiarrhythmic drug mexiletine was shown to alleviate muscle cramps in MJD, without 
improving ataxia (148).  
Liu et al gave 50 mg/day of lamotrigine to six patients with MJD, and observed 
improvement in one leg stance and tandem gait. They proposed that this beneficial effect 
could be due to enhanced expression of ataxin 3, induced by the drug (149).  
Dentatorubral-pallidoluysian atrophy is a dominantly transmitted illness caused by an 
abnormal expansion of a CAG triplet in the atrophyn gene, in 12p13.31, that codifies 
polyglutamine sequences of abnormal length that exert a toxic action (as in other diseases 
caused by expansion of CAG triplets) (150). An important neuronal loss in the dentate and 
red nuclei is found. Less intense degeneration of the subthalamic nuclei and external part of 
the globus pallidus is also present, while the cerebellar cortex is preserved. Some studies 
have described spinal cord lesions identical to FRDA in DRPLA, in addition to those 
described (151); demyelinization in the superior cerebellar peduncles and efferent tracts of 
the pallidum has been noted, as well. These lesions may be asymmetric (152). Polyglutamine 
nuclear inclusions have been found in neurons and oligodendrocytes (153).  
The clinical manifestations of DRPLA are heterogeneous. Cerebellar ataxia and dementia are 
considered cardinal signs, accompanied by progressive myoclonic epilepsy in cases with 
onset before the age of 20, or choreoathetosis and psychiatric symptoms when onset occurs 
later. It has been determined that there is an inverse correlation between the number of CAG 
triplets and age at onset of the disease. The differential diagnosis includes Huntington’s 
disease due to the possible association of chorea and dementia (150).  
The neurochemical alterations in DRPLA are centred on a reduction of GABA and substance 
P in the globus pallidus and substantia nigra, and reduced choline-acetyltransferase activity 
in the caudate and putamen, in spite of preservation of the small striatal neurons; this result 
points to cell hypofunction as its cause (154). In CSF, the concentration of GABA was found 
to be very low in five cases of DRPLA, whilst levels of HVA and 5-HIAA were normal (151).   
Recently, an accumulation of 8-hydroxi-2’-deoxyguanosine and 8-hydroxyguanosine, and a 
reduction of immunoreactivity to Cu/Zn superoxide dismutase, were found in the lentiform 
and dentate nuclei of DRPLA brains, suggesting the possibility that oxidative stress might 
play a part in the genesis of this disease (155). 
No clinical assay dedicated to the treatment of ataxia caused by DRPLA has been performed 
to date.  
8. Episodic ataxias 
Episodic ataxias are transmitted by autosomal dominant inheritance, and are amenable to 
drug treatment.  
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Episodic ataxia type 1 (EA1), also known as episodic ataxia with myokymia, has its onset in 
infancy or early adolescence, and associates interictal myokymia in the face and limbs 
(identified by electromyography) with brief episodes of unsteadiness, tremor and 
dysarthria. The attacks are brought about by voluntary movement or startle, and may occur 
many times every day. They can be prevented with acetazolamide or phenytoin. EA1 is 
caused by mutations in the KCNA1 gene in 12p13, which encodes the voltage- dependent 
potassium channel KCNA1, widely expressed in the cerebellum and peripheral nerve (156-
159). It has been demonstrated that the mutated channels increase cellular excitability, and 
prevent physiological repolarization (160).   
Episodic ataxia type 2 (EA2) is caused by mutations in CACNA1A, that give rise to truncated 
1A subunits (161). Electrophysiological characterisation of the abnormal proteins has 
demonstrated reduced channel conductance, causing an abnormally low calcium ingress, 
with the consequent cell damage (162,163).  
EA2 appears in infancy and is associated with crises of ataxia, vertigo and nausea that last 
hours or days and are precipitated by emotional stress, fatigue or ingestion of coffee or 
ethanol. Interictal nystagmus, permanent ataxia and atrophy of the cerebellar vermis may 
coexist. Diagnosis may be difficult, as EA2 may be confused with anxiety or paroxysmal 
vertigo. The ataxic episodes respond to prophylaxis with acetazolamide (156,161).   
Episodic ataxia type 3 (EA3) appears between the age of one year, and forty. It is associated 
with ataxia, vertigo and tinnitus, frequently headache, diplopia and blurred vision; interictal 
myokymia is also present. It may be distinguished from EA1 by the presence of vertigo and 
tinnitus, and from EA2 by the absence of interictal nystagmus and the short duration of the 
attacks, which are prevented by acetazolamide (164). The responsible gene is located in 1q42 
(165).   
Episodic ataxia type 4 (EA4), or vestibulocerebellar ataxia, was described by Farmer and 
Mustian in 1963 and is characterised by vertigo, diplopia, and mild or moderate ataxia that 
lasts from a few minutes to several weeks. It appears at an average age of 23 years (166). 
Defects have been found in smooth ocular pursuit and suppression of the vestibulo-ocular 
reflex, in addition to gaze-evoked nystagmus (167). Some patients develop progressive 
ataxia (166). EA4 responds to prophylaxis with dimenhydrinate (166) and is genetically 
distinct from SCA1, 2, 3, 4, 5, EA1, EA2 and DRPLA (168).  
Episodic ataxia type 5 (EA5) is caused by a point mutation in CACNB4 (2q22-q23), that 
causes a change of one amino-acid (C104F) in the 4 subunit of the VDCC. It was described 
in patients with French-Canadian ancestry, and its clinical symptoms (ataxia and vertigo) 
and duration are similar to EA2; there is interictal nystagmus and it responds to prophylaxis 
with acetazolamide. The main difference is a later age of onset (169).  
Episodic ataxia type-6 (EA6) was described in a ten year-old child that exhibited 
transitory episodes of ataxia and dysarthria in addition to epilepsy, migraine and 
alternating hemiplegia. A heterozygote mutation was identified in SLC1A3 (5p13), the 
gene that encodes the excitatory amino-acid transporter 1 (EAAT1, GLAST1), pointing to 
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As may be deduced from the exposed data, pharmacological trials of cerebellar ataxias have 
been flawed by a number of factors, like the recruitment of very scarce numbers of patients, 
the predominance of clinical assays which include patients with more than one disease, the 
lack of an ataxia rating scale of generalized use and that of quantitative means of measuring 
ataxic symptoms, the absence of standard doses of the drugs under investigation, and 
probably the most important, the usual lack of application of the available 
pathophysiological data to the trials performed to date. 
The basic neurochemical anomaly in idiopathic CCA consists in a lowering of the cerebellar 
content of GABA. In OPCA, deficits of glutamate, dopamine, and probably, noradrenaline, 
are present as well. Glutamate is essentially the deficient neurotransmitter in FRDA. A 
deficiency of serotonin has not been demonstrated conclusively in degenerative ataxias. The 
neurotransmitter abnormalities of MJD and DRPLA have not been well defined yet. Thus, it 
seems obvious that the neurochemical complexity of these disorders is one of the reasons for 
the lack of effective treatments.  
Some tests have shown that the drugs gabapentin, pregabalin and tiagabine are effective in 
ataxias that associate a predominant deficiency of GABA in the cerebellum, like CCA and 
OPCA. Presumably, the more selective the deficit of GABA, the more effective the 
GABAergic substitution.   
Agents capable of restoring the physiological action of glutamate (associated with 
neuroprotective molecules to prevent excitotoxic phenomena) could be useful in disorders 
like OPCA and FRDA. Conversely, the usefulness of the peptide TRH is conditioned by the 
risk of hyperthyroidism. Idebenone and other agents used to treat FRDA have to prove their 
effectiveness on ataxia, in a definite manner. The lack of effectiveness of physostigmine and 
choline chloride discards them as therapeutic agents for CCA and OPCA. The use of 
serotonergic agents in the cerebellar ataxias must be considered controversial at least, due to 
insufficient neurochemical evidence, and that of riluzole should be investigated in depth, as 
it could benefit patients with multisystem atrophy.  
Given the severity of many of the ataxias considered in this work, treatable causes, such as 
vitamin E deficiency, should be ruled out when faced with phenotypes similar to FRDA. In a 
similar way, therapeutic trials with acetazolamide should be undertaken in cases with 
uncertain diagnoses, with the aim of recognising ataxias that respond to this drug.  
Research aimed at identifying effective drugs to treat the cerebellar ataxias should, 
ideally, look for agents able to neutralize the causes of these diseases. However, as this is 
not possible in most cases, neurochemical evidence might provide useful clues in the 
search for therapeutic remedies (171,172). The study of animal and experimental models 
of disease, the use of precise methods for the measurement of ataxia (clinical semi-
quantitative scales, quantitative movement analysis, etc) and the recruitment of 
homogenous study populations (22), are all highly recommended. In this way, the 
currently exiguous therapeutic panorama of the cerebellar ataxias could be amplified until 
etiological remedies are found. 
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